Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],9.0 x 10(3),308,DB00682,Warfarin
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],2.34 x 10(5),309,DB00682,Warfarin
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],3.4 x 10(3),310,DB00682,Warfarin
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],1.44 x 10(5),311,DB00682,Warfarin
,3710629,"apparent volume of distribution, V/F","An apparent volume of distribution, V/F, of 0.17 l/kg was used in calculating CL/F.",Screening for the influence of host factors on warfarin clearance using a single dose single sample procedure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710629/),[l] / [kg],0.17,458,DB00682,Warfarin
,3710629,CL/F,After a single dose of warfarin single sample values of CL/F averaged 0.243 l/h +/- 0.042 (N = 12) which compared well with a multiple sample-based value of CL/F which was 0.243 l/h +/- 0.046 (N = 12).,Screening for the influence of host factors on warfarin clearance using a single dose single sample procedure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710629/),[l] / [h],0.243,459,DB00682,Warfarin
,3710629,CL/F,After a single dose of warfarin single sample values of CL/F averaged 0.243 l/h +/- 0.042 (N = 12) which compared well with a multiple sample-based value of CL/F which was 0.243 l/h +/- 0.046 (N = 12).,Screening for the influence of host factors on warfarin clearance using a single dose single sample procedure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710629/),[l] / [h],0.243,460,DB00682,Warfarin
,3710629,elimination,When an erythromycin pretreatment was started before warfarin ingestion and continued throughout the period of warfarin elimination CL/F decreased to 0.208 l/h +/- 0.047 while CL/F decreased to 0.210 l/h +/- 0.061.,Screening for the influence of host factors on warfarin clearance using a single dose single sample procedure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710629/),[l] / [h],0.208,461,DB00682,Warfarin
,3710629,CL/F,When an erythromycin pretreatment was started before warfarin ingestion and continued throughout the period of warfarin elimination CL/F decreased to 0.208 l/h +/- 0.047 while CL/F decreased to 0.210 l/h +/- 0.061.,Screening for the influence of host factors on warfarin clearance using a single dose single sample procedure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710629/),[l] / [h],0.208,462,DB00682,Warfarin
,3710629,CL/F,When an erythromycin pretreatment was started before warfarin ingestion and continued throughout the period of warfarin elimination CL/F decreased to 0.208 l/h +/- 0.047 while CL/F decreased to 0.210 l/h +/- 0.061.,Screening for the influence of host factors on warfarin clearance using a single dose single sample procedure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710629/),[l] / [h],0.210,463,DB00682,Warfarin
,10496299,absolute bioavailability,It is rapidly absorbed with an absolute bioavailability of between 40 and 50%.,Clinical pharmacokinetics of troglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),%,40 and 50,2272,DB00682,Warfarin
,10496299,elimination half-life,"The mean elimination half-life ranges from 7.6 to 24 hours, which facilitates a once daily administration regimen.",Clinical pharmacokinetics of troglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),h,7.6 to 24,2273,DB00682,Warfarin
,11680668,oral clearance (CL),"The population estimates and 90% confidence intervals (CI) for oral clearance (CL) and apparent volume of distribution of the plasma compartment (Vc) were 0.0176 l/h/kg (CI = 0.012-0.023) and 0.098 l/kg (CI = 0.088 - 0.109), respectively.",Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),[l] / [h·kg],0.0176,2486,DB00682,Warfarin
,11680668,apparent volume of distribution of the plasma compartment (Vc),"The population estimates and 90% confidence intervals (CI) for oral clearance (CL) and apparent volume of distribution of the plasma compartment (Vc) were 0.0176 l/h/kg (CI = 0.012-0.023) and 0.098 l/kg (CI = 0.088 - 0.109), respectively.",Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),[l] / [kg],0.098,2487,DB00682,Warfarin
,11680668,elimination half-life,The elimination half-life was 3.9 h (CI = 2.5-5.2).,Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),h,3.9,2488,DB00682,Warfarin
,11103757,unbound oral clearance,"Although the unbound oral clearance of (S)-warfarin for the prepubertal patients was significantly (P < .01) less than that for the adult group (346 versus 637 mL/min), the body weight-normalized unbound oral clearance for the prepubertal patients was significantly (P < .01) greater than that for the adults and showed a negative correlation (P < .05) with age.",Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103757/),[ml] / [min],346,3083,DB00682,Warfarin
,11103757,unbound oral clearance,"Although the unbound oral clearance of (S)-warfarin for the prepubertal patients was significantly (P < .01) less than that for the adult group (346 versus 637 mL/min), the body weight-normalized unbound oral clearance for the prepubertal patients was significantly (P < .01) greater than that for the adults and showed a negative correlation (P < .05) with age.",Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103757/),[ml] / [min],637,3084,DB00682,Warfarin
,20875232,flow rate,"The final HPLC conditions were as follows: mobile phase MeOH-ammonium acetate (0.5 M) triethylamine buffer (pH 5, 51:49, v/v); analytical column Luna C₁₈ ODS2; wavelength 260 nm; flow rate of 1.5 mL/min; and warfarin as internal standard (5 μg/mL).",An HPLC method for the determination of bromadiolone plasma kinetics and its residues in hen eggs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20875232/),[ml] / [min],1.5,5322,DB00682,Warfarin
,20875232,Recoveries,Recoveries for bromadiolone were in the range of 72-80% with RSD lower than 10%.,An HPLC method for the determination of bromadiolone plasma kinetics and its residues in hen eggs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20875232/),%,72-80,5323,DB00682,Warfarin
,18520598,AUC[0-infinity],"During the placebo phase, area under the plasma concentration-time curve (AUC) and elimination half-life (t1/2) of R-warfarin in PMs was significantly greater than those in hmEMs (AUC[0-infinity], 42,938/34,613 ng h/mL [PM/hmEM], P = 0.004; t1/2, 48.8/40.8 hours [PM/hmEM], P = 0.013).",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"42,938",6842,DB00682,Warfarin
,18520598,AUC[0-infinity],"During the placebo phase, area under the plasma concentration-time curve (AUC) and elimination half-life (t1/2) of R-warfarin in PMs was significantly greater than those in hmEMs (AUC[0-infinity], 42,938/34,613 ng h/mL [PM/hmEM], P = 0.004; t1/2, 48.8/40.8 hours [PM/hmEM], P = 0.013).",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"34,613",6843,DB00682,Warfarin
,18520598,t1/2,"During the placebo phase, area under the plasma concentration-time curve (AUC) and elimination half-life (t1/2) of R-warfarin in PMs was significantly greater than those in hmEMs (AUC[0-infinity], 42,938/34,613 ng h/mL [PM/hmEM], P = 0.004; t1/2, 48.8/40.8 hours [PM/hmEM], P = 0.013).",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),h,48.8,6844,DB00682,Warfarin
,18520598,t1/2,"During the placebo phase, area under the plasma concentration-time curve (AUC) and elimination half-life (t1/2) of R-warfarin in PMs was significantly greater than those in hmEMs (AUC[0-infinity], 42,938/34,613 ng h/mL [PM/hmEM], P = 0.004; t1/2, 48.8/40.8 hours [PM/hmEM], P = 0.013).",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),h,40.8,6845,DB00682,Warfarin
,18520598,AUC(0-infinity),"Omeprazole treatment significantly increased the AUC(0-infinity) (41,387 ng h/mL, P = 0.004) and t1/2 (46.4 hours, P = 0.017) of R-warfarin in hmEMs to levels comparable to those in the PMs.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"41,387",6846,DB00682,Warfarin
,18520598,t1/2,"Omeprazole treatment significantly increased the AUC(0-infinity) (41,387 ng h/mL, P = 0.004) and t1/2 (46.4 hours, P = 0.017) of R-warfarin in hmEMs to levels comparable to those in the PMs.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),h,46.4,6847,DB00682,Warfarin
,18520598,AUC[0-infinity],"There were no differences in S-warfarin pharmacokinetics between the CYP2C19 genotypes (AUC[0-infinity], 15,851/16,968 ng*h/mL [PM/hmEM]; t1/2, 22.7/25.4 h [PM/hmEM]), or between the two treatment phases (AUC[0-infinity], 14,756/18,166 ng h/mL [PM/hmEM]; t1/2, 27.0/25.4 hours [PM/hmEM] in the omeprazole phase) as well as anticoagulant effects.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"15,851",6848,DB00682,Warfarin
,18520598,AUC[0-infinity],"There were no differences in S-warfarin pharmacokinetics between the CYP2C19 genotypes (AUC[0-infinity], 15,851/16,968 ng*h/mL [PM/hmEM]; t1/2, 22.7/25.4 h [PM/hmEM]), or between the two treatment phases (AUC[0-infinity], 14,756/18,166 ng h/mL [PM/hmEM]; t1/2, 27.0/25.4 hours [PM/hmEM] in the omeprazole phase) as well as anticoagulant effects.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"16,968",6849,DB00682,Warfarin
,18520598,t1/2,"There were no differences in S-warfarin pharmacokinetics between the CYP2C19 genotypes (AUC[0-infinity], 15,851/16,968 ng*h/mL [PM/hmEM]; t1/2, 22.7/25.4 h [PM/hmEM]), or between the two treatment phases (AUC[0-infinity], 14,756/18,166 ng h/mL [PM/hmEM]; t1/2, 27.0/25.4 hours [PM/hmEM] in the omeprazole phase) as well as anticoagulant effects.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),h,22.7,6850,DB00682,Warfarin
,18520598,AUC[0-infinity],"There were no differences in S-warfarin pharmacokinetics between the CYP2C19 genotypes (AUC[0-infinity], 15,851/16,968 ng*h/mL [PM/hmEM]; t1/2, 22.7/25.4 h [PM/hmEM]), or between the two treatment phases (AUC[0-infinity], 14,756/18,166 ng h/mL [PM/hmEM]; t1/2, 27.0/25.4 hours [PM/hmEM] in the omeprazole phase) as well as anticoagulant effects.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),[h·ng] / [ml],"14,756",6851,DB00682,Warfarin
,18520598,t1/2,"There were no differences in S-warfarin pharmacokinetics between the CYP2C19 genotypes (AUC[0-infinity], 15,851/16,968 ng*h/mL [PM/hmEM]; t1/2, 22.7/25.4 h [PM/hmEM]), or between the two treatment phases (AUC[0-infinity], 14,756/18,166 ng h/mL [PM/hmEM]; t1/2, 27.0/25.4 hours [PM/hmEM] in the omeprazole phase) as well as anticoagulant effects.",The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520598/),h,27.0,6852,DB00682,Warfarin
,22623082,total run time,"The total run time was 3 min and the elution of HMB and IS occurred at 1.48 and 1.75 min respectively; this was achieved with a mobile phase consisting of 0.1% formic acid in a water-acetonitrile mixture (15:85, v/v) at a flow rate of 1.0 mL/min on a Agilent Eclipse XDB C(8) (150 × 4.6, 5 µm) column.",Development and validation of LC-MS/MS method for the estimation of β-hydroxy-β-methylbutyrate in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22623082/),min,3,7845,DB00682,Warfarin
,22623082,total run time,"The total run time was 3 min and the elution of HMB and IS occurred at 1.48 and 1.75 min respectively; this was achieved with a mobile phase consisting of 0.1% formic acid in a water-acetonitrile mixture (15:85, v/v) at a flow rate of 1.0 mL/min on a Agilent Eclipse XDB C(8) (150 × 4.6, 5 µm) column.",Development and validation of LC-MS/MS method for the estimation of β-hydroxy-β-methylbutyrate in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22623082/),min,1.48,7846,DB00682,Warfarin
,22623082,flow rate,"The total run time was 3 min and the elution of HMB and IS occurred at 1.48 and 1.75 min respectively; this was achieved with a mobile phase consisting of 0.1% formic acid in a water-acetonitrile mixture (15:85, v/v) at a flow rate of 1.0 mL/min on a Agilent Eclipse XDB C(8) (150 × 4.6, 5 µm) column.",Development and validation of LC-MS/MS method for the estimation of β-hydroxy-β-methylbutyrate in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22623082/),[ml] / [min],1.0,7847,DB00682,Warfarin
,23535530,half-life,"Apixaban has a half-life of about 12 hours, and the normal dosage is 5 mg orally twice daily.",Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23535530/),h,12,8513,DB00682,Warfarin
,12742279,International Normalized Ratio,"In a fourth group, warfarin (n = 67) was managed and monitored according to normal routines, aiming for an International Normalized Ratio of 2.0 to 3.0.","Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742279/),,2.0 to 3.0,9596,DB00682,Warfarin
,12814453,area under the plasma nifedipine concentration-time curve (AUC0-alpha),The area under the plasma nifedipine concentration-time curve (AUC0-alpha) in nafcillin-pretreated subjects (80.9 +/- 32.9 micro g l-1 h-1) was significantly decreased compared with subjects who received only nifedipine (216.4 +/- 93.2 micro g l-1 h-1) (P < 0.001).,Evidence of an interaction between nifedipine and nafcillin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[μg] / [h·l],80.9,10400,DB00682,Warfarin
,12814453,area under the plasma nifedipine concentration-time curve (AUC0-alpha),The area under the plasma nifedipine concentration-time curve (AUC0-alpha) in nafcillin-pretreated subjects (80.9 +/- 32.9 micro g l-1 h-1) was significantly decreased compared with subjects who received only nifedipine (216.4 +/- 93.2 micro g l-1 h-1) (P < 0.001).,Evidence of an interaction between nifedipine and nafcillin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[μg] / [h·l],216.4,10401,DB00682,Warfarin
,12814453,Total plasma clearance of nifedipine (CL/F),Total plasma clearance of nifedipine (CL/F) was significantly increased with nafcillin pretreatment (138.5 +/- 42.0 l h-1 vs 56.5 +/- 32.0 l h-1) (P < 0.002).,Evidence of an interaction between nifedipine and nafcillin in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[l] / [h],138.5,10402,DB00682,Warfarin
,12814453,Total plasma clearance of nifedipine (CL/F),Total plasma clearance of nifedipine (CL/F) was significantly increased with nafcillin pretreatment (138.5 +/- 42.0 l h-1 vs 56.5 +/- 32.0 l h-1) (P < 0.002).,Evidence of an interaction between nifedipine and nafcillin in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[l] / [h],56.5,10403,DB00682,Warfarin
,17724088,half-life,"A slightly greater value of half-life for (R)-warfarin was observed when coadministered with ciprofloxacin PR compared with warfarin administered alone (52.6 vs 50.1 hours, P = .029).",Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724088/),h,52.6,11612,DB00682,Warfarin
,17724088,half-life,"A slightly greater value of half-life for (R)-warfarin was observed when coadministered with ciprofloxacin PR compared with warfarin administered alone (52.6 vs 50.1 hours, P = .029).",Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724088/),h,50.1,11613,DB00682,Warfarin
,12423514,peak increment,"Both types of FFP exhibited comparable FVII kinetics, with a mean peak increment of 0.10 to 0.12 IU per mL occurring at the end of infusion.",Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12423514/),[iu] / [ml],0.10 to 0.12,13886,DB00682,Warfarin
,8181197,unbound plasma clearance,"The unbound plasma clearance of (R)-warfarin was not significantly (p > 0.05) different between the cystic fibrosis and the control groups (cystic fibrosis, 997 +/- 483 ml/hr/kg; control, 788 +/- 219 ml/hr/kg).",Disposition of drugs in cystic fibrosis. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181197/),[ml] / [h·kg],997,15040,DB00682,Warfarin
,8181197,unbound plasma clearance,"The unbound plasma clearance of (R)-warfarin was not significantly (p > 0.05) different between the cystic fibrosis and the control groups (cystic fibrosis, 997 +/- 483 ml/hr/kg; control, 788 +/- 219 ml/hr/kg).",Disposition of drugs in cystic fibrosis. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181197/),[ml] / [h·kg],788,15041,DB00682,Warfarin
,8181197,unbound metabolic clearances,"The unbound metabolic clearances of (R)-warfarin to its oxidative metabolites--6-hydroxywarfarin, 7-hydroxywarfarin, 8-hydroxywarfarin, and 10-hydroxywarfarin (mediated by P450 3A4)--were also similar (p > 0.05) in the two groups (6-hydroxywarfarin: cystic fibrosis: 124.2 +/- 72.8 ml/hr/kg, control: 99.4 +/- 37.3 ml/hr/kg; 7-hydroxywarfarin: cystic fibrosis: 43.8 +/- 32.2 ml/hr/kg, control: 34.5 +/- 10.6 ml/hr/kg; 8-hydroxywarfarin: cystic fibrosis: 80.4 +/- 85.4 ml/hr/kg, control: 69.5 +/- 39.5 ml/hr/kg; 10-hydroxywarfarin: cystic fibrosis: 4.38 +/- 2.72 ml/hr/kg, control: 16.28 +/- 13.71 ml/hr/kg).",Disposition of drugs in cystic fibrosis. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181197/),[ml] / [h·kg],124.2,15042,DB00682,Warfarin
,8181197,unbound metabolic clearances,"The unbound metabolic clearances of (R)-warfarin to its oxidative metabolites--6-hydroxywarfarin, 7-hydroxywarfarin, 8-hydroxywarfarin, and 10-hydroxywarfarin (mediated by P450 3A4)--were also similar (p > 0.05) in the two groups (6-hydroxywarfarin: cystic fibrosis: 124.2 +/- 72.8 ml/hr/kg, control: 99.4 +/- 37.3 ml/hr/kg; 7-hydroxywarfarin: cystic fibrosis: 43.8 +/- 32.2 ml/hr/kg, control: 34.5 +/- 10.6 ml/hr/kg; 8-hydroxywarfarin: cystic fibrosis: 80.4 +/- 85.4 ml/hr/kg, control: 69.5 +/- 39.5 ml/hr/kg; 10-hydroxywarfarin: cystic fibrosis: 4.38 +/- 2.72 ml/hr/kg, control: 16.28 +/- 13.71 ml/hr/kg).",Disposition of drugs in cystic fibrosis. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181197/),[ml] / [h·kg],99.4,15043,DB00682,Warfarin
,8181197,unbound metabolic clearances,"The unbound metabolic clearances of (R)-warfarin to its oxidative metabolites--6-hydroxywarfarin, 7-hydroxywarfarin, 8-hydroxywarfarin, and 10-hydroxywarfarin (mediated by P450 3A4)--were also similar (p > 0.05) in the two groups (6-hydroxywarfarin: cystic fibrosis: 124.2 +/- 72.8 ml/hr/kg, control: 99.4 +/- 37.3 ml/hr/kg; 7-hydroxywarfarin: cystic fibrosis: 43.8 +/- 32.2 ml/hr/kg, control: 34.5 +/- 10.6 ml/hr/kg; 8-hydroxywarfarin: cystic fibrosis: 80.4 +/- 85.4 ml/hr/kg, control: 69.5 +/- 39.5 ml/hr/kg; 10-hydroxywarfarin: cystic fibrosis: 4.38 +/- 2.72 ml/hr/kg, control: 16.28 +/- 13.71 ml/hr/kg).",Disposition of drugs in cystic fibrosis. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181197/),[ml] / [h·kg],43.8,15044,DB00682,Warfarin
,8181197,unbound metabolic clearances,"The unbound metabolic clearances of (R)-warfarin to its oxidative metabolites--6-hydroxywarfarin, 7-hydroxywarfarin, 8-hydroxywarfarin, and 10-hydroxywarfarin (mediated by P450 3A4)--were also similar (p > 0.05) in the two groups (6-hydroxywarfarin: cystic fibrosis: 124.2 +/- 72.8 ml/hr/kg, control: 99.4 +/- 37.3 ml/hr/kg; 7-hydroxywarfarin: cystic fibrosis: 43.8 +/- 32.2 ml/hr/kg, control: 34.5 +/- 10.6 ml/hr/kg; 8-hydroxywarfarin: cystic fibrosis: 80.4 +/- 85.4 ml/hr/kg, control: 69.5 +/- 39.5 ml/hr/kg; 10-hydroxywarfarin: cystic fibrosis: 4.38 +/- 2.72 ml/hr/kg, control: 16.28 +/- 13.71 ml/hr/kg).",Disposition of drugs in cystic fibrosis. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181197/),[ml] / [h·kg],34.5,15045,DB00682,Warfarin
,8181197,unbound metabolic clearances,"The unbound metabolic clearances of (R)-warfarin to its oxidative metabolites--6-hydroxywarfarin, 7-hydroxywarfarin, 8-hydroxywarfarin, and 10-hydroxywarfarin (mediated by P450 3A4)--were also similar (p > 0.05) in the two groups (6-hydroxywarfarin: cystic fibrosis: 124.2 +/- 72.8 ml/hr/kg, control: 99.4 +/- 37.3 ml/hr/kg; 7-hydroxywarfarin: cystic fibrosis: 43.8 +/- 32.2 ml/hr/kg, control: 34.5 +/- 10.6 ml/hr/kg; 8-hydroxywarfarin: cystic fibrosis: 80.4 +/- 85.4 ml/hr/kg, control: 69.5 +/- 39.5 ml/hr/kg; 10-hydroxywarfarin: cystic fibrosis: 4.38 +/- 2.72 ml/hr/kg, control: 16.28 +/- 13.71 ml/hr/kg).",Disposition of drugs in cystic fibrosis. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181197/),[ml] / [h·kg],80.4,15046,DB00682,Warfarin
,8181197,unbound metabolic clearances,"The unbound metabolic clearances of (R)-warfarin to its oxidative metabolites--6-hydroxywarfarin, 7-hydroxywarfarin, 8-hydroxywarfarin, and 10-hydroxywarfarin (mediated by P450 3A4)--were also similar (p > 0.05) in the two groups (6-hydroxywarfarin: cystic fibrosis: 124.2 +/- 72.8 ml/hr/kg, control: 99.4 +/- 37.3 ml/hr/kg; 7-hydroxywarfarin: cystic fibrosis: 43.8 +/- 32.2 ml/hr/kg, control: 34.5 +/- 10.6 ml/hr/kg; 8-hydroxywarfarin: cystic fibrosis: 80.4 +/- 85.4 ml/hr/kg, control: 69.5 +/- 39.5 ml/hr/kg; 10-hydroxywarfarin: cystic fibrosis: 4.38 +/- 2.72 ml/hr/kg, control: 16.28 +/- 13.71 ml/hr/kg).",Disposition of drugs in cystic fibrosis. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181197/),[ml] / [h·kg],69.5,15047,DB00682,Warfarin
,9342502,oral bioavailability,Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20%.,Clinical pharmacokinetics of nefazodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342502/),%,20,16638,DB00682,Warfarin
,54415,biological half-life,The biological half-life of dicumarol ranged from 5 to 28 hr; that of warfarin ranged from 9 to 30 hr.,Comparative pharmacokinetics of coumarin anticoagulants XV: relationship between pharmacokinetics of dicumarol and warfarin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/54415/),h,5 to 28,17066,DB00682,Warfarin
,54415,biological half-life,The biological half-life of dicumarol ranged from 5 to 28 hr; that of warfarin ranged from 9 to 30 hr.,Comparative pharmacokinetics of coumarin anticoagulants XV: relationship between pharmacokinetics of dicumarol and warfarin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/54415/),h,9 to 30,17067,DB00682,Warfarin
,9105544,plasma radioactivity,"In normal skin mice and rabbits, the plasma radioactivity peaked at 8 h (40.8 ng eq./ml) and at 12 h (34.0 ng eq./ml) after application, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),[eq·ng] / [ml],40.8,17098,DB00682,Warfarin
,9105544,plasma radioactivity,"In normal skin mice and rabbits, the plasma radioactivity peaked at 8 h (40.8 ng eq./ml) and at 12 h (34.0 ng eq./ml) after application, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),[eq·ng] / [ml],34.0,17099,DB00682,Warfarin
,9105544,Percutaneous absorption,"Percutaneous absorption of 14C-Am-80 was less than 2% of the dose for dogs, 34% for mice and 23% for rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,34,17100,DB00682,Warfarin
,9105544,Percutaneous absorption,"Percutaneous absorption of 14C-Am-80 was less than 2% of the dose for dogs, 34% for mice and 23% for rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,23,17101,DB00682,Warfarin
,9105544,half-lives,"After subcutaneous administration at a dose of 1 mg/kg to mice, dogs and rabbits, plasma levels of radioactivity peaked at 1, 4 and 4 h after dosing with a concentration of 614.0, 902.9 and 757.7 ng eq./ml and then it declined with half-lives of 2.4, 7.2 and 4.1 h, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),h,2.4,17102,DB00682,Warfarin
,9105544,half-lives,"After subcutaneous administration at a dose of 1 mg/kg to mice, dogs and rabbits, plasma levels of radioactivity peaked at 1, 4 and 4 h after dosing with a concentration of 614.0, 902.9 and 757.7 ng eq./ml and then it declined with half-lives of 2.4, 7.2 and 4.1 h, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),h,7.2,17103,DB00682,Warfarin
,9105544,half-lives,"After subcutaneous administration at a dose of 1 mg/kg to mice, dogs and rabbits, plasma levels of radioactivity peaked at 1, 4 and 4 h after dosing with a concentration of 614.0, 902.9 and 757.7 ng eq./ml and then it declined with half-lives of 2.4, 7.2 and 4.1 h, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),h,4.1,17104,DB00682,Warfarin
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,3.5,17105,DB00682,Warfarin
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,94.7,17106,DB00682,Warfarin
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,27.0,17107,DB00682,Warfarin
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,73.2,17108,DB00682,Warfarin
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,43.5,17109,DB00682,Warfarin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,3.5,17110,DB00682,Warfarin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,94.7,17111,DB00682,Warfarin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,27.0,17112,DB00682,Warfarin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,73.2,17113,DB00682,Warfarin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,43.5,17114,DB00682,Warfarin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,45.6,17115,DB00682,Warfarin
more,9105544,plasma protein binding,In vivo plasma protein binding of 14C-Am-80 and/or its radioactive metabolites was also found to be more than 98% in rats and dogs after subcutaneous administration of 14C-Am-80.,"Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,98,17116,DB00682,Warfarin
,2407090,apparent volume of distribution,"The drug has a large apparent volume of distribution (approximately 4 liters/kg), exhibits extensive plasma protein binding (approximately 95%) and produces at least 30 metabolites.",Clinical pharmacokinetics of moricizine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),[l] / [kg],4,17631,DB00682,Warfarin
,2407090,plasma protein binding,"The drug has a large apparent volume of distribution (approximately 4 liters/kg), exhibits extensive plasma protein binding (approximately 95%) and produces at least 30 metabolites.",Clinical pharmacokinetics of moricizine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),%,95,17632,DB00682,Warfarin
,2407090,elimination half-life,"The elimination half-life of moricizine is 2 to 6 hours, but its duration of antiarrhythmic action is much longer suggesting active metabolites.",Clinical pharmacokinetics of moricizine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),h,2 to 6,17633,DB00682,Warfarin
,9812177,peak concentrations (Cmax),Mean peak concentrations (Cmax) of 2.86 to 6.50 mg/L were achieved within 1.22 to 2.75 hours of administration.,Clinical pharmacokinetics of nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[mg] / [l],2.86 to 6.50,18714,DB00682,Warfarin
,9812177,bioavailability,"When nimesulide was administered in the suppository form, the Cmax was lower and occurred later than after oral administration; the bioavailability of nimesulide via suppository ranged from 54 to 64%, relative to that of orally administered formulations.",Clinical pharmacokinetics of nimesulide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,54 to 64,18715,DB00682,Warfarin
,9812177,apparent volume of distribution,Nimesulide is rapidly distributed and has an apparent volume of distribution ranging between 0.18 and 0.39 L/kg.,Clinical pharmacokinetics of nimesulide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[l] / [kg],0.18 and 0.39,18716,DB00682,Warfarin
,9812177,unbound fraction,It is extensively bound to albumin; the unbound fraction in plasma was 1%.,Clinical pharmacokinetics of nimesulide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,1,18717,DB00682,Warfarin
,9812177,terminal elimination half-life,The estimated mean terminal elimination half-life varied from 1.80 to 4.73 hours.,Clinical pharmacokinetics of nimesulide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),h,1.80 to 4.73,18718,DB00682,Warfarin
,9812177,total plasma clearance,"The total plasma clearance of nimesulide, was 31.02 to 106.16 ml/h/kg, reflecting almost exclusive metabolic clearance.",Clinical pharmacokinetics of nimesulide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[ml] / [h·kg],31.02 to 106.16,18719,DB00682,Warfarin
,9812177,extraction ratio,"The drug has a low extraction ratio, close to 0.1.",Clinical pharmacokinetics of nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),,0.1,18720,DB00682,Warfarin
,25002684,linear dynamic,"The assay exhibited a linear dynamic range of 2.50-3,000 ng/mL for karanjin.",Development and validation of an LC-MS method for determination of Karanjin in rat plasma: application to preclinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25002684/),[ng] / [ml],"2.50-3,000",21257,DB00682,Warfarin
,5440596,half-life,The mean cephaloridine half-life was 10.4 hours.,Cephaloridine serum levels in patients on maintenance haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5440596/),h,10.4,21681,DB00682,Warfarin
,32403135,flow-rate,"Chromatographic resolution of SAFit-1, SAFit-2 and the internal standard (warfarin) was achieved on an X-Terra phenyl column using 0.2% formic acid:acetonitrile (20:80, v/v) as an eluent, which was delivered at a flow-rate of 0.9 mL/min.",Validated LC-MS/MS Method for Simultaneous Quantitation of SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403135/),[ml] / [min],0.9,21744,DB00682,Warfarin
,32403135,m/,"The MS/MS ion transitions monitored were m/z 748.4→420.4, 803.7→384.3 and 309.2 →163.2 for SAFit-1, SAFit-2 and the internal standard, respectively.",Validated LC-MS/MS Method for Simultaneous Quantitation of SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403135/),,748.4,21745,DB00682,Warfarin
,32403135,m/,"The MS/MS ion transitions monitored were m/z 748.4→420.4, 803.7→384.3 and 309.2 →163.2 for SAFit-1, SAFit-2 and the internal standard, respectively.",Validated LC-MS/MS Method for Simultaneous Quantitation of SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403135/),,420.4,21746,DB00682,Warfarin
,32403135,m/,"The MS/MS ion transitions monitored were m/z 748.4→420.4, 803.7→384.3 and 309.2 →163.2 for SAFit-1, SAFit-2 and the internal standard, respectively.",Validated LC-MS/MS Method for Simultaneous Quantitation of SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403135/),,803.7,21747,DB00682,Warfarin
,32403135,m/,"The MS/MS ion transitions monitored were m/z 748.4→420.4, 803.7→384.3 and 309.2 →163.2 for SAFit-1, SAFit-2 and the internal standard, respectively.",Validated LC-MS/MS Method for Simultaneous Quantitation of SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403135/),,309.2,21748,DB00682,Warfarin
,1763520,whole-body,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,10.2,21980,DB00682,Warfarin
,1763520,whole-body,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,1.2,21981,DB00682,Warfarin
,1763520,half-life,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,10.2,21982,DB00682,Warfarin
,1763520,half-life,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,1.2,21983,DB00682,Warfarin
,1763520,half-life,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,0.37,21984,DB00682,Warfarin
,30411284,Elimination half-lives,Elimination half-lives could be estimated in eight patients and ranged between 14.6 and 59.7 h (median 21.6).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,21.6,22073,DB00682,Warfarin
,30411284,waiting time for,The observed waiting time for surgery was longer for patients using DOACs than warfarin (median 44 vs. 25 h).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,44,22074,DB00682,Warfarin
,30411284,waiting time for,The observed waiting time for surgery was longer for patients using DOACs than warfarin (median 44 vs. 25 h).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,25,22075,DB00682,Warfarin
,26829518,association constant K(A),"The association constant K(A) (L mol(-1)) of the binding reaches 10(6) order of magnitude, which is significantly stronger than the other components of propolis.",Caffeic acid phenethyl ester exhibiting distinctive binding interaction with human serum albumin implies the pharmacokinetic basis of propolis bioactive components. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829518/),order,10,22687,DB00682,Warfarin
,26829518,binding distance,"Based on the theory of fluorescence resonance energy transfer, the binding distance was calculated as 5.7 nm, which is longer than that of the other components of propolis.",Caffeic acid phenethyl ester exhibiting distinctive binding interaction with human serum albumin implies the pharmacokinetic basis of propolis bioactive components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829518/),nm,5.7,22688,DB00682,Warfarin
,30822797,oral bioavailability,The oral bioavailability was 48%.,"Quantitation of Ivosidenib, A Novel Mutant IDH1 Inhibitoron Mice DBS: Application to a Pharmacokinetic Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30822797/),%,48,22826,DB00682,Warfarin
,11168909,t1/2,"Median pharmacokinetic parameters associated with the intravenous administration of 0.5 mg/kg racemic warfarin were as follows: t1/2 (S:28.2, R:18.3 h), area under the plasma concentration-time curve (AUC; S:33.0, R:24.6 h*microg/mL), area under the moment curve (AUMC; S:1889, R:527.8 h*h*microg/mL), and mean residence time (MRT; S:38.7, R:20.9 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),h,28.2,23567,DB00682,Warfarin
,11168909,t1/2,"Median pharmacokinetic parameters associated with the intravenous administration of 0.5 mg/kg racemic warfarin were as follows: t1/2 (S:28.2, R:18.3 h), area under the plasma concentration-time curve (AUC; S:33.0, R:24.6 h*microg/mL), area under the moment curve (AUMC; S:1889, R:527.8 h*h*microg/mL), and mean residence time (MRT; S:38.7, R:20.9 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),h,18.3,23568,DB00682,Warfarin
,11168909,area under the plasma concentration-time curve (AUC,"Median pharmacokinetic parameters associated with the intravenous administration of 0.5 mg/kg racemic warfarin were as follows: t1/2 (S:28.2, R:18.3 h), area under the plasma concentration-time curve (AUC; S:33.0, R:24.6 h*microg/mL), area under the moment curve (AUMC; S:1889, R:527.8 h*h*microg/mL), and mean residence time (MRT; S:38.7, R:20.9 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),[h·μg] / [ml],33.0,23569,DB00682,Warfarin
,11168909,area under the plasma concentration-time curve (AUC,"Median pharmacokinetic parameters associated with the intravenous administration of 0.5 mg/kg racemic warfarin were as follows: t1/2 (S:28.2, R:18.3 h), area under the plasma concentration-time curve (AUC; S:33.0, R:24.6 h*microg/mL), area under the moment curve (AUMC; S:1889, R:527.8 h*h*microg/mL), and mean residence time (MRT; S:38.7, R:20.9 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),[h·μg] / [ml],24.6,23570,DB00682,Warfarin
,11168909,area under the moment curve (AUMC,"Median pharmacokinetic parameters associated with the intravenous administration of 0.5 mg/kg racemic warfarin were as follows: t1/2 (S:28.2, R:18.3 h), area under the plasma concentration-time curve (AUC; S:33.0, R:24.6 h*microg/mL), area under the moment curve (AUMC; S:1889, R:527.8 h*h*microg/mL), and mean residence time (MRT; S:38.7, R:20.9 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),[h·h·μg] / [ml],1889,23571,DB00682,Warfarin
,11168909,area under the moment curve (AUMC,"Median pharmacokinetic parameters associated with the intravenous administration of 0.5 mg/kg racemic warfarin were as follows: t1/2 (S:28.2, R:18.3 h), area under the plasma concentration-time curve (AUC; S:33.0, R:24.6 h*microg/mL), area under the moment curve (AUMC; S:1889, R:527.8 h*h*microg/mL), and mean residence time (MRT; S:38.7, R:20.9 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),[h·h·μg] / [ml],527.8,23572,DB00682,Warfarin
,11168909,mean residence time (MRT,"Median pharmacokinetic parameters associated with the intravenous administration of 0.5 mg/kg racemic warfarin were as follows: t1/2 (S:28.2, R:18.3 h), area under the plasma concentration-time curve (AUC; S:33.0, R:24.6 h*microg/mL), area under the moment curve (AUMC; S:1889, R:527.8 h*h*microg/mL), and mean residence time (MRT; S:38.7, R:20.9 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),h,38.7,23573,DB00682,Warfarin
,11168909,mean residence time (MRT,"Median pharmacokinetic parameters associated with the intravenous administration of 0.5 mg/kg racemic warfarin were as follows: t1/2 (S:28.2, R:18.3 h), area under the plasma concentration-time curve (AUC; S:33.0, R:24.6 h*microg/mL), area under the moment curve (AUMC; S:1889, R:527.8 h*h*microg/mL), and mean residence time (MRT; S:38.7, R:20.9 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),h,20.9,23574,DB00682,Warfarin
,11168909,AU,"Oral dosage significantly influenced maximum plasma concentration (ng/mL, S:1267, R:1355 at 0.5 mg/kg; S:614.9, R:679.4 at 0.25 mg/kg; S:250.5, R:367.6 at 0.1 mg/kg), AUC (h*microg/mL, S:45.12, R:30.91 at 0.5 mg/kg; S:22.98:, R:18.99 at 0.25 mg/kg; S:3.922, R:3.570 at 0.1 mg/kg) and AUMC (h*h*microg/mL, S:2135, R:1062 at 0.5 mg/kg; S:943.1, R:599.9 at 0.25 mg/kg; S:132.2, R:59.03 at 0.1 mg/kg), but not t1/2 (S:23.5, R:11.6 h) nor MRT (S:26.3, R:13.5 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),[h·μg] / [ml],30,23575,DB00682,Warfarin
,11168909,AU,"Oral dosage significantly influenced maximum plasma concentration (ng/mL, S:1267, R:1355 at 0.5 mg/kg; S:614.9, R:679.4 at 0.25 mg/kg; S:250.5, R:367.6 at 0.1 mg/kg), AUC (h*microg/mL, S:45.12, R:30.91 at 0.5 mg/kg; S:22.98:, R:18.99 at 0.25 mg/kg; S:3.922, R:3.570 at 0.1 mg/kg) and AUMC (h*h*microg/mL, S:2135, R:1062 at 0.5 mg/kg; S:943.1, R:599.9 at 0.25 mg/kg; S:132.2, R:59.03 at 0.1 mg/kg), but not t1/2 (S:23.5, R:11.6 h) nor MRT (S:26.3, R:13.5 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),[h·μg] / [ml],22,23576,DB00682,Warfarin
,11168909,AUMC,"Oral dosage significantly influenced maximum plasma concentration (ng/mL, S:1267, R:1355 at 0.5 mg/kg; S:614.9, R:679.4 at 0.25 mg/kg; S:250.5, R:367.6 at 0.1 mg/kg), AUC (h*microg/mL, S:45.12, R:30.91 at 0.5 mg/kg; S:22.98:, R:18.99 at 0.25 mg/kg; S:3.922, R:3.570 at 0.1 mg/kg) and AUMC (h*h*microg/mL, S:2135, R:1062 at 0.5 mg/kg; S:943.1, R:599.9 at 0.25 mg/kg; S:132.2, R:59.03 at 0.1 mg/kg), but not t1/2 (S:23.5, R:11.6 h) nor MRT (S:26.3, R:13.5 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),[h·h·μg] / [ml],213,23577,DB00682,Warfarin
,11168909,AUMC,"Oral dosage significantly influenced maximum plasma concentration (ng/mL, S:1267, R:1355 at 0.5 mg/kg; S:614.9, R:679.4 at 0.25 mg/kg; S:250.5, R:367.6 at 0.1 mg/kg), AUC (h*microg/mL, S:45.12, R:30.91 at 0.5 mg/kg; S:22.98:, R:18.99 at 0.25 mg/kg; S:3.922, R:3.570 at 0.1 mg/kg) and AUMC (h*h*microg/mL, S:2135, R:1062 at 0.5 mg/kg; S:943.1, R:599.9 at 0.25 mg/kg; S:132.2, R:59.03 at 0.1 mg/kg), but not t1/2 (S:23.5, R:11.6 h) nor MRT (S:26.3, R:13.5 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),[h·h·μg] / [ml],943,23578,DB00682,Warfarin
,11168909,AUMC,"Oral dosage significantly influenced maximum plasma concentration (ng/mL, S:1267, R:1355 at 0.5 mg/kg; S:614.9, R:679.4 at 0.25 mg/kg; S:250.5, R:367.6 at 0.1 mg/kg), AUC (h*microg/mL, S:45.12, R:30.91 at 0.5 mg/kg; S:22.98:, R:18.99 at 0.25 mg/kg; S:3.922, R:3.570 at 0.1 mg/kg) and AUMC (h*h*microg/mL, S:2135, R:1062 at 0.5 mg/kg; S:943.1, R:599.9 at 0.25 mg/kg; S:132.2, R:59.03 at 0.1 mg/kg), but not t1/2 (S:23.5, R:11.6 h) nor MRT (S:26.3, R:13.5 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),[h·h·μg] / [ml],132.,23579,DB00682,Warfarin
,11168909,t1/2,"Oral dosage significantly influenced maximum plasma concentration (ng/mL, S:1267, R:1355 at 0.5 mg/kg; S:614.9, R:679.4 at 0.25 mg/kg; S:250.5, R:367.6 at 0.1 mg/kg), AUC (h*microg/mL, S:45.12, R:30.91 at 0.5 mg/kg; S:22.98:, R:18.99 at 0.25 mg/kg; S:3.922, R:3.570 at 0.1 mg/kg) and AUMC (h*h*microg/mL, S:2135, R:1062 at 0.5 mg/kg; S:943.1, R:599.9 at 0.25 mg/kg; S:132.2, R:59.03 at 0.1 mg/kg), but not t1/2 (S:23.5, R:11.6 h) nor MRT (S:26.3, R:13.5 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),h,23.5,23580,DB00682,Warfarin
,11168909,t1/2,"Oral dosage significantly influenced maximum plasma concentration (ng/mL, S:1267, R:1355 at 0.5 mg/kg; S:614.9, R:679.4 at 0.25 mg/kg; S:250.5, R:367.6 at 0.1 mg/kg), AUC (h*microg/mL, S:45.12, R:30.91 at 0.5 mg/kg; S:22.98:, R:18.99 at 0.25 mg/kg; S:3.922, R:3.570 at 0.1 mg/kg) and AUMC (h*h*microg/mL, S:2135, R:1062 at 0.5 mg/kg; S:943.1, R:599.9 at 0.25 mg/kg; S:132.2, R:59.03 at 0.1 mg/kg), but not t1/2 (S:23.5, R:11.6 h) nor MRT (S:26.3, R:13.5 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),h,11.6,23581,DB00682,Warfarin
,11168909,MRT,"Oral dosage significantly influenced maximum plasma concentration (ng/mL, S:1267, R:1355 at 0.5 mg/kg; S:614.9, R:679.4 at 0.25 mg/kg; S:250.5, R:367.6 at 0.1 mg/kg), AUC (h*microg/mL, S:45.12, R:30.91 at 0.5 mg/kg; S:22.98:, R:18.99 at 0.25 mg/kg; S:3.922, R:3.570 at 0.1 mg/kg) and AUMC (h*h*microg/mL, S:2135, R:1062 at 0.5 mg/kg; S:943.1, R:599.9 at 0.25 mg/kg; S:132.2, R:59.03 at 0.1 mg/kg), but not t1/2 (S:23.5, R:11.6 h) nor MRT (S:26.3, R:13.5 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),h,26.3,23582,DB00682,Warfarin
,11168909,MRT,"Oral dosage significantly influenced maximum plasma concentration (ng/mL, S:1267, R:1355 at 0.5 mg/kg; S:614.9, R:679.4 at 0.25 mg/kg; S:250.5, R:367.6 at 0.1 mg/kg), AUC (h*microg/mL, S:45.12, R:30.91 at 0.5 mg/kg; S:22.98:, R:18.99 at 0.25 mg/kg; S:3.922, R:3.570 at 0.1 mg/kg) and AUMC (h*h*microg/mL, S:2135, R:1062 at 0.5 mg/kg; S:943.1, R:599.9 at 0.25 mg/kg; S:132.2, R:59.03 at 0.1 mg/kg), but not t1/2 (S:23.5, R:11.6 h) nor MRT (S:26.3, R:13.5 h).",Plasma pharmacokinetics of warfarin enantiomers in cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168909/),h,13.5,23583,DB00682,Warfarin
,19188097,flow rate,"After vortex mixing and centrifugation, the supernatants were diluted with water (1:5) and then directly injected onto a Phenomenex Synergi Max RP column (75 mm x 2.0 mm ID, 4 microm) with isocratic elution at a flow rate of 0.2 mL/min.",Determination of visnagin in rat plasma by liquid chromatography with tandem mass spectrometry and its application to in vivo pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188097/),[ml] / [min],0.2,25829,DB00682,Warfarin
less,19188097,total run time,The total run time (injection to injection) was less than 4 min.,Determination of visnagin in rat plasma by liquid chromatography with tandem mass spectrometry and its application to in vivo pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188097/),min,4,25830,DB00682,Warfarin
,10497145,K(i),"In vitro studies with recombinant human cytochrome P-450 2C9 and liver microsomes showed that bucolome was a potent mixed-type inhibitor for (S)-warfarin 7-hydroxylation, with K(i) of 8.2 and 20.2 microM, respectively.","Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497145/),μM,8.2,26760,DB00682,Warfarin
,10497145,K(i),"In vitro studies with recombinant human cytochrome P-450 2C9 and liver microsomes showed that bucolome was a potent mixed-type inhibitor for (S)-warfarin 7-hydroxylation, with K(i) of 8.2 and 20.2 microM, respectively.","Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497145/),μM,20.2,26761,DB00682,Warfarin
,15315768,total run time,Chromatographic separation was achieved on a reversed-phase Luna C18 column and step gradient elution resulted in a total run time of about 13 min.,"Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315768/),min,13,27254,DB00682,Warfarin
<,15315768,limit of detection (LOD),Limits of quantification (LOQ) were < or = 40 nM for the parent compounds and < or = 25 nM for the metabolites and the limit of detection (LOD) was < or = 2.5 nM for all analytes.,"Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315768/),nM,2.5,27255,DB00682,Warfarin
,15315768,recovery,"Average recovery was 84% (+/- 3.7) and 74% (+/- 13.2) in plasma and urine, respectively.","Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315768/),%,84,27256,DB00682,Warfarin
,15315768,recovery,"Average recovery was 84% (+/- 3.7) and 74% (+/- 13.2) in plasma and urine, respectively.","Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315768/),%,74,27257,DB00682,Warfarin
,4819677,half-life,The mean plasma warfarin half-life was 36.3 +/- 3.5 hours by liquid chromatography but 55.9 +/- 8.4 hours by a currently used fluorimetric assay that fails to separate warfarin from its metabolites.,Liquid chromatographic assay of warfarin: similarity of warfarin half-lives in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4819677/),h,36.3,27442,DB00682,Warfarin
,4819677,half-life,The mean plasma warfarin half-life was 36.3 +/- 3.5 hours by liquid chromatography but 55.9 +/- 8.4 hours by a currently used fluorimetric assay that fails to separate warfarin from its metabolites.,Liquid chromatographic assay of warfarin: similarity of warfarin half-lives in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4819677/),h,55.9,27443,DB00682,Warfarin
,26114209,Bioavailabilities,"3. Bioavailabilities were ∼100% for caffeine and warfarin, but <25% for omeprazole and metoprolol.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,∼100,27489,DB00682,Warfarin
<,26114209,Bioavailabilities,"3. Bioavailabilities were ∼100% for caffeine and warfarin, but <25% for omeprazole and metoprolol.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,25,27490,DB00682,Warfarin
,26114209,Bioavailability,"Bioavailability of midazolam was 4% in marmosets, presumably because of contribution of marmoset P450 3A4 expressed in small intestine and liver, with a high catalytic efficiency for midazolam 1'-hydroxylation as evident in the recombinant system.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,4,27491,DB00682,Warfarin
,8220911,Kis,6. Sulphaphenazole competitively inhibits the 7- and in some samples partly (up to 50%) the 6-hydroxylation of S-warfarin as well as the 7-hydroxylation of R- and S-acenocoumarol and the 6-hydroxylation of S-acenocoumarol (Kis ranging from 0.5-1.3 microM).,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,0.5-1.3,27727,DB00682,Warfarin
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,99,27728,DB00682,Warfarin
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,117,27729,DB00682,Warfarin
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,219,27730,DB00682,Warfarin
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,7.2,27731,DB00682,Warfarin
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,6.1,27732,DB00682,Warfarin
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,7.7,27733,DB00682,Warfarin
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],659.8,27752,DB00682,Warfarin
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],878.1,27753,DB00682,Warfarin
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],1125.2,27754,DB00682,Warfarin
,17295362,AUC,"After oral administration of warfarin at a dose of 2 mg/kg to male rats with oxolamine at doses of 10 and 50 mg/kg, the AUC values of warfarin were significantly greater than the controls (254 and 330 versus 180 microg h/ml).",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[h·μg] / [ml],254,28416,DB00682,Warfarin
,17295362,AUC,"After oral administration of warfarin at a dose of 2 mg/kg to male rats with oxolamine at doses of 10 and 50 mg/kg, the AUC values of warfarin were significantly greater than the controls (254 and 330 versus 180 microg h/ml).",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[h·μg] / [ml],330,28417,DB00682,Warfarin
,17295362,AUC,"After oral administration of warfarin at a dose of 2 mg/kg to male rats with oxolamine at doses of 10 and 50 mg/kg, the AUC values of warfarin were significantly greater than the controls (254 and 330 versus 180 microg h/ml).",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[h·μg] / [ml],180,28418,DB00682,Warfarin
,17295362,AUC,"After oral oxolamine at doses of 10 and 50 mg/kg, the AUC of phenytoin was significantly greater (1280 and 1640 versus 938 microg min/ml), however, the AUC values of torasemide and clarithromycin were independent of oxolamine.",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[min·μg] / [ml],1280,28419,DB00682,Warfarin
,17295362,AUC,"After oral oxolamine at doses of 10 and 50 mg/kg, the AUC of phenytoin was significantly greater (1280 and 1640 versus 938 microg min/ml), however, the AUC values of torasemide and clarithromycin were independent of oxolamine.",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[min·μg] / [ml],1640,28420,DB00682,Warfarin
,17295362,AUC,"After oral oxolamine at doses of 10 and 50 mg/kg, the AUC of phenytoin was significantly greater (1280 and 1640 versus 938 microg min/ml), however, the AUC values of torasemide and clarithromycin were independent of oxolamine.",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[min·μg] / [ml],938,28421,DB00682,Warfarin
,16697485,absolute bioavailabilities,Mean absolute bioavailabilities were 51% and 59% for the two tested doses.,Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16697485/),%,51,29171,DB00682,Warfarin
,16697485,absolute bioavailabilities,Mean absolute bioavailabilities were 51% and 59% for the two tested doses.,Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16697485/),%,59,29172,DB00682,Warfarin
,29436624,times,"In addition, the mean and median times for patients to obtain a stable dose in the experimental group were significantly shorter than those in the control group (mean, 18.2±1.7 and 27.3±2.0 days; and median, 11.7±1.1 and 20.5±1.8 days, respectively).",Clinical verification of Lou type warfarin pharmacokinetic dosing algorithms equation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436624/),d,18.2,30040,DB00682,Warfarin
,29436624,times,"In addition, the mean and median times for patients to obtain a stable dose in the experimental group were significantly shorter than those in the control group (mean, 18.2±1.7 and 27.3±2.0 days; and median, 11.7±1.1 and 20.5±1.8 days, respectively).",Clinical verification of Lou type warfarin pharmacokinetic dosing algorithms equation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436624/),d,27.3,30041,DB00682,Warfarin
,29436624,times,"In addition, the mean and median times for patients to obtain a stable dose in the experimental group were significantly shorter than those in the control group (mean, 18.2±1.7 and 27.3±2.0 days; and median, 11.7±1.1 and 20.5±1.8 days, respectively).",Clinical verification of Lou type warfarin pharmacokinetic dosing algorithms equation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436624/),d,11.7,30042,DB00682,Warfarin
,29436624,times,"In addition, the mean and median times for patients to obtain a stable dose in the experimental group were significantly shorter than those in the control group (mean, 18.2±1.7 and 27.3±2.0 days; and median, 11.7±1.1 and 20.5±1.8 days, respectively).",Clinical verification of Lou type warfarin pharmacokinetic dosing algorithms equation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436624/),d,20.5,30043,DB00682,Warfarin
,29436624,adverse reaction rate,The adverse reaction rate of the experimental group (9.5%) was markedly lower than that of the control group (26.7%).,Clinical verification of Lou type warfarin pharmacokinetic dosing algorithms equation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436624/),%,9.5,30044,DB00682,Warfarin
,29436624,adverse reaction rate,The adverse reaction rate of the experimental group (9.5%) was markedly lower than that of the control group (26.7%).,Clinical verification of Lou type warfarin pharmacokinetic dosing algorithms equation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436624/),%,26.7,30045,DB00682,Warfarin
,29436624,adverse reactions,"The occurrence of adverse reactions in the experimental group was also significantly later when compared with the control group (43.9±1.6 and 38.6±1.5 days, respectively).",Clinical verification of Lou type warfarin pharmacokinetic dosing algorithms equation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436624/),d,43.9,30046,DB00682,Warfarin
,29436624,adverse reactions,"The occurrence of adverse reactions in the experimental group was also significantly later when compared with the control group (43.9±1.6 and 38.6±1.5 days, respectively).",Clinical verification of Lou type warfarin pharmacokinetic dosing algorithms equation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436624/),d,38.6,30047,DB00682,Warfarin
,11673753,E(max),The mean E(max) (maximum increase in the QTc interval for the E(max) models) was a 61.7 ms increase from baseline.,A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673753/),ms,61.7,31488,DB00682,Warfarin
,6674482,saliva vs. plasma (S/P) ratio,The saliva vs. plasma (S/P) ratio was approximately 0.07.,Salivary excretion of warfarin in rabbits: relationship between pharmacological effect and salivary pharmacokinetics of warfarin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6674482/),,0.07,32172,DB00682,Warfarin
,6674482,saliva vs.,The saliva vs. plasma protein-unbound fraction (S/Pf) ratio was approximately 0.92.,Salivary excretion of warfarin in rabbits: relationship between pharmacological effect and salivary pharmacokinetics of warfarin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6674482/),,0.92,32173,DB00682,Warfarin
,6674482,plasma protein-unbound fraction (S/Pf) ratio,The saliva vs. plasma protein-unbound fraction (S/Pf) ratio was approximately 0.92.,Salivary excretion of warfarin in rabbits: relationship between pharmacological effect and salivary pharmacokinetics of warfarin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6674482/),,0.92,32174,DB00682,Warfarin
,19609394,flow rate,"Griseofulvin and warfarin were baseline separated and quantitated on a C(18) reversed phase column (4.6 x 150 mm, 3.5 microm), using a mobile phase composed of a 20 mM aqueous solution of sodium dihydrogen phosphate-acetonitrile (55:45, v/v, pH 3.5) delivered at a flow rate of 1.0 mL/min, and with fluorescence detection (lambda(excitation) = 300 nm, lambda(emission) = 418 nm).",Development and validation of a HPLC method to determine griseofulvin in rat plasma: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19609394/),[ml] / [min],1.0,34886,DB00682,Warfarin
,19609394,recovery,The mean recovery of griseofulvin from rat plasma was found to be 99.2%.,Development and validation of a HPLC method to determine griseofulvin in rat plasma: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19609394/),%,99.2,34887,DB00682,Warfarin
,19609394,limit of detection (LOD),"The limit of detection (LOD) and the limit of quantification (LOQ) of griseofulvin were determined to be 1 ng/mL and 10 ng/mL, respectively.",Development and validation of a HPLC method to determine griseofulvin in rat plasma: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19609394/),[ng] / [ml],1,34888,DB00682,Warfarin
,19609394,limit of quantification (LOQ),"The limit of detection (LOD) and the limit of quantification (LOQ) of griseofulvin were determined to be 1 ng/mL and 10 ng/mL, respectively.",Development and validation of a HPLC method to determine griseofulvin in rat plasma: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19609394/),,10,34889,DB00682,Warfarin
,3061720,systemic bioavailability,"It is well absorbed after oral administration, but systemic bioavailability is only 12% after a 300-mg dose.",Propafenone: a new antiarrhythmic agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),%,12,37633,DB00682,Warfarin
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,5.5,37634,DB00682,Warfarin
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,17.2,37635,DB00682,Warfarin
,31542982,area under the curve,"The pharmacokinetic results indicated that co-administration of GA could increase the systemic exposure of warfarin, including area under the curve (48.87 ± 2.89 µg·h·mL-1 without GA versus 58.63 ± 1.90 µg·h·mL-1 with GA), maximum plasma concentration and t1/2.",Influence of glycyrrhetinic acid on the pharmacokinetics of warfarin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542982/),[h·μg] / [ml],48.87,38733,DB00682,Warfarin
,31542982,area under the curve,"The pharmacokinetic results indicated that co-administration of GA could increase the systemic exposure of warfarin, including area under the curve (48.87 ± 2.89 µg·h·mL-1 without GA versus 58.63 ± 1.90 µg·h·mL-1 with GA), maximum plasma concentration and t1/2.",Influence of glycyrrhetinic acid on the pharmacokinetics of warfarin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542982/),[h·μg] / [ml],58.63,38734,DB00682,Warfarin
,31542982,metabolic stability,The metabolic stability of warfarin increased from 23.8 ± 5.9 to 41.4 ± 7.1 min with the pretreatment of GA.5.,Influence of glycyrrhetinic acid on the pharmacokinetics of warfarin in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542982/),min,23.8,38735,DB00682,Warfarin
,31542982,metabolic stability,The metabolic stability of warfarin increased from 23.8 ± 5.9 to 41.4 ± 7.1 min with the pretreatment of GA.5.,Influence of glycyrrhetinic acid on the pharmacokinetics of warfarin in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542982/),min,41.4,38736,DB00682,Warfarin
,29983086,area under the curve,"The pharmacokinetic results indicated that co-administration of andrographolide could increase the systemic exposure of warfarin significantly, including area under the curve (118.92 ± 18.08 vs. 60.58 ± 9.46 μg × h/mL), maximum plasma concentration (3.32 ± 0.41 vs. 2.35 ± 0.25 μg/mL) and t1/2 (22.73 ± 3.28 vs. 14.27 ± 2.67 h).",Influence of andrographolide on the pharmacokinetics of warfarin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29983086/),[h·μg] / [ml],118.92,39217,DB00682,Warfarin
,29983086,area under the curve,"The pharmacokinetic results indicated that co-administration of andrographolide could increase the systemic exposure of warfarin significantly, including area under the curve (118.92 ± 18.08 vs. 60.58 ± 9.46 μg × h/mL), maximum plasma concentration (3.32 ± 0.41 vs. 2.35 ± 0.25 μg/mL) and t1/2 (22.73 ± 3.28 vs. 14.27 ± 2.67 h).",Influence of andrographolide on the pharmacokinetics of warfarin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29983086/),[h·μg] / [ml],60.58,39218,DB00682,Warfarin
,29983086,maximum plasma concentration,"The pharmacokinetic results indicated that co-administration of andrographolide could increase the systemic exposure of warfarin significantly, including area under the curve (118.92 ± 18.08 vs. 60.58 ± 9.46 μg × h/mL), maximum plasma concentration (3.32 ± 0.41 vs. 2.35 ± 0.25 μg/mL) and t1/2 (22.73 ± 3.28 vs. 14.27 ± 2.67 h).",Influence of andrographolide on the pharmacokinetics of warfarin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29983086/),[μg] / [ml],3.32,39219,DB00682,Warfarin
,29983086,maximum plasma concentration,"The pharmacokinetic results indicated that co-administration of andrographolide could increase the systemic exposure of warfarin significantly, including area under the curve (118.92 ± 18.08 vs. 60.58 ± 9.46 μg × h/mL), maximum plasma concentration (3.32 ± 0.41 vs. 2.35 ± 0.25 μg/mL) and t1/2 (22.73 ± 3.28 vs. 14.27 ± 2.67 h).",Influence of andrographolide on the pharmacokinetics of warfarin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29983086/),[μg] / [ml],2.35,39220,DB00682,Warfarin
,29983086,t1/2,"The pharmacokinetic results indicated that co-administration of andrographolide could increase the systemic exposure of warfarin significantly, including area under the curve (118.92 ± 18.08 vs. 60.58 ± 9.46 μg × h/mL), maximum plasma concentration (3.32 ± 0.41 vs. 2.35 ± 0.25 μg/mL) and t1/2 (22.73 ± 3.28 vs. 14.27 ± 2.67 h).",Influence of andrographolide on the pharmacokinetics of warfarin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29983086/),h,22.73,39221,DB00682,Warfarin
,29983086,t1/2,"The pharmacokinetic results indicated that co-administration of andrographolide could increase the systemic exposure of warfarin significantly, including area under the curve (118.92 ± 18.08 vs. 60.58 ± 9.46 μg × h/mL), maximum plasma concentration (3.32 ± 0.41 vs. 2.35 ± 0.25 μg/mL) and t1/2 (22.73 ± 3.28 vs. 14.27 ± 2.67 h).",Influence of andrographolide on the pharmacokinetics of warfarin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29983086/),h,14.27,39222,DB00682,Warfarin
,29983086,metabolic stability,"Additionally, the metabolic stability of warfarin increased from 23.5 ± 4.7 to 38.7 ± 6.1 min with the pretreatment of andrographolide, and the difference was significant (p < 0.05).",Influence of andrographolide on the pharmacokinetics of warfarin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29983086/),min,23.5,39223,DB00682,Warfarin
,29983086,metabolic stability,"Additionally, the metabolic stability of warfarin increased from 23.5 ± 4.7 to 38.7 ± 6.1 min with the pretreatment of andrographolide, and the difference was significant (p < 0.05).",Influence of andrographolide on the pharmacokinetics of warfarin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29983086/),min,38.7,39224,DB00682,Warfarin
,29433307,Michaelis-Menten constant ( Km),"Using stably transfected HEK293 cells, both enantiomers were found to be substrates of organic anion transporter (OAT)2 with a Michaelis-Menten constant ( Km) of ∼7-12 μM but did not show substrate affinity for other major hepatic uptake transporters.",Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29433307/),μM,∼7-12,41110,DB00682,Warfarin
,29433307,Km,"Uptake of both enantiomers by primary human hepatocytes was saturable ( Km ≈ 7-10 μM) and inhibitable by OAT2 inhibitors (e.g., ketoprofen) but not by OATP1B1/1B3 inhibitors (e.g., cyclosporine).",Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29433307/),μM,7-10,41111,DB00682,Warfarin
,11740344,elimination half-life,She exhibited extremely poor clearance of phenytoin with an elimination half-life of approximately 13 days.,Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11740344/),d,13,42025,DB00682,Warfarin
,22531852,size,"Microparticle size and encapsulation efficiencies ranged from 54.0 to 80.0 μm and 37.0 to 47.0%, respectively.",Evaluation of subcutaneous forms in the improvement of pharmacokinetic profile of warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22531852/),μm,54.0 to 80.0,44544,DB00682,Warfarin
,22531852,encapsulation efficiencies,"Microparticle size and encapsulation efficiencies ranged from 54.0 to 80.0 μm and 37.0 to 47.0%, respectively.",Evaluation of subcutaneous forms in the improvement of pharmacokinetic profile of warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22531852/),%,37.0 to 47.0,44545,DB00682,Warfarin
,22531852,drug release,"After 72 h, warfarin microparticles exhibited in vitro drug release ranging from 62.0 to 80.0%.",Evaluation of subcutaneous forms in the improvement of pharmacokinetic profile of warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22531852/),%,62.0 to 80.0,44546,DB00682,Warfarin
,22531852,relative bioavailabilities,"The observed relative bioavailabilities calculated from plasma concentrations and prothrombin times were 54.2 and 92.1%, and 61.8 and 61.4% for suspension and microparticles, respectively.",Evaluation of subcutaneous forms in the improvement of pharmacokinetic profile of warfarin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22531852/),%,54.2,44547,DB00682,Warfarin
,22531852,relative bioavailabilities,"The observed relative bioavailabilities calculated from plasma concentrations and prothrombin times were 54.2 and 92.1%, and 61.8 and 61.4% for suspension and microparticles, respectively.",Evaluation of subcutaneous forms in the improvement of pharmacokinetic profile of warfarin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22531852/),%,92.1,44548,DB00682,Warfarin
,22531852,relative bioavailabilities,"The observed relative bioavailabilities calculated from plasma concentrations and prothrombin times were 54.2 and 92.1%, and 61.8 and 61.4% for suspension and microparticles, respectively.",Evaluation of subcutaneous forms in the improvement of pharmacokinetic profile of warfarin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22531852/),%,61.8,44549,DB00682,Warfarin
,22531852,relative bioavailabilities,"The observed relative bioavailabilities calculated from plasma concentrations and prothrombin times were 54.2 and 92.1%, and 61.8 and 61.4% for suspension and microparticles, respectively.",Evaluation of subcutaneous forms in the improvement of pharmacokinetic profile of warfarin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22531852/),%,61.4,44550,DB00682,Warfarin
,2938614,plasma half-life,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),h,47.8,45288,DB00682,Warfarin
,2938614,plasma half-life,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),h,57.8,45289,DB00682,Warfarin
,2938614,plasma clearance,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),[ml] / [h·kg],2.3,45290,DB00682,Warfarin
,2938614,plasma clearance,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),[ml] / [h·kg],1.7,45291,DB00682,Warfarin
,6337802,peak serum concentration,Amiodarone is incompletely (approximately 50 percent) and slowly (peak serum concentration approximately 6 h) absorbed.,"Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6337802/),h,6,47537,DB00682,Warfarin
,6337802,apparent elimination half-life,"It has an apparent elimination half-life of 15-45 days, which presents unique dosing problems.","Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6337802/),d,15-45,47538,DB00682,Warfarin
,6337802,apparent therapeutic range,The apparent therapeutic range is 0.6-3 microgram/ml.,"Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6337802/),[μg] / [ml],0.6-3,47539,DB00682,Warfarin
,7656504,plasma elimination half-life (t1/2),Mean plasma elimination half-life (t1/2) is between 1.3 and 2.1 hours in healthy volunteers.,Clinical pharmacokinetics of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656504/),h,1.3 and 2.1,47682,DB00682,Warfarin
,15080764,protein binding,"Thalidomide interconverts between the (R)- and (S)-enantiomers in plasma, with protein binding of 55% and 65%, respectively.",Clinical pharmacokinetics of thalidomide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),,55,47836,DB00682,Warfarin
,15080764,protein binding,"Thalidomide interconverts between the (R)- and (S)-enantiomers in plasma, with protein binding of 55% and 65%, respectively.",Clinical pharmacokinetics of thalidomide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),,65,47837,DB00682,Warfarin
,15080764,peak concentration (C(max)),"After a single oral dose of thalidomide 200 mg (as the US-approved capsule formulation) in healthy volunteers, absorption is slow and extensive, resulting in a peak concentration (C(max)) of 1-2 mg/L at 3-4 hours after administration, absorption lag time of 30 minutes, total exposure (AUC( infinity )) of 18 mg.",Clinical pharmacokinetics of thalidomide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),[mg] / [l],1-2,47838,DB00682,Warfarin
,15080764,absorption lag time,"After a single oral dose of thalidomide 200 mg (as the US-approved capsule formulation) in healthy volunteers, absorption is slow and extensive, resulting in a peak concentration (C(max)) of 1-2 mg/L at 3-4 hours after administration, absorption lag time of 30 minutes, total exposure (AUC( infinity )) of 18 mg.",Clinical pharmacokinetics of thalidomide. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),min,30,47839,DB00682,Warfarin
,15080764,total exposure (AUC( infinity )),"After a single oral dose of thalidomide 200 mg (as the US-approved capsule formulation) in healthy volunteers, absorption is slow and extensive, resulting in a peak concentration (C(max)) of 1-2 mg/L at 3-4 hours after administration, absorption lag time of 30 minutes, total exposure (AUC( infinity )) of 18 mg.",Clinical pharmacokinetics of thalidomide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),mg,18,47840,DB00682,Warfarin
,15080764,apparent elimination half-life,"h/L, apparent elimination half-life of 6 hours and apparent systemic clearance of 10 L/h.",Clinical pharmacokinetics of thalidomide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),h,6,47841,DB00682,Warfarin
,15080764,apparent systemic clearance,"h/L, apparent elimination half-life of 6 hours and apparent systemic clearance of 10 L/h.",Clinical pharmacokinetics of thalidomide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),[l] / [h],10,47842,DB00682,Warfarin
,15080764,apparent elimination half-life,"The apparent elimination half-life of 6 hours therefore represents absorption, not elimination.",Clinical pharmacokinetics of thalidomide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),h,6,47843,DB00682,Warfarin
,15080764,apparent volume of distribution,The 'true' apparent volume of distribution was estimated to be 16L by use of the faster elimination-rate half-life.,Clinical pharmacokinetics of thalidomide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),l,16,47844,DB00682,Warfarin
,15080764,steady-state C(max) (C(ss)(max)),"Multiple doses of thalidomide 200 mg/day over 21 days cause no change in the pharmacokinetics, with a steady-state C(max) (C(ss)(max)) of 1.2 mg/L.",Clinical pharmacokinetics of thalidomide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),[mg] / [l],1.2,47845,DB00682,Warfarin
,15080764,C(ss)(max),"Simulation of 400 and 800 mg/day also shows no accumulation, with C(ss)(max) of 3.5 and 6.0 mg/L, respectively.",Clinical pharmacokinetics of thalidomide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),[mg] / [l],3.5,47846,DB00682,Warfarin
,15080764,C(ss)(max),"Simulation of 400 and 800 mg/day also shows no accumulation, with C(ss)(max) of 3.5 and 6.0 mg/L, respectively.",Clinical pharmacokinetics of thalidomide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),[mg] / [l],6.0,47847,DB00682,Warfarin
,12236851,AUC,"No differences were found in the AUC (43 vs 44 mg l(-1) h), Cmax (645 vs 678 ng ml(-1)) or elimination half-life (13.8 vs 14.1 h) of fondaparinux between the pentasaccharide-only and the combination treatment.",Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236851/),[h·mg] / [l],43,48619,DB00682,Warfarin
,12236851,AUC,"No differences were found in the AUC (43 vs 44 mg l(-1) h), Cmax (645 vs 678 ng ml(-1)) or elimination half-life (13.8 vs 14.1 h) of fondaparinux between the pentasaccharide-only and the combination treatment.",Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236851/),[h·mg] / [l],44,48620,DB00682,Warfarin
,12236851,Cmax,"No differences were found in the AUC (43 vs 44 mg l(-1) h), Cmax (645 vs 678 ng ml(-1)) or elimination half-life (13.8 vs 14.1 h) of fondaparinux between the pentasaccharide-only and the combination treatment.",Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236851/),[ng] / [ml],645,48621,DB00682,Warfarin
,12236851,Cmax,"No differences were found in the AUC (43 vs 44 mg l(-1) h), Cmax (645 vs 678 ng ml(-1)) or elimination half-life (13.8 vs 14.1 h) of fondaparinux between the pentasaccharide-only and the combination treatment.",Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236851/),[ng] / [ml],678,48622,DB00682,Warfarin
,12236851,elimination half-life,"No differences were found in the AUC (43 vs 44 mg l(-1) h), Cmax (645 vs 678 ng ml(-1)) or elimination half-life (13.8 vs 14.1 h) of fondaparinux between the pentasaccharide-only and the combination treatment.",Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236851/),h,13.8,48623,DB00682,Warfarin
,12236851,elimination half-life,"No differences were found in the AUC (43 vs 44 mg l(-1) h), Cmax (645 vs 678 ng ml(-1)) or elimination half-life (13.8 vs 14.1 h) of fondaparinux between the pentasaccharide-only and the combination treatment.",Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236851/),h,14.1,48624,DB00682,Warfarin
,12236851,maximal increase,The effect of warfarin on PT (mean maximal increase: 8.2 s.) was not influenced by the presence of the pentasaccharide (mean maximal increase in PT: 9.1 s.).,Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236851/),s,8.2,48625,DB00682,Warfarin
,12236851,maximal increase,The effect of warfarin on PT (mean maximal increase: 8.2 s.) was not influenced by the presence of the pentasaccharide (mean maximal increase in PT: 9.1 s.).,Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236851/),s,9.1,48626,DB00682,Warfarin
,8471414,systemic clearance,The mean (+/- s.d.) systemic clearance of vitamin K was similar in all subjects before (114 +/- 35 ml min-1) and after (112 +/- 40 ml min-1) warfarin therapy.,High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],114,50033,DB00682,Warfarin
,8471414,systemic clearance,The mean (+/- s.d.) systemic clearance of vitamin K was similar in all subjects before (114 +/- 35 ml min-1) and after (112 +/- 40 ml min-1) warfarin therapy.,High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],112,50034,DB00682,Warfarin
,8471414,AUC,The mean (+/- s.d.) AUC value for vitamin K epoxide was increased by warfarin treatment (6.5 +/- 5.4 micrograms ml-1 min before and 139 +/- 78 micrograms ml-1 min after) in all subjects.,High clearance of (S)-warfarin in a warfarin-resistant subject. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[μg] / [ml],6.5,50035,DB00682,Warfarin
,8471414,AUC,The mean (+/- s.d.) AUC value for vitamin K epoxide was increased by warfarin treatment (6.5 +/- 5.4 micrograms ml-1 min before and 139 +/- 78 micrograms ml-1 min after) in all subjects.,High clearance of (S)-warfarin in a warfarin-resistant subject. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[min·μg] / [ml],139,50036,DB00682,Warfarin
,8471414,oral clearance,"In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],14.5,50037,DB00682,Warfarin
,8471414,clearance ratio,"In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],2.6,50038,DB00682,Warfarin
,8471414,clearance ratio,"In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],4.3,50039,DB00682,Warfarin
,8471414,clearance ratio,"In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),,1.2,50040,DB00682,Warfarin
,8471414,clearance,"In one sister of the propositus, the stereoselective disposition of warfarin was comparable with that of her brother ((S)-warfarin clearance = 16.2 ml min-1; and (S)/(R)-warfarin clearance ratio = 2.7).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],16.2,50041,DB00682,Warfarin
,8471414,clearance ratio,"In one sister of the propositus, the stereoselective disposition of warfarin was comparable with that of her brother ((S)-warfarin clearance = 16.2 ml min-1; and (S)/(R)-warfarin clearance ratio = 2.7).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),,2.7,50042,DB00682,Warfarin
,26719074,Progression-free survival,Progression-free survival ranged from 0.2 to 13.8 months in all patients.,A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26719074/),month,0.2 to 13.8,52995,DB00682,Warfarin
,19000263,plasma elimination half-life,"Coumatetralyl, a first-generation product, had a plasma elimination half-life of 0.52 days.",Pharmacokinetics of eight anticoagulant rodenticides in mice after single oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000263/),d,0.52,53386,DB00682,Warfarin
,19000263,plasma elimination half-life,"Brodifacoum, a second-generation product, showed a plasma elimination half-life of 91.7 days.",Pharmacokinetics of eight anticoagulant rodenticides in mice after single oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000263/),d,91.7,53387,DB00682,Warfarin
,19000263,elimination half-lives,The elimination half-lives in liver varied from 15.8 days for coumatetralyl to 307.4 days for brodifacoum.,Pharmacokinetics of eight anticoagulant rodenticides in mice after single oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000263/),d,15.8,53388,DB00682,Warfarin
,19000263,elimination half-lives,The elimination half-lives in liver varied from 15.8 days for coumatetralyl to 307.4 days for brodifacoum.,Pharmacokinetics of eight anticoagulant rodenticides in mice after single oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000263/),d,307.4,53389,DB00682,Warfarin
,22616655,"AUC(PT) (0,168 h","(R)-warfarin 80 mg alone resulted in a mean AUC(PT) (0,168 h) of 3550 s h (95% CI 3220, 3880).",The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616655/),h·s,3550,54738,DB00682,Warfarin
,30327682,flow rate,Ammonium acetate aqueous solution (1 mmol/L) and acetonitrile were used as the mobile phase and the flow rate was 0.3 mL/min.,Simultaneous Determination of Columbianadin and Its Metabolite Columbianetin in Rat Plasma by LC-MS/MS: Application to Pharmacokinetics of Columbianadin after Oral Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327682/),[ml] / [min],0.3,55213,DB00682,Warfarin
,1491,plasma half-life,This inhibition as evaluated by a kinetic method was accompanied by a two-fold decrease in the plasma half-life of warfarin from 18-4 h in control animals to 9-6 h in phenylbutazone-treated animals.,Phenylbutazone-warfarin interaction in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491/),h,18-4,56997,DB00682,Warfarin
,1491,plasma half-life,This inhibition as evaluated by a kinetic method was accompanied by a two-fold decrease in the plasma half-life of warfarin from 18-4 h in control animals to 9-6 h in phenylbutazone-treated animals.,Phenylbutazone-warfarin interaction in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491/),h,9-6,56998,DB00682,Warfarin
,1491,unbound fraction,The unbound fraction of warfarin in canine plasma ranged from 1-7 to 4-3% indicating individual differences in the extent of the plasma binding of warfarin in the dog.,Phenylbutazone-warfarin interaction in the dog. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491/),%,1-7,56999,DB00682,Warfarin
,1491,unbound fraction,The unbound fraction of warfarin in canine plasma ranged from 1-7 to 4-3% indicating individual differences in the extent of the plasma binding of warfarin in the dog.,Phenylbutazone-warfarin interaction in the dog. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491/),%,4-3,57000,DB00682,Warfarin
,28180234,Elimination T1/2,Elimination T1/2 ranged from 87-136 hours (h) across all doses.,"Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28180234/),(h)·h,87-136,58064,DB00682,Warfarin
,28180234,Elimination T1/2,Elimination T1/2 ranged from 107-140 h.,"Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28180234/),h,107-140,58065,DB00682,Warfarin
,20671233,terminal half-life,The terminal half-life of dabigatran is 12 to 14 hours in elderly volunteers.,Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20671233/),h,12 to 14,59588,DB00682,Warfarin
,3768021,tissue to plasma ratio,"Following the chronic administration, warfarin tissue to plasma ratio was about 3 for liver, but 0.5 for kidney and testis.","The effect of S-warfarin administration on vitamin K 2,3-epoxide reductase activity in liver, kidney and testis of the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768021/),,3,62519,DB00682,Warfarin
,3768021,tissue to plasma ratio,"Following the chronic administration, warfarin tissue to plasma ratio was about 3 for liver, but 0.5 for kidney and testis.","The effect of S-warfarin administration on vitamin K 2,3-epoxide reductase activity in liver, kidney and testis of the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768021/),,0.5,62520,DB00682,Warfarin
,17529891,total time for,"The peaks were monitored with an ultraviolet detector set at a wavelength of 312 nm, and total time for chromatographic separation was approximately 25 minutes.",Simultaneous determination of warfarin enantiomers and its metabolite in human plasma by column-switching high-performance liquid chromatography with chiral separation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529891/),min,25,63034,DB00682,Warfarin
,16722839,AU,"The mean PT AUC and Cmax ratio (90% confidence interval) was 91.9 (89.6, 94.2) and 84.2 (80.6, 87.8), respectively.",Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16722839/),,91,63400,DB00682,Warfarin
,2264055,plasma half-life (beta-phase),"The average plasma half-life (beta-phase) was 22 hours, the apparent volume of distribution was 0.61 l/kg, Cltot was 25.2 ml/kg/h (13.9-40.9 ml/kg/h).",[The treatment basis for anticoagulants in horses]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2264055/),h,22,64536,DB00682,Warfarin
,2264055,apparent volume of distribution,"The average plasma half-life (beta-phase) was 22 hours, the apparent volume of distribution was 0.61 l/kg, Cltot was 25.2 ml/kg/h (13.9-40.9 ml/kg/h).",[The treatment basis for anticoagulants in horses]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2264055/),[l] / [kg],0.61,64537,DB00682,Warfarin
,2264055,Cltot,"The average plasma half-life (beta-phase) was 22 hours, the apparent volume of distribution was 0.61 l/kg, Cltot was 25.2 ml/kg/h (13.9-40.9 ml/kg/h).",[The treatment basis for anticoagulants in horses]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2264055/),[ml] / [h·kg],25.2,64538,DB00682,Warfarin
,2264055,systemic bioavailability,"The systemic bioavailability of oral phenprocoumon was 97.6%, Tmax was found to be 4-12 hours.",[The treatment basis for anticoagulants in horses]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2264055/),%,97.6,64539,DB00682,Warfarin
,2264055,Tmax,"The systemic bioavailability of oral phenprocoumon was 97.6%, Tmax was found to be 4-12 hours.",[The treatment basis for anticoagulants in horses]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2264055/),h,4-12,64540,DB00682,Warfarin
,21374651,extraction efficiency,The mean extraction efficiency was 88.6-107.2% of free and total warfarin.,Determination of free and total warfarin concentrations in plasma using UPLC MS/MS and its application to a patient samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21374651/),%,88.6-107.2,66107,DB00682,Warfarin
,15776499,AUC,"After oral administration of warfarin to female rats, the AUC was significantly greater (345 compared with 180 microg h/ml) than that in male rats.",Gender differences in pharmacokinetics of oral warfarin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776499/),[h·μg] / [ml],345,67102,DB00682,Warfarin
,15776499,AUC,"After oral administration of warfarin to female rats, the AUC was significantly greater (345 compared with 180 microg h/ml) than that in male rats.",Gender differences in pharmacokinetics of oral warfarin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776499/),[h·μg] / [ml],180,67103,DB00682,Warfarin
,3542339,maximum plasma concentration,"Warfarin is essentially completely absorbed, reaching a maximum plasma concentration between 2 and 6 hours.",Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542339/),h,2 and 6,67282,DB00682,Warfarin
,3542339,volume of distribution,It distributes into a small volume of distribution (10 L/70kg) and is eliminated by hepatic metabolism with a very small clearance (0.2 L/h/70kg).,Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542339/),[l] / [70],10,67283,DB00682,Warfarin
,3542339,clearance,It distributes into a small volume of distribution (10 L/70kg) and is eliminated by hepatic metabolism with a very small clearance (0.2 L/h/70kg).,Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542339/),[l] / [70kg·h],0.2,67284,DB00682,Warfarin
,3542339,elimination half-life,The elimination half-life is about 35 hours.,Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542339/),h,35,67285,DB00682,Warfarin
,3542339,synthesis rate,The synthesis rate is about 5%/h/70kg and the elimination half-life estimated from changes in prothrombin time is approximately 17 hours.,Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542339/),[%] / [70kg·h],5,67286,DB00682,Warfarin
,3542339,elimination half-life,The synthesis rate is about 5%/h/70kg and the elimination half-life estimated from changes in prothrombin time is approximately 17 hours.,Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542339/),h,17,67287,DB00682,Warfarin
,8786959,apparent volume of distribution (V/F),"As the dose decreased from 5 to 2 mg, the apparent volume of distribution (V/F) increased from 12 to 21 liters and the terminal half-life (t1/2) increased from 47 to 71 hours.",Dose-dependent pharmacokinetics of warfarin in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786959/),l,12 to 21,67612,DB00682,Warfarin
,8786959,terminal half-life (t1/2),"As the dose decreased from 5 to 2 mg, the apparent volume of distribution (V/F) increased from 12 to 21 liters and the terminal half-life (t1/2) increased from 47 to 71 hours.",Dose-dependent pharmacokinetics of warfarin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786959/),h,47 to 71,67613,DB00682,Warfarin
,8786959,t1/2,The t1/2 of this terminal phase was determined to be approximately one week.,Dose-dependent pharmacokinetics of warfarin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786959/),week,one,67614,DB00682,Warfarin
,8786959,t1/2,This is the first report that documents the dose-dependent pharmacokinetics of warfarin and the previously unreported long t1/2 of one week for warfarin in humans.,Dose-dependent pharmacokinetics of warfarin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786959/),week,one,67615,DB00682,Warfarin
,9884313,unbound fraction,"Compared with control rabbits, in conscious hypoalbuminemic rabbits, furosemide unbound fraction was enhanced from 1.2 +/- 0.1% to 5.5 +/- 0.5% (p <. 001), and its urinary excretion, diuresis, and sodium excretion were reduced by 22% (p <.05).",Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884313/),,1.2,68140,DB00682,Warfarin
,9884313,unbound fraction,"Compared with control rabbits, in conscious hypoalbuminemic rabbits, furosemide unbound fraction was enhanced from 1.2 +/- 0.1% to 5.5 +/- 0.5% (p <. 001), and its urinary excretion, diuresis, and sodium excretion were reduced by 22% (p <.05).",Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884313/),%,5.,68141,DB00682,Warfarin
,25652102,clearance,"R-warfarin clearance was 32% higher in carriers of CYP2C19*17 than in carriers of CYP2C19*2 (mean 2.5 mL/min, 95% confidence interval (CI) 2.3-2.8 vs. 1.9 mL/min, 95% CI 1.7-2.2; P post hoc = 0.01).",CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652102/),[ml] / [min],2.5,68486,DB00682,Warfarin
,25652102,clearance,"R-warfarin clearance was 32% higher in carriers of CYP2C19*17 than in carriers of CYP2C19*2 (mean 2.5 mL/min, 95% confidence interval (CI) 2.3-2.8 vs. 1.9 mL/min, 95% CI 1.7-2.2; P post hoc = 0.01).",CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652102/),[ml] / [min],1.9,68487,DB00682,Warfarin
,25652102,clearance,"Patients with CYP2C19*1/*1 genotype had an intermediate clearance (mean 2.1 mL/min, 95% CI 1.8-2.4).",CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652102/),[ml] / [min],2.1,68488,DB00682,Warfarin
,24023446,retention time,"Warfarin, 7-hydroxy warfarin and carbamazepine (internal standard) were separated on a C18 column and had the retention time 3.6 min, 2.9 min and 5.9 min, respectively.",Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023446/),min,3.6,69579,DB00682,Warfarin
,24023446,retention time,"Warfarin, 7-hydroxy warfarin and carbamazepine (internal standard) were separated on a C18 column and had the retention time 3.6 min, 2.9 min and 5.9 min, respectively.",Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023446/),min,2.9,69580,DB00682,Warfarin
,24023446,retention time,"Warfarin, 7-hydroxy warfarin and carbamazepine (internal standard) were separated on a C18 column and had the retention time 3.6 min, 2.9 min and 5.9 min, respectively.",Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023446/),min,5.9,69581,DB00682,Warfarin
,24023446,extraction recovery,The extraction recovery was found to be ≃85%.,Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023446/),%,≃85,69582,DB00682,Warfarin
higher,16480934,Recoveries,Recoveries were higher than 90% and the quantitation limit was 1.5 ng mL(-1) plasma for both enantiomers.,Chiral evaluation of fluvastatin in human plasma by high-performance liquid chromatography electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16480934/),%,90,69770,DB00682,Warfarin
,16480934,Recoveries,Recoveries were higher than 90% and the quantitation limit was 1.5 ng mL(-1) plasma for both enantiomers.,Chiral evaluation of fluvastatin in human plasma by high-performance liquid chromatography electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16480934/),[ng·plasma] / [ml],1.5,69771,DB00682,Warfarin
,16480934,AUC (-)/(+),"The data showed higher plasma concentrations of the (-)-3S,5R-fluvastatin enantiomer, with an AUC (-)/(+) of 1.84.",Chiral evaluation of fluvastatin in human plasma by high-performance liquid chromatography electrospray mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16480934/),,1.84,69772,DB00682,Warfarin
,16480934,Oral clearance values (CL/F),"Oral clearance values (CL/F) were 29.27 and 49.58 L/h, respectively, for the (-)-3S,5R- and (+)-3R,5S-fluvastatin enantiomers.",Chiral evaluation of fluvastatin in human plasma by high-performance liquid chromatography electrospray mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16480934/),[l] / [h],29.27,69773,DB00682,Warfarin
,16480934,Oral clearance values (CL/F),"Oral clearance values (CL/F) were 29.27 and 49.58 L/h, respectively, for the (-)-3S,5R- and (+)-3R,5S-fluvastatin enantiomers.",Chiral evaluation of fluvastatin in human plasma by high-performance liquid chromatography electrospray mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16480934/),[l] / [h],49.58,69774,DB00682,Warfarin
,9094197,clearances,"The mean (SD) clearances derived from steady-state AUC values, following therapeutic dosing, for racemic warfarin, R-warfarin, and S-warfarin were 2.40 (0.82), 2.30 (0.65), and 2.80 (1.17) ml/h/kg, respectively.",Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9094197/),[ml] / [h·kg],2.40,70455,DB00682,Warfarin
,9094197,clearances,"The mean (SD) clearances derived from steady-state AUC values, following therapeutic dosing, for racemic warfarin, R-warfarin, and S-warfarin were 2.40 (0.82), 2.30 (0.65), and 2.80 (1.17) ml/h/kg, respectively.",Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9094197/),[ml] / [h·kg],2.30,70456,DB00682,Warfarin
,9094197,clearances,"The mean (SD) clearances derived from steady-state AUC values, following therapeutic dosing, for racemic warfarin, R-warfarin, and S-warfarin were 2.40 (0.82), 2.30 (0.65), and 2.80 (1.17) ml/h/kg, respectively.",Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9094197/),[ml] / [h·kg],2.80,70457,DB00682,Warfarin
,15568889,absolute bioavailability,The absolute bioavailability is about 50%.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),%,50,73755,DB00682,Warfarin
,15568889,volume of distribution,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),l,30,73756,DB00682,Warfarin
,15568889,clearance,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),[l] / [h],17,73757,DB00682,Warfarin
,15568889,terminal half-life,The terminal half-life after oral administration is 5.4 hours and is unchanged at steady state.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),h,5.4,73758,DB00682,Warfarin
,8162655,elimination half-life,The elimination half-life varies between 30 and 70 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30 and 70,74980,DB00682,Warfarin
,8162655,oral bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,100,74981,DB00682,Warfarin
,8162655,bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,80,74982,DB00682,Warfarin
,8162655,elimination half-life,The mean elimination half-life is 60 to 75 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,60 to 75,74983,DB00682,Warfarin
,8162655,elimination half-life,The mean elimination half-life is 30 hours and does not appear to be affected by the age of the patient.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30,74984,DB00682,Warfarin
,8162655,elimination half-life,Lornoxicam differs from other oxicam NSAIDs because it has a short elimination half-life of 3 to 4 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,3 to 4,74985,DB00682,Warfarin
,3698349,plasma clearance,"Low serum albumin in NS patients induced a twofold increase of unbound warfarin vs controls (3.5% vs 1.8%, p less than 0.001) which led to a threefold increase in plasma clearance of warfarin (9.70 vs 3.26 ml X min-1, p less than 0.001); as warfarin distribution volume showed only a slight (non significant) increase in NS patients, the elimination half-life was thus markedly shortened in NS patients vs controls (18 vs 36 h, p less than 0.01).",Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698349/),[ml] / [min],9.70,75162,DB00682,Warfarin
,3698349,plasma clearance,"Low serum albumin in NS patients induced a twofold increase of unbound warfarin vs controls (3.5% vs 1.8%, p less than 0.001) which led to a threefold increase in plasma clearance of warfarin (9.70 vs 3.26 ml X min-1, p less than 0.001); as warfarin distribution volume showed only a slight (non significant) increase in NS patients, the elimination half-life was thus markedly shortened in NS patients vs controls (18 vs 36 h, p less than 0.01).",Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698349/),[ml] / [min],3.26,75163,DB00682,Warfarin
,3698349,elimination half-life,"Low serum albumin in NS patients induced a twofold increase of unbound warfarin vs controls (3.5% vs 1.8%, p less than 0.001) which led to a threefold increase in plasma clearance of warfarin (9.70 vs 3.26 ml X min-1, p less than 0.001); as warfarin distribution volume showed only a slight (non significant) increase in NS patients, the elimination half-life was thus markedly shortened in NS patients vs controls (18 vs 36 h, p less than 0.01).",Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698349/),h,18,75164,DB00682,Warfarin
,3698349,elimination half-life,"Low serum albumin in NS patients induced a twofold increase of unbound warfarin vs controls (3.5% vs 1.8%, p less than 0.001) which led to a threefold increase in plasma clearance of warfarin (9.70 vs 3.26 ml X min-1, p less than 0.001); as warfarin distribution volume showed only a slight (non significant) increase in NS patients, the elimination half-life was thus markedly shortened in NS patients vs controls (18 vs 36 h, p less than 0.01).",Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698349/),h,36,75165,DB00682,Warfarin
,30663096,flow rate,"The method employs liquid extraction of enasidenib from DBS disks of mouse whole blood followed by chromatographic separation using 0.2% formic acid-acetonitrile (25:75, v/v) at a flow rate of 1.0 mL/min on an Atlantis dC18 column with a total run time of 2.0 min.",Quantitative analysis of enasidenib in dried blood spots of mouse blood using an increased-sensitivity LC-MS/MS method: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30663096/),[ml] / [min],1.0,77393,DB00682,Warfarin
,30663096,total run time,"The method employs liquid extraction of enasidenib from DBS disks of mouse whole blood followed by chromatographic separation using 0.2% formic acid-acetonitrile (25:75, v/v) at a flow rate of 1.0 mL/min on an Atlantis dC18 column with a total run time of 2.0 min.",Quantitative analysis of enasidenib in dried blood spots of mouse blood using an increased-sensitivity LC-MS/MS method: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30663096/),min,2.0,77394,DB00682,Warfarin
,30663096,m/,The MS/MS ion transitions monitored were m/z 474.0 → 267.1 for enasidenib and m/z 309.2 → 251.3 for the internal standard (warfarin).,Quantitative analysis of enasidenib in dried blood spots of mouse blood using an increased-sensitivity LC-MS/MS method: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30663096/),,474.0,77395,DB00682,Warfarin
,30663096,m/z,The MS/MS ion transitions monitored were m/z 474.0 → 267.1 for enasidenib and m/z 309.2 → 251.3 for the internal standard (warfarin).,Quantitative analysis of enasidenib in dried blood spots of mouse blood using an increased-sensitivity LC-MS/MS method: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30663096/),,309.2,77396,DB00682,Warfarin
,30663096,m/z,The MS/MS ion transitions monitored were m/z 474.0 → 267.1 for enasidenib and m/z 309.2 → 251.3 for the internal standard (warfarin).,Quantitative analysis of enasidenib in dried blood spots of mouse blood using an increased-sensitivity LC-MS/MS method: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30663096/),,251.3,77397,DB00682,Warfarin
,6886970,Kd,"One tissue exhibited Michaelis-Menten saturation kinetics with Kd and maximum capacity estimated at 1.49E - 3 micrograms/ml and 2.72 micrograms/ml, respectively.",The effect of hepatic uptake on the disappearance of warfarin from the plasma of rats: a kinetic analysis. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6886970/),[μg] / [ml],1.49E,78131,DB00682,Warfarin
,6886970,maximum capacity,"One tissue exhibited Michaelis-Menten saturation kinetics with Kd and maximum capacity estimated at 1.49E - 3 micrograms/ml and 2.72 micrograms/ml, respectively.",The effect of hepatic uptake on the disappearance of warfarin from the plasma of rats: a kinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6886970/),[μg] / [ml],2.72,78132,DB00682,Warfarin
,2020000,clearance,Concurrent diltiazem administration decreased total racemic warfarin clearance (+/- S.D.) [3.60 +/- 0.99 (control) versus 3.19 +/- 0.86 (diltiazem) ml/min; P less than .05].,Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [min],3.60,78213,DB00682,Warfarin
,2020000,clearance,Concurrent diltiazem administration decreased total racemic warfarin clearance (+/- S.D.) [3.60 +/- 0.99 (control) versus 3.19 +/- 0.86 (diltiazem) ml/min; P less than .05].,Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [min],3.19,78214,DB00682,Warfarin
,2020000,total clearance,In contrast total clearance of R-warfarin was decreased [3.47 +/- 1.10 (control) versus 2.77 +/- 0.92 ml/min; P less than .05].,Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [min],3.47,78215,DB00682,Warfarin
,2020000,total clearance,In contrast total clearance of R-warfarin was decreased [3.47 +/- 1.10 (control) versus 2.77 +/- 0.92 ml/min; P less than .05].,Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [min],2.77,78216,DB00682,Warfarin
,2020000,clearance,"R-6-hydroxywarfarin clearance (+/- S.E.) [29.5 +/- 7.2 (control) versus 15.7 +/- 2.8 ml/h; P less than 0.05] and R-8-hydroxywarfarin clearance [21.1 +/- 3.6 (control) versus 11.2 +/- 2.0 ml/h; P less than .05] were selectively decreased with no significant change in the urinary clearance of R-dehydro, R-4-hydroxy and R-7-hydroxywarfarin.",Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [h],29.5,78217,DB00682,Warfarin
,2020000,clearance,"R-6-hydroxywarfarin clearance (+/- S.E.) [29.5 +/- 7.2 (control) versus 15.7 +/- 2.8 ml/h; P less than 0.05] and R-8-hydroxywarfarin clearance [21.1 +/- 3.6 (control) versus 11.2 +/- 2.0 ml/h; P less than .05] were selectively decreased with no significant change in the urinary clearance of R-dehydro, R-4-hydroxy and R-7-hydroxywarfarin.",Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [h],15.7,78218,DB00682,Warfarin
,2020000,clearance,"R-6-hydroxywarfarin clearance (+/- S.E.) [29.5 +/- 7.2 (control) versus 15.7 +/- 2.8 ml/h; P less than 0.05] and R-8-hydroxywarfarin clearance [21.1 +/- 3.6 (control) versus 11.2 +/- 2.0 ml/h; P less than .05] were selectively decreased with no significant change in the urinary clearance of R-dehydro, R-4-hydroxy and R-7-hydroxywarfarin.",Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [h],21.1,78219,DB00682,Warfarin
,2020000,clearance,"R-6-hydroxywarfarin clearance (+/- S.E.) [29.5 +/- 7.2 (control) versus 15.7 +/- 2.8 ml/h; P less than 0.05] and R-8-hydroxywarfarin clearance [21.1 +/- 3.6 (control) versus 11.2 +/- 2.0 ml/h; P less than .05] were selectively decreased with no significant change in the urinary clearance of R-dehydro, R-4-hydroxy and R-7-hydroxywarfarin.",Selective inhibition of warfarin metabolism by diltiazem in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2020000/),[ml] / [h],11.2,78220,DB00682,Warfarin
<,10613612,Ki,Benzbromarone was found to be a potent competitive inhibitor (Ki < 0.01 micromol/L) for (S)-warfarin 7-hydroxylation mediated by CYP2C9.,Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613612/),[μM] / [l],0.01,78401,DB00682,Warfarin
,14531724,elimination half-life,"The elimination half-life of linezolid is 5-7 hours, and twice-daily administration of 400-600 mg provides steady-state concentrations in the therapeutic range.","Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531724/),h,5-7,79676,DB00682,Warfarin
,1127135,half-life,"The mean half-life of the drug in man is 13 hours, close to ideal for twice-daily administration.",Naproxen metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127135/),h,13,80169,DB00682,Warfarin
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB00682,Warfarin
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB00682,Warfarin
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB00682,Warfarin
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB00682,Warfarin
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB00682,Warfarin
,7349326,elimination half-life,"Values for the elimination half-life and apparent specific volume of distribution were 14.5 +/- 4.1 h and 0.22 +/- 0.04 litre/kg, respectively.",Warfarin in the dog: pharmacokinetics as related to clinical response. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349326/),h,14.5,81100,DB00682,Warfarin
,7349326,apparent specific volume of distribution,"Values for the elimination half-life and apparent specific volume of distribution were 14.5 +/- 4.1 h and 0.22 +/- 0.04 litre/kg, respectively.",Warfarin in the dog: pharmacokinetics as related to clinical response. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349326/),[l] / [kg],0.22,81101,DB00682,Warfarin
,7349326,Prothrombin times,Prothrombin times increased from a control value of 8.6 +/- 0.3 sec to 55.2 +/- 5.2 sec over a period of 96 h.,Warfarin in the dog: pharmacokinetics as related to clinical response. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349326/),s,8.6,81102,DB00682,Warfarin
,7349326,Prothrombin times,Prothrombin times increased from a control value of 8.6 +/- 0.3 sec to 55.2 +/- 5.2 sec over a period of 96 h.,Warfarin in the dog: pharmacokinetics as related to clinical response. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349326/),s,55.2,81103,DB00682,Warfarin
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],3.1,82553,DB00682,Warfarin
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],7.0,82554,DB00682,Warfarin
,2260347,Protein binding,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),%,11,82555,DB00682,Warfarin
,2260347,cerebrospinal fluid to serum ratio,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),,0.58 to 0.89,82556,DB00682,Warfarin
,2260347,Serum half-life,Serum half-life is long (22-32 hours) and elimination is via renal clearance of unchanged drug.,Fluconazole: a new triazole antifungal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),h,22-32,82557,DB00682,Warfarin
,15089812,apparent clearances,"The apparent clearances of S-warfarin after warfarin alone or with St John's wort or ginseng were, respectively, 198 +/- 38 ml h(-1), 270 +/- 44 ml h(-1) and 220 +/- 29 ml h(-1).",Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089812/),[ml] / [h],198,83462,DB00682,Warfarin
,15089812,apparent clearances,"The apparent clearances of S-warfarin after warfarin alone or with St John's wort or ginseng were, respectively, 198 +/- 38 ml h(-1), 270 +/- 44 ml h(-1) and 220 +/- 29 ml h(-1).",Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089812/),[ml] / [h],270,83463,DB00682,Warfarin
,15089812,apparent clearances,"The apparent clearances of S-warfarin after warfarin alone or with St John's wort or ginseng were, respectively, 198 +/- 38 ml h(-1), 270 +/- 44 ml h(-1) and 220 +/- 29 ml h(-1).",Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089812/),[ml] / [h],220,83464,DB00682,Warfarin
,15089812,apparent clearances,"The respective apparent clearances of R-warfarin were 110 +/- 25 ml h(-1), 142 +/- 29 ml h(-1) and 119 +/- 20 ml h(-1) [corrected].",Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089812/),[ml] / [h],110,83465,DB00682,Warfarin
,15089812,apparent clearances,"The respective apparent clearances of R-warfarin were 110 +/- 25 ml h(-1), 142 +/- 29 ml h(-1) and 119 +/- 20 ml h(-1) [corrected].",Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089812/),[ml] / [h],142,83466,DB00682,Warfarin
,15089812,apparent clearances,"The respective apparent clearances of R-warfarin were 110 +/- 25 ml h(-1), 142 +/- 29 ml h(-1) and 119 +/- 20 ml h(-1) [corrected].",Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089812/),[ml] / [h],119,83467,DB00682,Warfarin
,32074068,flow rate,"The simple and sensitive method was developed using Fortis® reversed-phase diphenyl column (150 × 4.6 mm, 3 μm) and a mobile phase composed of phosphate buffer (25 mmol L-1)/methanol/acetonitrile (70:20:10, V/V/V), adjusted to pH 7.4, at a flow rate of 0.8 mL min-1.",Simultaneous determination of warfarin and 7-hydroxywarfarin in rat plasma by HPLC-FLD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32074068/),[ml] / [min],0.8,83831,DB00682,Warfarin
,1139863,half-life (T/2),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,11.8,85544,DB00682,Warfarin
,1139863,half-life (T/2),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,19.6,85545,DB00682,Warfarin
,1139863,metabolic clearance rate (MCR),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],43.7,85546,DB00682,Warfarin
,1139863,metabolic clearance rate (MCR),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],28.1,85547,DB00682,Warfarin
,1139863,metabolic clearance rate (MCR),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,9.2,85548,DB00682,Warfarin
,1139863,MCR,"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],17.0,85549,DB00682,Warfarin
,1139863,MCR,"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],10.5,85550,DB00682,Warfarin
,1139863,T/2,In 2 patients warfarin T/2 increased fron an average of 64.7 to 92.7 hr and MCR decreased from 1.65 ml/min to 1.05 ml/min.,"Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,64.7 to 92.7,85551,DB00682,Warfarin
,1139863,MCR,In 2 patients warfarin T/2 increased fron an average of 64.7 to 92.7 hr and MCR decreased from 1.65 ml/min to 1.05 ml/min.,"Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],1.65,85552,DB00682,Warfarin
,1139863,MCR,In 2 patients warfarin T/2 increased fron an average of 64.7 to 92.7 hr and MCR decreased from 1.65 ml/min to 1.05 ml/min.,"Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],1.05,85553,DB00682,Warfarin
,16372823,acid dissociation constant [pKa],"Lumiracoxib possesses a carboxylic acid group that makes it weakly acidic (acid dissociation constant [pKa] 4.7), distinguishing it from other selective COX-2 inhibitors.",Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),,4.7,89509,DB00682,Warfarin
,16372823,oral bioavailability,Lumiracoxib has good oral bioavailability (74%).,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),%,74,89510,DB00682,Warfarin
,16372823,elimination half-life,Lumiracoxib has a short elimination half-life from plasma (mean 4 hours) and demonstrates dose-proportional plasma pharmacokinetics with no accumulation during multiple dosing.,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),h,4,89511,DB00682,Warfarin
,11978144,half-life,"Following intravitreal administration, fomivirsen is slowly cleared from vitreous with a half-life of approximately 55 hours in humans.",Fomivirsen: clinical pharmacology and potential drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978144/),h,55,90169,DB00682,Warfarin
,11978144,half-life for clearance,The estimated half-life for clearance of fomivirsen from retina was 78 hours in monkeys following a 115-microg dose.,Fomivirsen: clinical pharmacology and potential drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978144/),h,78,90170,DB00682,Warfarin
,6538427,half-life,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),h,12.7,90690,DB00682,Warfarin
,6538427,half-life,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),h,15.5,90691,DB00682,Warfarin
,6538427,total plasma clearance,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),[ml] / [min],40.9,90692,DB00682,Warfarin
,6538427,total plasma clearance,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),[ml] / [min],33.9,90693,DB00682,Warfarin
,76673,Clearance,Clearance values ranged from 1.46 to 27.0 ml/hr/kg.,Comparative pharmacokinetics of coumarin anticoagulants XXXIII: frequency distribution of dicumarol total clearance in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/76673/),[ml] / [h·kg],1.46 to 27.0,90898,DB00682,Warfarin
,76673,total clearance,"Statistical analysis of a histogram of the total clearance values indicated a trimodal distribution, with modes at 6.28, 14.8, and 23.7 ml/hr/kg.",Comparative pharmacokinetics of coumarin anticoagulants XXXIII: frequency distribution of dicumarol total clearance in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/76673/),[ml] / [h·kg],6.28,90899,DB00682,Warfarin
,76673,total clearance,"Statistical analysis of a histogram of the total clearance values indicated a trimodal distribution, with modes at 6.28, 14.8, and 23.7 ml/hr/kg.",Comparative pharmacokinetics of coumarin anticoagulants XXXIII: frequency distribution of dicumarol total clearance in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/76673/),[ml] / [h·kg],14.8,90900,DB00682,Warfarin
,76673,total clearance,"Statistical analysis of a histogram of the total clearance values indicated a trimodal distribution, with modes at 6.28, 14.8, and 23.7 ml/hr/kg.",Comparative pharmacokinetics of coumarin anticoagulants XXXIII: frequency distribution of dicumarol total clearance in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/76673/),[ml] / [h·kg],23.7,90901,DB00682,Warfarin
,16238904,absolute oral bioavailability,"The absolute oral bioavailability of telithromycin is approximately 57%, which is unaffected by food intake.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),%,57,91339,DB00682,Warfarin
,16238904,steady-state concentration,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),[μg] / [ml],2,91340,DB00682,Warfarin
,16238904,elimination half-life,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),h,10,91341,DB00682,Warfarin
,21184622,C(max),"Mean ± SD serum nilotinib C(max) was 1872 ± 560 ng/mL, which is comparable to steady-state C(max) in CML and gastrointestinal stromal tumour patients receiving twice-daily 400 mg doses.","Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21184622/),[ng] / [ml],1872,92199,DB00682,Warfarin
>,15301575,bioavailability,"After oral ingestion, levetiracetam is rapidly absorbed, with peak concentration occurring after 1.3 hours, and its bioavailability is >95%.",Clinical pharmacokinetics of levetiracetam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),%,95,93302,DB00682,Warfarin
,15301575,volume of distribution,Levetiracetam is not bound to plasma proteins and has a volume of distribution of 0.5-0.7 L/kg.,Clinical pharmacokinetics of levetiracetam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),[l] / [kg],0.5-0.7,93303,DB00682,Warfarin
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,6-8,93304,DB00682,Warfarin
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,5-7,93305,DB00682,Warfarin
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,10-11,93306,DB00682,Warfarin
,3515929,systemic availability,The mean systemic availability is approximately 4 percent.,Metabolism and disposition of buspirone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),%,4,93421,DB00682,Warfarin
,3515929,Half-life,Half-life values observed in healthy volunteers ranged from two to 33 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,two to 33,93422,DB00682,Warfarin
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,2,93423,DB00682,Warfarin
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,11,93424,DB00682,Warfarin
,29558780,flow rate,"Plasma samples were extracted by liquid-liquid extraction and the chromatographic separation was achieved on a Chiralpak IA column with an isocratic mobile phase 5 mM ammonium acetate:absolute alcohol (20:80, v/v) at a flow rate of 1.0 mL/min.",Validated Chiral LC-ESI-MS/MS Method for the Simultaneous Quantification of Darolutamide Diastereomers and Its Active Metabolite in Mice Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29558780/),[ml] / [min],1.0,93539,DB00682,Warfarin
,25499099,oral clearance,We found oral clearance of S-warfarin to be higher among carriers of the minor rs7089580 allele (T) compared with wild-type homozygotes (3.73 ± 1.46 vs 2.95 ± 1.39 mL/min; P = 0.04).,Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25499099/),[ml] / [min],3.73,94433,DB00682,Warfarin
,25499099,oral clearance,We found oral clearance of S-warfarin to be higher among carriers of the minor rs7089580 allele (T) compared with wild-type homozygotes (3.73 ± 1.46 vs 2.95 ± 1.39 mL/min; P = 0.04).,Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25499099/),[ml] / [min],2.95,94434,DB00682,Warfarin
,12867493,Kiiv,"Kiiv, values calculated from these data based on plasma fluconazole levels at each dose and data from earlier work at 400-mg daily doses of fluconazole were 30.7 +/- 23.7, 19.6 +/- 3.8, 17.9 +/- 7.5, and 19.8 +/- 3.5 microM, respectively.","Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867493/),μM,30.7,94518,DB00682,Warfarin
,12867493,Kiiv,"Kiiv, values calculated from these data based on plasma fluconazole levels at each dose and data from earlier work at 400-mg daily doses of fluconazole were 30.7 +/- 23.7, 19.6 +/- 3.8, 17.9 +/- 7.5, and 19.8 +/- 3.5 microM, respectively.","Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867493/),μM,19.6,94519,DB00682,Warfarin
,12867493,Kiiv,"Kiiv, values calculated from these data based on plasma fluconazole levels at each dose and data from earlier work at 400-mg daily doses of fluconazole were 30.7 +/- 23.7, 19.6 +/- 3.8, 17.9 +/- 7.5, and 19.8 +/- 3.5 microM, respectively.","Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867493/),μM,17.9,94520,DB00682,Warfarin
,12867493,Kiiv,"Kiiv, values calculated from these data based on plasma fluconazole levels at each dose and data from earlier work at 400-mg daily doses of fluconazole were 30.7 +/- 23.7, 19.6 +/- 3.8, 17.9 +/- 7.5, and 19.8 +/- 3.5 microM, respectively.","Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12867493/),μM,19.8,94521,DB00682,Warfarin
,8216438,area under the plasma concentration-time curve,"Concurrent administration of LNC-834 decreased significantly the area under the plasma concentration-time curve of warfarin (117,889 +/- 25,010 (A) vs. 125,294 +/- 22,314 ng/ml.h (B); p = 0.0488).","Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216438/),[ng] / [h·ml],"117,889",94998,DB00682,Warfarin
,8216438,area under the plasma concentration-time curve,"Concurrent administration of LNC-834 decreased significantly the area under the plasma concentration-time curve of warfarin (117,889 +/- 25,010 (A) vs. 125,294 +/- 22,314 ng/ml.h (B); p = 0.0488).","Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216438/),[ng] / [h·ml],"125,294",94999,DB00682,Warfarin
,8216438,apparent oral clearance (CL/f),"Thus, a significant increase in apparent oral clearance (CL/f) of warfarin in the presence of LNC-834 was determined (3.98 +/- 0.63 vs. 3.71 +/- 0.50 ml/min; p = 0.0488).","Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216438/),[ml] / [min],3.98,95000,DB00682,Warfarin
,8216438,apparent oral clearance (CL/f),"Thus, a significant increase in apparent oral clearance (CL/f) of warfarin in the presence of LNC-834 was determined (3.98 +/- 0.63 vs. 3.71 +/- 0.50 ml/min; p = 0.0488).","Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216438/),[ml] / [min],3.71,95001,DB00682,Warfarin
,15831771,time to peak concentration,"Etanercept is absorbed slowly from the site of subcutaneous injection, with time to peak concentration at approximately 48 to 60 hours, and is cleared slowly from the body with a t(1/2) of 70 to 100 hours.",Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831771/),h,48 to 60,95896,DB00682,Warfarin
,15831771,t(1/2),"Etanercept is absorbed slowly from the site of subcutaneous injection, with time to peak concentration at approximately 48 to 60 hours, and is cleared slowly from the body with a t(1/2) of 70 to 100 hours.",Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831771/),h,70 to 100,95897,DB00682,Warfarin
,15831771,absolute bioavailability,The absolute bioavailability of etanercept was 58% in healthy subjects following subcutaneous administration.,Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831771/),%,58,95898,DB00682,Warfarin
,25393417,Ki,"Consistent with its inhibitory effects on UGT2B7 activity, warfarin inhibited AZT glucuronidation in HLM (Ki = 74.9-96.3 μM) and RLM (Ki = 190-230 μM).",Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393417/),μM,74.9-96.3,96091,DB00682,Warfarin
,25393417,Ki,"Consistent with its inhibitory effects on UGT2B7 activity, warfarin inhibited AZT glucuronidation in HLM (Ki = 74.9-96.3 μM) and RLM (Ki = 190-230 μM).",Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393417/),μM,190-230,96092,DB00682,Warfarin
,7127318,Overall median survival,Overall median survival was 19.2 months.,Clinical and pharmacokinetic effects of combined warfarin and 5-flourouracil in advanced colon cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127318/),month,19.2,98067,DB00682,Warfarin
,6881659,biological half-life,"Analysis of the data, according to 2-compartment kinetics, revealed the following constants: biological half-life was 13.3 hours, apparent volume of distribution was 0.46 L X kg-1, body clearance was 25.3 ml X hour-1 X kg-1.",Warfarin pharmacokinetics in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6881659/),h,13.3,98095,DB00682,Warfarin
,6881659,apparent volume of distribution,"Analysis of the data, according to 2-compartment kinetics, revealed the following constants: biological half-life was 13.3 hours, apparent volume of distribution was 0.46 L X kg-1, body clearance was 25.3 ml X hour-1 X kg-1.",Warfarin pharmacokinetics in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6881659/),[l] / [kg],0.46,98096,DB00682,Warfarin
,6881659,body clearance,"Analysis of the data, according to 2-compartment kinetics, revealed the following constants: biological half-life was 13.3 hours, apparent volume of distribution was 0.46 L X kg-1, body clearance was 25.3 ml X hour-1 X kg-1.",Warfarin pharmacokinetics in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6881659/),[ml] / [h·kg],25.3,98097,DB00682,Warfarin
,12537513,elimination half-life,"The elimination half-life is approximately 12-15 hours, which is largely reflective of the pharmacokinetics of the longer-lived l-enantiomer.",Clinical pharmacokinetic profile of modafinil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12537513/),h,12-15,99272,DB00682,Warfarin
,24846496,time (tmax ) to reach the,The median time (tmax ) to reach the maximum plasma-free dabigatran concentration (Cmax ) was 2 hours (range 1-3 hours).,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),h,2,99542,DB00682,Warfarin
,24846496,Cmax,The mean free dabigatran Cmax was 95.5 ± 33.4 ng/mL.,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),[ng] / [ml],95.5,99543,DB00682,Warfarin
,24846496,elimination half-lives,"The mean elimination half-lives on and off hemodialysis were, respectively, 2.6 ± 1.3 and 30.2 ± 7.8 hours.",An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),h,2.6,99544,DB00682,Warfarin
,24846496,elimination half-lives,"The mean elimination half-lives on and off hemodialysis were, respectively, 2.6 ± 1.3 and 30.2 ± 7.8 hours.",An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),h,30.2,99545,DB00682,Warfarin
,24846496,extraction ratio,Hemodialysis effectively removed dabigatran with an extraction ratio of 0.63 ± 0.07.,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),,0.63,99546,DB00682,Warfarin
,24846496,maximal TT ratio,The maximal TT ratio was 2.1 and the TT ratio demonstrated a strong linear dependence on free dabigatran concentration (r(2) = 0.741).,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),,2.1,99547,DB00682,Warfarin
,8276058,oral plasma clearance,"Mean oral plasma clearance of (R)-warfarin was 175 ml.h-1 in the absence and 181 ml.h-1 in the presence of moexipril, and the corresponding values for (S)-warfarin were 248 ml.h-1 and 249 ml.h-1.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),[ml] / [h],175,100317,DB00682,Warfarin
,8276058,oral plasma clearance,"Mean oral plasma clearance of (R)-warfarin was 175 ml.h-1 in the absence and 181 ml.h-1 in the presence of moexipril, and the corresponding values for (S)-warfarin were 248 ml.h-1 and 249 ml.h-1.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),[ml] / [h],181,100318,DB00682,Warfarin
,8276058,oral plasma clearance,"Mean oral plasma clearance of (R)-warfarin was 175 ml.h-1 in the absence and 181 ml.h-1 in the presence of moexipril, and the corresponding values for (S)-warfarin were 248 ml.h-1 and 249 ml.h-1.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),[ml] / [h],248,100319,DB00682,Warfarin
,8276058,oral plasma clearance,"Mean oral plasma clearance of (R)-warfarin was 175 ml.h-1 in the absence and 181 ml.h-1 in the presence of moexipril, and the corresponding values for (S)-warfarin were 248 ml.h-1 and 249 ml.h-1.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),[ml] / [h],249,100320,DB00682,Warfarin
,8276058,maximum prothrombin time,"Moexipril did not alter the maximum prothrombin time (20.3 versus 20.1 s, respectively in the absence and presence of moexipril), time to maximum response (48.0 versus 50 h) and area under the prothrombin time versus time curve.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),s,20.3,100321,DB00682,Warfarin
,8276058,maximum prothrombin time,"Moexipril did not alter the maximum prothrombin time (20.3 versus 20.1 s, respectively in the absence and presence of moexipril), time to maximum response (48.0 versus 50 h) and area under the prothrombin time versus time curve.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),s,20.1,100322,DB00682,Warfarin
,8276058,time to maximum response,"Moexipril did not alter the maximum prothrombin time (20.3 versus 20.1 s, respectively in the absence and presence of moexipril), time to maximum response (48.0 versus 50 h) and area under the prothrombin time versus time curve.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),h,48.0,100323,DB00682,Warfarin
,8276058,time to maximum response,"Moexipril did not alter the maximum prothrombin time (20.3 versus 20.1 s, respectively in the absence and presence of moexipril), time to maximum response (48.0 versus 50 h) and area under the prothrombin time versus time curve.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),h,50,100324,DB00682,Warfarin
,19489169,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),min,30,100644,DB00682,Warfarin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,40,100645,DB00682,Warfarin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,60,100646,DB00682,Warfarin
,28302754,area under the concentration-time curve from 0 to 24 hours,The area under the concentration-time curve from 0 to 24 hours increased from 628 to 2054 ng h/ml (P<0.001).,Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302754/),[h·ng] / [ml],628 to 2054,101998,DB00682,Warfarin
,28302754,Trough levels,Trough levels increased from 45 to 132 ng/ml (P<0.001).,Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302754/),[ng] / [ml],45 to 132,101999,DB00682,Warfarin
,28302754,area under the concentration-time curve,"The area under the concentration-time curve further increased to 6045 ng h/ml (P=0.03), and trough levels increased to 218 ng/ml (P=0.03), above the 90th percentile for the 5-mg dose in patients with preserved renal function.",Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302754/),[h·ng] / [ml],6045,102000,DB00682,Warfarin
,28302754,trough levels,"The area under the concentration-time curve further increased to 6045 ng h/ml (P=0.03), and trough levels increased to 218 ng/ml (P=0.03), above the 90th percentile for the 5-mg dose in patients with preserved renal function.",Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302754/),[ng] / [ml],218,102001,DB00682,Warfarin
,7587949,Ki's,"Kinetic studies conducted on sulfinpyrazone and two major metabolites, sulfinpyrazone sulfide and sulfinpyrazone sulfone, in microsomes prepared from three human livers give mean Ki's of 230 microM, 17 microM, and 73 microM respectively.",Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587949/),μM,230,102161,DB00682,Warfarin
,7587949,Ki's,"Kinetic studies conducted on sulfinpyrazone and two major metabolites, sulfinpyrazone sulfide and sulfinpyrazone sulfone, in microsomes prepared from three human livers give mean Ki's of 230 microM, 17 microM, and 73 microM respectively.",Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587949/),μM,17,102162,DB00682,Warfarin
,7587949,Ki's,"Kinetic studies conducted on sulfinpyrazone and two major metabolites, sulfinpyrazone sulfide and sulfinpyrazone sulfone, in microsomes prepared from three human livers give mean Ki's of 230 microM, 17 microM, and 73 microM respectively.",Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587949/),μM,73,102163,DB00682,Warfarin
,21437357,Oral bioavailability,"Oral bioavailability of LHD in mice, rats and monkeys were 16.1 ± 3.0, 15.6 ± 6.1, and 15.8 ± 2.5%, respectively.",Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21437357/),%,16.1,102192,DB00682,Warfarin
,21437357,Oral bioavailability,"Oral bioavailability of LHD in mice, rats and monkeys were 16.1 ± 3.0, 15.6 ± 6.1, and 15.8 ± 2.5%, respectively.",Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21437357/),%,15.6,102193,DB00682,Warfarin
,21437357,Oral bioavailability,"Oral bioavailability of LHD in mice, rats and monkeys were 16.1 ± 3.0, 15.6 ± 6.1, and 15.8 ± 2.5%, respectively.",Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21437357/),%,15.8,102194,DB00682,Warfarin
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,0.85,103134,DB00682,Warfarin
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,1.82,103135,DB00682,Warfarin
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,4.48,103136,DB00682,Warfarin
,17944539,rate constant k,The alkylation rate constant k for HSA was 20 M(-1) min(-1).,Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),1/[M·min],20,103137,DB00682,Warfarin
,4007030,clearance,"Warfarin clearance was lower in amiodarone-treated patients than in the controls (1.4 vs 3.1 ml/min, p less than 0.01) with similar plasma concentrations (1.5 vs 1.2 micrograms/ml) despite administration of lower doses (23.3 vs 39 mg/week respectively).",Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007030/),[ml] / [min],1.4,103237,DB00682,Warfarin
,4007030,clearance,"Warfarin clearance was lower in amiodarone-treated patients than in the controls (1.4 vs 3.1 ml/min, p less than 0.01) with similar plasma concentrations (1.5 vs 1.2 micrograms/ml) despite administration of lower doses (23.3 vs 39 mg/week respectively).",Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007030/),[ml] / [min],3.1,103238,DB00682,Warfarin
,2778004,limit of detection,"The limit of detection (50 and 80 ng/ml) and precision (less than 5%) of the method are adequate for pharmacokinetic and enantioselective disposition studies, respectively, of phenprocoumon.",Separation of the enantiomers of phenprocoumon and warfarin by high-performance liquid chromatography using a chiral stationary phase. Determination of the enantiomeric ratio of phenprocoumon in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778004/),[ng] / [ml],50,105100,DB00682,Warfarin
,2778004,limit of detection,"The limit of detection (50 and 80 ng/ml) and precision (less than 5%) of the method are adequate for pharmacokinetic and enantioselective disposition studies, respectively, of phenprocoumon.",Separation of the enantiomers of phenprocoumon and warfarin by high-performance liquid chromatography using a chiral stationary phase. Determination of the enantiomeric ratio of phenprocoumon in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778004/),[ng] / [ml],80,105101,DB00682,Warfarin
,22493814,flow-rate,"R-warfarin, S-warfarin and methyclothiazide were extracted with ethylether : methylenechloride (3 : 2), then separated on a Astec Chirobiotic V (150 mm x 4.6 mm ID, 5 microm) column using 5 mmol x L(-1) ammonium acetate (pH 4.0) - acetonitrile as mobile phase at a flow-rate of 1.5 mL x min(-1).",[Enantioselective determinination of R-warfarin/S-warfarin in human plasma using liquid chromatography-tandem mass spectrometry and its application in a drug-drug interaction study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22493814/),[ml] / [min],1.5,108977,DB00682,Warfarin
,22493814,resolution,The resolution of warfarin enantiomers is 1.56.,[Enantioselective determinination of R-warfarin/S-warfarin in human plasma using liquid chromatography-tandem mass spectrometry and its application in a drug-drug interaction study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22493814/),,1.56,108978,DB00682,Warfarin
,17192504,AUC(inf),"(S)-Warfarin AUC(inf) and t(1/2) were 106,471 h x microg/L and 82.92 hours versus 33,148 h x microg/L under HMR1766 and 31.72 hours under placebo, and the maximum decrease in prothrombin time values after warfarin dosing was 58.75% versus 39.94%.",Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192504/),[h·μg] / [l],"106,471",111837,DB00682,Warfarin
,17192504,AUC(inf),"(S)-Warfarin AUC(inf) and t(1/2) were 106,471 h x microg/L and 82.92 hours versus 33,148 h x microg/L under HMR1766 and 31.72 hours under placebo, and the maximum decrease in prothrombin time values after warfarin dosing was 58.75% versus 39.94%.",Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192504/),[h·μg] / [l],"33,148",111838,DB00682,Warfarin
,17192504,t(1/2),"(S)-Warfarin AUC(inf) and t(1/2) were 106,471 h x microg/L and 82.92 hours versus 33,148 h x microg/L under HMR1766 and 31.72 hours under placebo, and the maximum decrease in prothrombin time values after warfarin dosing was 58.75% versus 39.94%.",Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192504/),h,82.92,111839,DB00682,Warfarin
,17192504,t(1/2),"(S)-Warfarin AUC(inf) and t(1/2) were 106,471 h x microg/L and 82.92 hours versus 33,148 h x microg/L under HMR1766 and 31.72 hours under placebo, and the maximum decrease in prothrombin time values after warfarin dosing was 58.75% versus 39.94%.",Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192504/),h,31.72,111840,DB00682,Warfarin
,21543033,Eax,"The corresponding Eax values for both INR and PT were slightly increased after co-administration of linagliptin and warfarin compared with warfarin alone, being 104.3 (85.2 - 127.6) and 15.1 (94.3 -140.6), respectively, reflecting the higher variability of these endpoints.",Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21543033/),,104.3,112854,DB00682,Warfarin
,21543033,Eax,"The corresponding Eax values for both INR and PT were slightly increased after co-administration of linagliptin and warfarin compared with warfarin alone, being 104.3 (85.2 - 127.6) and 15.1 (94.3 -140.6), respectively, reflecting the higher variability of these endpoints.",Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21543033/),,15.1,112855,DB00682,Warfarin
,30815847,CL(S),"Similar to our previous findings, the median CL(S) was 30% lower in African American patients than Asian and White patients (169 vs. 243 and 234 mL/h, p < 0.01).",Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815847/),[ml] / [h],169,114937,DB00682,Warfarin
,30815847,CL(S),"Similar to our previous findings, the median CL(S) was 30% lower in African American patients than Asian and White patients (169 vs. 243 and 234 mL/h, p < 0.01).",Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815847/),[ml] / [h],243,114938,DB00682,Warfarin
,30815847,CL(S),"Similar to our previous findings, the median CL(S) was 30% lower in African American patients than Asian and White patients (169 vs. 243 and 234 mL/h, p < 0.01).",Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815847/),[ml] / [h],234,114939,DB00682,Warfarin
,30815847,EC50,"EC50 showed a greater racial difference than CL(S) [1.03, 1.70 and 2.76 μg/mL for Asian, White and African American patients, respectively, p < 0.01).",Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815847/),[μg] / [ml],1.03,114940,DB00682,Warfarin
,30815847,EC50,"EC50 showed a greater racial difference than CL(S) [1.03, 1.70 and 2.76 μg/mL for Asian, White and African American patients, respectively, p < 0.01).",Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815847/),[μg] / [ml],1.70,114941,DB00682,Warfarin
,30815847,CL(S),"EC50 showed a greater racial difference than CL(S) [1.03, 1.70 and 2.76 μg/mL for Asian, White and African American patients, respectively, p < 0.01).",Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815847/),[μg] / [ml],1.03,114942,DB00682,Warfarin
,30815847,CL(S),"EC50 showed a greater racial difference than CL(S) [1.03, 1.70 and 2.76 μg/mL for Asian, White and African American patients, respectively, p < 0.01).",Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815847/),[μg] / [ml],1.70,114943,DB00682,Warfarin
,30815847,CL(S),"EC50 showed a greater racial difference than CL(S) [1.03, 1.70 and 2.76 μg/mL for Asian, White and African American patients, respectively, p < 0.01).",Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815847/),[μg] / [ml],2.76,114944,DB00682,Warfarin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.90,115460,DB00682,Warfarin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.52,115461,DB00682,Warfarin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.84,115462,DB00682,Warfarin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.01,115463,DB00682,Warfarin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.02,115464,DB00682,Warfarin
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.27,115465,DB00682,Warfarin
,28261644,absolute bioavailabilities,"Ponatinib showed dose-dependent exposure in the circulation system, and the absolute bioavailabilities of ponatinib were 43.95 ± 2.40%, 47.69 ± 5.08% and 55.02 ± 2.50% after intragastric administration of 7.5, 15.0 and 30.0 mg/kg ponatinib in rats, respectively.",Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261644/),%,43.95,117741,DB00682,Warfarin
,28261644,absolute bioavailabilities,"Ponatinib showed dose-dependent exposure in the circulation system, and the absolute bioavailabilities of ponatinib were 43.95 ± 2.40%, 47.69 ± 5.08% and 55.02 ± 2.50% after intragastric administration of 7.5, 15.0 and 30.0 mg/kg ponatinib in rats, respectively.",Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261644/),%,47.69,117742,DB00682,Warfarin
,28261644,absolute bioavailabilities,"Ponatinib showed dose-dependent exposure in the circulation system, and the absolute bioavailabilities of ponatinib were 43.95 ± 2.40%, 47.69 ± 5.08% and 55.02 ± 2.50% after intragastric administration of 7.5, 15.0 and 30.0 mg/kg ponatinib in rats, respectively.",Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261644/),%,55.02,117743,DB00682,Warfarin
,28261644,AUC0-∞,"After consecutive administration at 3.75 mg/kg for 7 days, there was distinct accumulation of ponatinib (AUC0-∞ = 5479.41 ± 757.07 μg h/L) relative to that of a single dose (AUC0-∞ = 2301.84 ± 787.10 μg h/L, p < 0.05), and the MRT increased from 16.77 ± 1.91 to 21.34 ± 1.27 h (p < 0.05).",Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261644/),[h·μg] / [l],5479.41,117744,DB00682,Warfarin
,28261644,AUC0-∞,"After consecutive administration at 3.75 mg/kg for 7 days, there was distinct accumulation of ponatinib (AUC0-∞ = 5479.41 ± 757.07 μg h/L) relative to that of a single dose (AUC0-∞ = 2301.84 ± 787.10 μg h/L, p < 0.05), and the MRT increased from 16.77 ± 1.91 to 21.34 ± 1.27 h (p < 0.05).",Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261644/),[h·μg] / [l],2301.84,117745,DB00682,Warfarin
,28261644,MRT,"After consecutive administration at 3.75 mg/kg for 7 days, there was distinct accumulation of ponatinib (AUC0-∞ = 5479.41 ± 757.07 μg h/L) relative to that of a single dose (AUC0-∞ = 2301.84 ± 787.10 μg h/L, p < 0.05), and the MRT increased from 16.77 ± 1.91 to 21.34 ± 1.27 h (p < 0.05).",Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261644/),h,16.77,117746,DB00682,Warfarin
,28261644,MRT,"After consecutive administration at 3.75 mg/kg for 7 days, there was distinct accumulation of ponatinib (AUC0-∞ = 5479.41 ± 757.07 μg h/L) relative to that of a single dose (AUC0-∞ = 2301.84 ± 787.10 μg h/L, p < 0.05), and the MRT increased from 16.77 ± 1.91 to 21.34 ± 1.27 h (p < 0.05).",Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261644/),h,21.34,117747,DB00682,Warfarin
,1806626,elimination half-life,The elimination half-life is about 32 h; metabolism is by demethylation to an inactive metabolite.,Clinical implications of the pharmacology of sertraline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1806626/),h,32,117841,DB00682,Warfarin
,10362265,plasma elimination half-lives (t1/2),"The plasma elimination half-lives (t1/2) were 1.2 h for antipyrine, 11.9 h for warfarin and 5.2-12.9 h for paracetamol.","Pharmacokinetics of antipyrine, warfarin and paracetamol in the brushtail possum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10362265/),h,1.2,123048,DB00682,Warfarin
,10362265,plasma elimination half-lives (t1/2),"The plasma elimination half-lives (t1/2) were 1.2 h for antipyrine, 11.9 h for warfarin and 5.2-12.9 h for paracetamol.","Pharmacokinetics of antipyrine, warfarin and paracetamol in the brushtail possum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10362265/),h,11.9,123049,DB00682,Warfarin
,10362265,plasma elimination half-lives (t1/2),"The plasma elimination half-lives (t1/2) were 1.2 h for antipyrine, 11.9 h for warfarin and 5.2-12.9 h for paracetamol.","Pharmacokinetics of antipyrine, warfarin and paracetamol in the brushtail possum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10362265/),h,5.2-12.9,123050,DB00682,Warfarin
,3978316,terminal half-life,"After administration of a single intravenous dose (20 mumol kg-1), plasma concentrations of warfarin underwent mono-exponential decay, with a terminal half-life of 5.6 +/- 0.7 h (mean +/- s.e. mean), whereas plasma concentrations of brodifacoum and difenacoum underwent bi-exponential decay with terminal half-lives of 60.8 +/- 1.9 h and 83.1 +/- 10.3 h respectively.","A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978316/),h,5.6,123467,DB00682,Warfarin
,3978316,terminal half-lives,"After administration of a single intravenous dose (20 mumol kg-1), plasma concentrations of warfarin underwent mono-exponential decay, with a terminal half-life of 5.6 +/- 0.7 h (mean +/- s.e. mean), whereas plasma concentrations of brodifacoum and difenacoum underwent bi-exponential decay with terminal half-lives of 60.8 +/- 1.9 h and 83.1 +/- 10.3 h respectively.","A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978316/),h,60.8,123468,DB00682,Warfarin
,3978316,terminal half-lives,"After administration of a single intravenous dose (20 mumol kg-1), plasma concentrations of warfarin underwent mono-exponential decay, with a terminal half-life of 5.6 +/- 0.7 h (mean +/- s.e. mean), whereas plasma concentrations of brodifacoum and difenacoum underwent bi-exponential decay with terminal half-lives of 60.8 +/- 1.9 h and 83.1 +/- 10.3 h respectively.","A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978316/),h,83.1,123469,DB00682,Warfarin
,3978316,plasma half-life,The plasma half-life of brodifacoum in a single patient poisoned with the compound was 487 h.,"A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978316/),h,487,123470,DB00682,Warfarin
,8521677,absolute bio-availability,Zolpidem is approximately 92% bound to plasma proteins; absolute bio-availability of zolpidem is about 70%.,Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),%,70,127592,DB00682,Warfarin
,8521677,peak plasma concentration,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[μg] / [l],192 to 324,127593,DB00682,Warfarin
,8521677,terminal elimination half-line,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),h,1.5 to 3.2,127594,DB00682,Warfarin
,8521677,total clearance,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[ml] / [kg·min],0.24 to 0.27,127595,DB00682,Warfarin
,6370540,oral bioavailability,Available evidence suggests that absorption of amiodarone following oral administration is erratic and unpredictable; oral bioavailability ranges from 22 to 86%.,Clinical pharmacokinetics of amiodarone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),%,22 to 86,128509,DB00682,Warfarin
,6370540,protein binding,In vitro protein binding of amiodarone has been reported to be 96.3 +/- 0.6%.,Clinical pharmacokinetics of amiodarone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),%,96.3,128510,DB00682,Warfarin
,6370540,plasma half-life,The plasma half-life of amiodarone after single-dose administration has been reported to be in the range of 3.2 to 79.7 hours.,Clinical pharmacokinetics of amiodarone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),h,3.2 to 79.7,128511,DB00682,Warfarin
,6370540,half-life,"However, after withdrawal of long term amiodarone treatment the half-life is as long as 100 days.",Clinical pharmacokinetics of amiodarone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),d,100,128512,DB00682,Warfarin
,6370540,Total body clearance,"Total body clearance ranges from 0.10 to 0.77 L/min after single-dose intravenous administration, and the apparent volume of distribution ranges between 0.9 and 148 L/kg.",Clinical pharmacokinetics of amiodarone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),[l] / [min],0.10 to 0.77,128513,DB00682,Warfarin
,6370540,apparent volume of distribution,"Total body clearance ranges from 0.10 to 0.77 L/min after single-dose intravenous administration, and the apparent volume of distribution ranges between 0.9 and 148 L/kg.",Clinical pharmacokinetics of amiodarone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),[l] / [kg],0.9 and 148,128514,DB00682,Warfarin
,6370540,time of onset of action,The time of onset of action of amiodarone after a single intravenous dose ranges between 1 and 30 minutes and its duration of effect between 1 and 3 hours.,Clinical pharmacokinetics of amiodarone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),min,1 and 30,128515,DB00682,Warfarin
,6370540,duration of effect,The time of onset of action of amiodarone after a single intravenous dose ranges between 1 and 30 minutes and its duration of effect between 1 and 3 hours.,Clinical pharmacokinetics of amiodarone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),h,1 and 3,128516,DB00682,Warfarin
,11503010,clearance,"Warfarin doses decreased with age as follows: 7.7 +/- 3.7 versus 4.9 +/- 2.9 mg/d at < 50 years and >66 years (P < .001), mainly as a result of decreased plasma warfarin clearance (2.8 +/- 1.4 mL/min versus 1.9 +/- 0.8 mL/min; P < .001).",Interindividual variability in sensitivity to warfarin--Nature or nurture? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11503010/),[ml] / [min],2.8,128613,DB00682,Warfarin
,11503010,clearance,"Warfarin doses decreased with age as follows: 7.7 +/- 3.7 versus 4.9 +/- 2.9 mg/d at < 50 years and >66 years (P < .001), mainly as a result of decreased plasma warfarin clearance (2.8 +/- 1.4 mL/min versus 1.9 +/- 0.8 mL/min; P < .001).",Interindividual variability in sensitivity to warfarin--Nature or nurture? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11503010/),[ml] / [min],1.9,128614,DB00682,Warfarin
,8801058,Ki,"This approach begins with a determination of an in vitro Ki value (22 microM), which may be used to relate fluconazole plasma concentrations to inhibitory effect on P4502C9 activity and (S)-warfarin half-life.",Warfarin-fluconazole. A rational approach to management of a metabolically based drug interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801058/),μM,22,128869,DB00682,Warfarin
,22339447,absolute bioavailability,"Following oral administration, vildagliptin is rapidly and well absorbed with an absolute bioavailability of 85%.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),%,85,128972,DB00682,Warfarin
,22339447,volume of distribution,"Vildagliptin is minimally bound to plasma proteins (9.3%) and, on the basis of a volume of distribution of 71 L, it is considered to distribute extensively into extravascular spaces.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),l,71,128973,DB00682,Warfarin
,22339447,Renal clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],13,128974,DB00682,Warfarin
,22339447,total body clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],41,128975,DB00682,Warfarin
,22339447,IC(50)),"Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[nM] / [l],4.5,128976,DB00682,Warfarin
,10511917,half-life,"Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),h,33,129674,DB00682,Warfarin
,10511917,apparent plasma clearance,"The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),[l] / [h],26,129675,DB00682,Warfarin
,21176310,terminal elimination half-life,"Warfarin has a long half-life; following a single dose, the terminal elimination half-life is about one week, with a mean effective half-life of 40 hours.","The ""warfarin window"" in pregnancy: the importance of half-life. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176310/),week,one,131307,DB00682,Warfarin
,21176310,effective half-life,"Warfarin has a long half-life; following a single dose, the terminal elimination half-life is about one week, with a mean effective half-life of 40 hours.","The ""warfarin window"" in pregnancy: the importance of half-life. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176310/),h,40,131308,DB00682,Warfarin
higher,23384552,recoveries,The mean recoveries of coumarins and IS were higher than 84%.,"Simultaneous determination of scopoletin, psoralen, bergapten, xanthotoxin, columbianetin acetate, imperatorin, osthole and isoimperatorin in rat plasma by LC-MS/MS for pharmacokinetic studies following oral administration of Radix Angelicae Pubescentis extract. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23384552/),%,84,132300,DB00682,Warfarin
,11422000,CL/F,"Administration of anastrozole resulted in no clinically significant changes in the pharmacokinetics of either R- or S-warfarin compared with placebo for AUC (ng ml-1 h) (glsmean, R-warfarin; anastrozole 93619.9, placebo 91127.91, 95%CI 0.988-1.068; S-warfarin; anastrozole 57129.21, placebo 55676.34, 95%CI 0.979-1.076), CL/F (ml min-1) (glsmean, R-warfarin; anastrozole 2.23, placebo 2.29, 95%CI 0.937-1.012; S-warfarin; anastrozole 3.65, placebo 3.74, 95%CI 0.929-1.021) and t1/2 (h) (lsmean, R-warfarin; anastrozole 55.40, placebo 55.15, 95%CI-2.083-2.592; S-warfarin; anastrozole 39.38, placebo 40.98, 95%CI-6.189-2.996).",The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422000/),[ml] / [min],2.23,132490,DB00682,Warfarin
,11422000,CL/F,"Administration of anastrozole resulted in no clinically significant changes in the pharmacokinetics of either R- or S-warfarin compared with placebo for AUC (ng ml-1 h) (glsmean, R-warfarin; anastrozole 93619.9, placebo 91127.91, 95%CI 0.988-1.068; S-warfarin; anastrozole 57129.21, placebo 55676.34, 95%CI 0.979-1.076), CL/F (ml min-1) (glsmean, R-warfarin; anastrozole 2.23, placebo 2.29, 95%CI 0.937-1.012; S-warfarin; anastrozole 3.65, placebo 3.74, 95%CI 0.929-1.021) and t1/2 (h) (lsmean, R-warfarin; anastrozole 55.40, placebo 55.15, 95%CI-2.083-2.592; S-warfarin; anastrozole 39.38, placebo 40.98, 95%CI-6.189-2.996).",The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422000/),[ml] / [min],2.29,132491,DB00682,Warfarin
,11422000,CL/F,"Administration of anastrozole resulted in no clinically significant changes in the pharmacokinetics of either R- or S-warfarin compared with placebo for AUC (ng ml-1 h) (glsmean, R-warfarin; anastrozole 93619.9, placebo 91127.91, 95%CI 0.988-1.068; S-warfarin; anastrozole 57129.21, placebo 55676.34, 95%CI 0.979-1.076), CL/F (ml min-1) (glsmean, R-warfarin; anastrozole 2.23, placebo 2.29, 95%CI 0.937-1.012; S-warfarin; anastrozole 3.65, placebo 3.74, 95%CI 0.929-1.021) and t1/2 (h) (lsmean, R-warfarin; anastrozole 55.40, placebo 55.15, 95%CI-2.083-2.592; S-warfarin; anastrozole 39.38, placebo 40.98, 95%CI-6.189-2.996).",The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422000/),[ml] / [min],3.65,132492,DB00682,Warfarin
,11422000,CL/F,"Administration of anastrozole resulted in no clinically significant changes in the pharmacokinetics of either R- or S-warfarin compared with placebo for AUC (ng ml-1 h) (glsmean, R-warfarin; anastrozole 93619.9, placebo 91127.91, 95%CI 0.988-1.068; S-warfarin; anastrozole 57129.21, placebo 55676.34, 95%CI 0.979-1.076), CL/F (ml min-1) (glsmean, R-warfarin; anastrozole 2.23, placebo 2.29, 95%CI 0.937-1.012; S-warfarin; anastrozole 3.65, placebo 3.74, 95%CI 0.929-1.021) and t1/2 (h) (lsmean, R-warfarin; anastrozole 55.40, placebo 55.15, 95%CI-2.083-2.592; S-warfarin; anastrozole 39.38, placebo 40.98, 95%CI-6.189-2.996).",The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422000/),[ml] / [min],3.74,132493,DB00682,Warfarin
,11422000,t1/2,"Administration of anastrozole resulted in no clinically significant changes in the pharmacokinetics of either R- or S-warfarin compared with placebo for AUC (ng ml-1 h) (glsmean, R-warfarin; anastrozole 93619.9, placebo 91127.91, 95%CI 0.988-1.068; S-warfarin; anastrozole 57129.21, placebo 55676.34, 95%CI 0.979-1.076), CL/F (ml min-1) (glsmean, R-warfarin; anastrozole 2.23, placebo 2.29, 95%CI 0.937-1.012; S-warfarin; anastrozole 3.65, placebo 3.74, 95%CI 0.929-1.021) and t1/2 (h) (lsmean, R-warfarin; anastrozole 55.40, placebo 55.15, 95%CI-2.083-2.592; S-warfarin; anastrozole 39.38, placebo 40.98, 95%CI-6.189-2.996).",The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422000/),l,55.,132494,DB00682,Warfarin
,11422000,t1/2,"Administration of anastrozole resulted in no clinically significant changes in the pharmacokinetics of either R- or S-warfarin compared with placebo for AUC (ng ml-1 h) (glsmean, R-warfarin; anastrozole 93619.9, placebo 91127.91, 95%CI 0.988-1.068; S-warfarin; anastrozole 57129.21, placebo 55676.34, 95%CI 0.979-1.076), CL/F (ml min-1) (glsmean, R-warfarin; anastrozole 2.23, placebo 2.29, 95%CI 0.937-1.012; S-warfarin; anastrozole 3.65, placebo 3.74, 95%CI 0.929-1.021) and t1/2 (h) (lsmean, R-warfarin; anastrozole 55.40, placebo 55.15, 95%CI-2.083-2.592; S-warfarin; anastrozole 39.38, placebo 40.98, 95%CI-6.189-2.996).",The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422000/),l,55.15,132495,DB00682,Warfarin
,11888331,terminal elimination half-life,"The drug binds to plasma proteins (>99%), predominantly to albumin, and has a mean terminal elimination half-life of approximately 10 hours in both healthy volunteers and patients with asthma.",Pharmacokinetic profile of zafirlukast. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888331/),h,10,132702,DB00682,Warfarin
more,2191442,oral bioavailability,"The pharmacokinetic profile of fluconazole clearly distinguishes it from other antifungal agents; oral bioavailability is more than 90%, and plasma protein binding is 12%.",The clinical pharmacology of fluconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),%,90,132916,DB00682,Warfarin
,2191442,plasma protein binding,"The pharmacokinetic profile of fluconazole clearly distinguishes it from other antifungal agents; oral bioavailability is more than 90%, and plasma protein binding is 12%.",The clinical pharmacology of fluconazole. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),%,12,132917,DB00682,Warfarin
,2191442,elimination half-life,The mean elimination half-life is approximately 30 hours.,The clinical pharmacology of fluconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),h,30,132918,DB00682,Warfarin
,3370058,plasma elimination half-life,In accordance with the pharmacodynamic characteristics plasma elimination half-life of torasemide was about 1.5 h in the rat and bioavailability was nearly complete.,Chemistry and pharmacological properties of the pyridine-3-sulfonylurea derivative torasemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370058/),h,1.5,135635,DB00682,Warfarin
,26041408,oral bioavailability,Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %.,"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),%,65,135780,DB00682,Warfarin
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,10.6,135781,DB00682,Warfarin
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,13.1,135782,DB00682,Warfarin
,23208431,Bioavailabilities,"Bioavailabilities were approximately 80% for caffeine and warfarin, but less than 10% for omeprazole, metoprolol, and midazolam.","Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208431/),%,80,137185,DB00682,Warfarin
less,23208431,Bioavailabilities,"Bioavailabilities were approximately 80% for caffeine and warfarin, but less than 10% for omeprazole, metoprolol, and midazolam.","Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208431/),%,10,137186,DB00682,Warfarin
,12775969,Area under the effect-time curve (AUEC(0-1)),"Area under the effect-time curve (AUEC(0-1)) and maximum effect over the entire sampling phase (E(max)) for warfarin INR were 219.58 and 2.071 with treprostinil and 218.93 and 2.041 with vehicle, respectively.",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),,219.58,138047,DB00682,Warfarin
,12775969,Area under the effect-time curve (AUEC(0-1)),"Area under the effect-time curve (AUEC(0-1)) and maximum effect over the entire sampling phase (E(max)) for warfarin INR were 219.58 and 2.071 with treprostinil and 218.93 and 2.041 with vehicle, respectively.",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),,218.93,138048,DB00682,Warfarin
,12775969,maximum effect over the entire sampling phase (E(max)),"Area under the effect-time curve (AUEC(0-1)) and maximum effect over the entire sampling phase (E(max)) for warfarin INR were 219.58 and 2.071 with treprostinil and 218.93 and 2.041 with vehicle, respectively.",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),,2.071,138049,DB00682,Warfarin
,12775969,maximum effect over the entire sampling phase (E(max)),"Area under the effect-time curve (AUEC(0-1)) and maximum effect over the entire sampling phase (E(max)) for warfarin INR were 219.58 and 2.071 with treprostinil and 218.93 and 2.041 with vehicle, respectively.",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),,2.041,138050,DB00682,Warfarin
,12775969,time to attain the peak concentration,"Mean time to attain the peak concentration of R-enantiomer of warfarin (T(max)), half-life, and elimination rate constant (k(el)) were 1.9 hours, 51.688 hours, and 0.0137 per hour, respectively, in the presence of treprostinil and 1.5 hours, 52.579 hours, and 0.0137 per hour, respectively, in the presence of vehicle (control).",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),h,1.9,138051,DB00682,Warfarin
,12775969,half-life,"Mean time to attain the peak concentration of R-enantiomer of warfarin (T(max)), half-life, and elimination rate constant (k(el)) were 1.9 hours, 51.688 hours, and 0.0137 per hour, respectively, in the presence of treprostinil and 1.5 hours, 52.579 hours, and 0.0137 per hour, respectively, in the presence of vehicle (control).",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),h,51.688,138052,DB00682,Warfarin
,12775969,half-life,"Mean time to attain the peak concentration of R-enantiomer of warfarin (T(max)), half-life, and elimination rate constant (k(el)) were 1.9 hours, 51.688 hours, and 0.0137 per hour, respectively, in the presence of treprostinil and 1.5 hours, 52.579 hours, and 0.0137 per hour, respectively, in the presence of vehicle (control).",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),h,1.5,138053,DB00682,Warfarin
,12775969,half-life,"Mean time to attain the peak concentration of R-enantiomer of warfarin (T(max)), half-life, and elimination rate constant (k(el)) were 1.9 hours, 51.688 hours, and 0.0137 per hour, respectively, in the presence of treprostinil and 1.5 hours, 52.579 hours, and 0.0137 per hour, respectively, in the presence of vehicle (control).",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),h,52.579,138054,DB00682,Warfarin
,12775969,elimination rate constant (k(el)),"Mean time to attain the peak concentration of R-enantiomer of warfarin (T(max)), half-life, and elimination rate constant (k(el)) were 1.9 hours, 51.688 hours, and 0.0137 per hour, respectively, in the presence of treprostinil and 1.5 hours, 52.579 hours, and 0.0137 per hour, respectively, in the presence of vehicle (control).",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),1/[h],0.0137,138055,DB00682,Warfarin
,21053991,elimination half-life,"Consistent with an elimination half-life of ∼24 hours, steady-state conditions are reached within 4 days of repeat dosing.",A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053991/),h,∼24,138379,DB00682,Warfarin
,15801937,apparent clearances,"The mean (95% CI) apparent clearances of S-warfarin after warfarin alone, with ginkgo or ginger were 189 (167-210) ml h(-1), 200 (173-227) ml h(-1) and 201 (171-231) ml h(-1), respectively.",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],189,138845,DB00682,Warfarin
,15801937,apparent clearances,"The mean (95% CI) apparent clearances of S-warfarin after warfarin alone, with ginkgo or ginger were 189 (167-210) ml h(-1), 200 (173-227) ml h(-1) and 201 (171-231) ml h(-1), respectively.",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],200,138846,DB00682,Warfarin
,15801937,apparent clearances,"The mean (95% CI) apparent clearances of S-warfarin after warfarin alone, with ginkgo or ginger were 189 (167-210) ml h(-1), 200 (173-227) ml h(-1) and 201 (171-231) ml h(-1), respectively.",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],201,138847,DB00682,Warfarin
,15801937,apparent clearances,"The respective apparent clearances of R-warfarin were 127 (106-149) ml h(-1), 126 (111-141) ml h(-1) and 131 (106-156) ml h(-1).",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],127,138848,DB00682,Warfarin
,15801937,apparent clearances,"The respective apparent clearances of R-warfarin were 127 (106-149) ml h(-1), 126 (111-141) ml h(-1) and 131 (106-156) ml h(-1).",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],126,138849,DB00682,Warfarin
,15801937,apparent clearances,"The respective apparent clearances of R-warfarin were 127 (106-149) ml h(-1), 126 (111-141) ml h(-1) and 131 (106-156) ml h(-1).",Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801937/),[ml] / [h],131,138850,DB00682,Warfarin
,29315691,flow rate,"Plasma samples were extracted by liquid-liquid extraction and the chromatographic separation was achieved on a Chiralpak IA column with an isocratic mobile phase 5 mm ammonium acetate-absolute alcohol (20:80, v/v) at a flow rate of 1.0 mL/min.",Validation of a chiral LC-MS/MS-ESI method for the simultaneous quantification of darolutamide diastereomers in mouse plasma and its application to a stereoselective pharmacokinetic study in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315691/),[ml] / [min],1.0,140000,DB00682,Warfarin
,29315691,maximum concentration,"Following oral administration of darolutamide at 10 mg/kg, maximum concentration in plasma was 4189 and 726 ng/mL for diastereomer-1 and diastereomer-2, respectively.",Validation of a chiral LC-MS/MS-ESI method for the simultaneous quantification of darolutamide diastereomers in mouse plasma and its application to a stereoselective pharmacokinetic study in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315691/),[ng] / [ml],4189,140001,DB00682,Warfarin
,29315691,maximum concentration,"Following oral administration of darolutamide at 10 mg/kg, maximum concentration in plasma was 4189 and 726 ng/mL for diastereomer-1 and diastereomer-2, respectively.",Validation of a chiral LC-MS/MS-ESI method for the simultaneous quantification of darolutamide diastereomers in mouse plasma and its application to a stereoselective pharmacokinetic study in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315691/),[ng] / [ml],726,140002,DB00682,Warfarin
,29315691,terminal half-life,The terminal half-life was found to be ~0.50 h for both the diastereomers.,Validation of a chiral LC-MS/MS-ESI method for the simultaneous quantification of darolutamide diastereomers in mouse plasma and its application to a stereoselective pharmacokinetic study in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315691/),h,0.50,140003,DB00682,Warfarin
,29315691,AUC(0-t),"The AUC(0-t) was found to be 18,961 ng*h/mL for diastereomer-1 and 1340 ng*h/mL diastereomer-2.",Validation of a chiral LC-MS/MS-ESI method for the simultaneous quantification of darolutamide diastereomers in mouse plasma and its application to a stereoselective pharmacokinetic study in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315691/),[h·ng] / [ml],"18,961",140004,DB00682,Warfarin
,29315691,AUC(0-t),"The AUC(0-t) was found to be 18,961 ng*h/mL for diastereomer-1 and 1340 ng*h/mL diastereomer-2.",Validation of a chiral LC-MS/MS-ESI method for the simultaneous quantification of darolutamide diastereomers in mouse plasma and its application to a stereoselective pharmacokinetic study in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315691/),[h·ng] / [ml],1340,140005,DB00682,Warfarin
,72818,total clearance,The total clearance of dicumarol in these animals ranged from 3.93 to 14.5 ml/kg/hr.,Comparative pharmacokinetics of coumarin anticoagulants XXX: Relationship between total clearance and serum protein binding of dicumarol in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/72818/),[ml] / [h·kg],3.93 to 14.5,141450,DB00682,Warfarin
,12621390,unbound oral clearance,"When interpopulation comparisons of CYP2C9 activity were made for genotype-matched subjects, Japanese patients with the homozygous CYP2C9*1 (wild-type) genotype (n = 85) had significantly (P <.01) greater median values for unbound oral clearance and formation clearance than Caucasian patients with the corresponding genotype (n = 26), 10.4 mL x min(-1) x kg(-1) versus 4.25 mL x min(-1) x kg(-1) and 0.015 mL x min(-1) x kg(-1) versus 0.010 mL x min(-1) x kg(-1), respectively.",Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621390/),[ml] / [kg·min],10.4,141967,DB00682,Warfarin
,12621390,unbound oral clearance,"When interpopulation comparisons of CYP2C9 activity were made for genotype-matched subjects, Japanese patients with the homozygous CYP2C9*1 (wild-type) genotype (n = 85) had significantly (P <.01) greater median values for unbound oral clearance and formation clearance than Caucasian patients with the corresponding genotype (n = 26), 10.4 mL x min(-1) x kg(-1) versus 4.25 mL x min(-1) x kg(-1) and 0.015 mL x min(-1) x kg(-1) versus 0.010 mL x min(-1) x kg(-1), respectively.",Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621390/),[ml] / [kg·min],4.25,141968,DB00682,Warfarin
,12621390,formation clearance,"When interpopulation comparisons of CYP2C9 activity were made for genotype-matched subjects, Japanese patients with the homozygous CYP2C9*1 (wild-type) genotype (n = 85) had significantly (P <.01) greater median values for unbound oral clearance and formation clearance than Caucasian patients with the corresponding genotype (n = 26), 10.4 mL x min(-1) x kg(-1) versus 4.25 mL x min(-1) x kg(-1) and 0.015 mL x min(-1) x kg(-1) versus 0.010 mL x min(-1) x kg(-1), respectively.",Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621390/),[ml] / [kg·min],4.25,141969,DB00682,Warfarin
,12621390,formation clearance,"When interpopulation comparisons of CYP2C9 activity were made for genotype-matched subjects, Japanese patients with the homozygous CYP2C9*1 (wild-type) genotype (n = 85) had significantly (P <.01) greater median values for unbound oral clearance and formation clearance than Caucasian patients with the corresponding genotype (n = 26), 10.4 mL x min(-1) x kg(-1) versus 4.25 mL x min(-1) x kg(-1) and 0.015 mL x min(-1) x kg(-1) versus 0.010 mL x min(-1) x kg(-1), respectively.",Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621390/),[ml] / [kg·min],0.015,141970,DB00682,Warfarin
,12621390,formation clearance,"When interpopulation comparisons of CYP2C9 activity were made for genotype-matched subjects, Japanese patients with the homozygous CYP2C9*1 (wild-type) genotype (n = 85) had significantly (P <.01) greater median values for unbound oral clearance and formation clearance than Caucasian patients with the corresponding genotype (n = 26), 10.4 mL x min(-1) x kg(-1) versus 4.25 mL x min(-1) x kg(-1) and 0.015 mL x min(-1) x kg(-1) versus 0.010 mL x min(-1) x kg(-1), respectively.",Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621390/),[ml] / [kg·min],0.010,141971,DB00682,Warfarin
,22853867,relative AUC0-12 ratio,The relative AUC0-12 ratio of lansoprazole in EMs and PMs was 1:3.3 - 4.3.,Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22853867/),,1,142475,DB00682,Warfarin
,22075505,Ratio of,"Pharmacodynamic sensitivity in older patients (≥ 75 years) with the CYP2C9 *1/*1 and VKORC1 1173 TT genotypes was significantly higher as compared to younger patients (<75 years) [Ratio of INR/S-warfarin concentration, 4.88 vs. 3.41; p = 0.026].","The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22075505/),,4.88,143055,DB00682,Warfarin
,22075505,Ratio of,"Pharmacodynamic sensitivity in older patients (≥ 75 years) with the CYP2C9 *1/*1 and VKORC1 1173 TT genotypes was significantly higher as compared to younger patients (<75 years) [Ratio of INR/S-warfarin concentration, 4.88 vs. 3.41; p = 0.026].","The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22075505/),,3.41,143056,DB00682,Warfarin
,21366359,maximum plasma concentration (C(max)),Duloxetine achieves a maximum plasma concentration (C(max)) of approximately 47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approximately 6 hours after dosing.,Duloxetine: clinical pharmacokinetics and drug interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),[ng] / [ml],47,143268,DB00682,Warfarin
,21366359,maximum plasma concentration (C(max)),Duloxetine achieves a maximum plasma concentration (C(max)) of approximately 47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approximately 6 hours after dosing.,Duloxetine: clinical pharmacokinetics and drug interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),[ng] / [ml],110,143269,DB00682,Warfarin
,21366359,elimination half-life,The elimination half-life of duloxetine is approximately 10-12 hours and the volume of distribution is approximately 1640 L.,Duloxetine: clinical pharmacokinetics and drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),h,10-12,143270,DB00682,Warfarin
,21366359,volume of distribution,The elimination half-life of duloxetine is approximately 10-12 hours and the volume of distribution is approximately 1640 L.,Duloxetine: clinical pharmacokinetics and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),l,1640,143271,DB00682,Warfarin
,25767371,maximum observed plasma concentration (C max),"The maximum observed plasma concentration (C max) values were 1.0167 (90% CI: 0.9507, 1.0872) for R-warfarin and 1.0028 (90% CI: 0.9518, 1.0992) for S-warfarin, both of which were contained in the interval 0.80-1.25.","Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767371/),,1.0167,144109,DB00682,Warfarin
,25767371,maximum observed plasma concentration (C max),"The maximum observed plasma concentration (C max) values were 1.0167 (90% CI: 0.9507, 1.0872) for R-warfarin and 1.0028 (90% CI: 0.9518, 1.0992) for S-warfarin, both of which were contained in the interval 0.80-1.25.","Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767371/),,1.0028,144110,DB00682,Warfarin
,26068539,Oral bioavailability,Oral bioavailability is 62% in healthy subjects and the terminal half-life is approximately 10-14 h.,Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068539/),%,62,146120,DB00682,Warfarin
,26068539,terminal half-life,Oral bioavailability is 62% in healthy subjects and the terminal half-life is approximately 10-14 h.,Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068539/),h,10-14,146121,DB00682,Warfarin
<,8024649,plasma clearances,"However, based on literature data for 18 non-steroidal anti-inflammatory drugs (NSAIDs) with low plasma clearances (< 60 ml/min), we have shown that most of these low-extraction compounds are non-restrictively eliminated, i.e. their hepatic extraction ratio exceeds their unbound fraction in plasma.",Non-steroidal anti-inflammatory drugs: restrictive or non-restrictive hepatic clearance? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8024649/),[ml] / [min],60,146392,DB00682,Warfarin
,1941624,maximum concentration,"In vivo, plasma concentrations of AW rose only slowly after a dose of 10 mg/kg AGAW i.v. to give a maximum concentration of about 3 micrograms AW/ml at t = 14 to 24 h.",Renal selective N-acetyl-L-gamma-glutamyl prodrugs. N-acetyl-L-gamma-glutamyl-4'-aminowarfarin is not targeted to the kidney but is selectively excreted into the bile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941624/),[aw·μg] / [ml],3,148255,DB00682,Warfarin
,28982059,total chromatographic run time,The total chromatographic run time was 3.2min.,"LC-MS/MS determination of tideglusib, a novel GSK-3β inhibitor in mice plasma and its application to a pharmacokinetic study in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28982059/),min,3.2,148855,DB00682,Warfarin
above,1978486,bioavailability,After oral administration the drug is rapidly and almost completely absorbed with a bioavailability above 90%.,Clinical pharmacokinetics of remoxipride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),%,90,148873,DB00682,Warfarin
,1978486,systemic plasma clearance,"Thus remoxipride is a low clearance drug, with a systemic plasma clearance of about 120 ml/min, and without any first-pass metabolism.",Clinical pharmacokinetics of remoxipride. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),[ml] / [min],120,148874,DB00682,Warfarin
,1978486,apparent volume of distribution,"The apparent volume of distribution is 0.7 1/kg, about 80% being bound to plasma proteins (mainly alpha 1-acid glycoprotein).",Clinical pharmacokinetics of remoxipride. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),[1] / [kg],0.7,148875,DB00682,Warfarin
,1978486,plasma half-life,Remoxipride has a plasma half-life in the range of 4-7 h and is eliminated by both hepatic metabolism and renal excretion.,Clinical pharmacokinetics of remoxipride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),h,4-7,148876,DB00682,Warfarin
,16027402,Cmax,"The Cmax of R- and S-warfarin was approximately 840 to 890 ng/mL and 680 to 730 ng/mL, respectively, and was similar in the absence and presence of pentosan polysulfate sodium.",Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027402/),[ng] / [ml],840 to 890,151060,DB00682,Warfarin
,16027402,Cmax,"The Cmax of R- and S-warfarin was approximately 840 to 890 ng/mL and 680 to 730 ng/mL, respectively, and was similar in the absence and presence of pentosan polysulfate sodium.",Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027402/),[ng] / [ml],680 to 730,151061,DB00682,Warfarin
,16027402,half-life,"The half-life for R- and S-warfarin was 52 to 56 hours and 36 to 40 hours, respectively.",Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027402/),h,52 to 56,151062,DB00682,Warfarin
,16027402,half-life,"The half-life for R- and S-warfarin was 52 to 56 hours and 36 to 40 hours, respectively.",Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027402/),h,36 to 40,151063,DB00682,Warfarin
,18679669,C(max),"For R-warfarin, mean +/- SD C(max) was 1,619 +/- 284 ng/mL for test and 1,649 +/- 357 ng/mL for reference, while AUC(0-t ) was 92,796 +/- 18,976 ng x h/mL (test) and 73,597 +/- 11,363 ng x h/mL (reference).",Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679669/),[ng] / [ml],"1,619",151233,DB00682,Warfarin
,18679669,C(max),"For R-warfarin, mean +/- SD C(max) was 1,619 +/- 284 ng/mL for test and 1,649 +/- 357 ng/mL for reference, while AUC(0-t ) was 92,796 +/- 18,976 ng x h/mL (test) and 73,597 +/- 11,363 ng x h/mL (reference).",Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679669/),[ng] / [ml],"1,649",151234,DB00682,Warfarin
,18679669,AUC(0-t ),"For R-warfarin, mean +/- SD C(max) was 1,619 +/- 284 ng/mL for test and 1,649 +/- 357 ng/mL for reference, while AUC(0-t ) was 92,796 +/- 18,976 ng x h/mL (test) and 73,597 +/- 11,363 ng x h/mL (reference).",Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679669/),[h·ng] / [ml],"92,796",151235,DB00682,Warfarin
,18679669,AUC(0-t ),"For R-warfarin, mean +/- SD C(max) was 1,619 +/- 284 ng/mL for test and 1,649 +/- 357 ng/mL for reference, while AUC(0-t ) was 92,796 +/- 18,976 ng x h/mL (test) and 73,597 +/- 11,363 ng x h/mL (reference).",Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679669/),[h·ng] / [ml],"73,597",151236,DB00682,Warfarin
,18679669,C(max),"For S-warfarin, mean +/- SD C(max) was 1,644 +/- 331 ng/mL for test and 1,739 +/- 392 ng/mL for reference, while AUC(0-t ) was 66,627 +/- 41,199 ng x h/mL (test) and 70,178 +/- 42,560 ng x h/mL (reference).",Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679669/),[ng] / [ml],"1,644",151237,DB00682,Warfarin
,18679669,C(max),"For S-warfarin, mean +/- SD C(max) was 1,644 +/- 331 ng/mL for test and 1,739 +/- 392 ng/mL for reference, while AUC(0-t ) was 66,627 +/- 41,199 ng x h/mL (test) and 70,178 +/- 42,560 ng x h/mL (reference).",Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679669/),[ng] / [ml],"1,739",151238,DB00682,Warfarin
,18679669,AUC(0-t ),"For S-warfarin, mean +/- SD C(max) was 1,644 +/- 331 ng/mL for test and 1,739 +/- 392 ng/mL for reference, while AUC(0-t ) was 66,627 +/- 41,199 ng x h/mL (test) and 70,178 +/- 42,560 ng x h/mL (reference).",Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679669/),[h·ng] / [ml],"66,627",151239,DB00682,Warfarin
,18679669,AUC(0-t ),"For S-warfarin, mean +/- SD C(max) was 1,644 +/- 331 ng/mL for test and 1,739 +/- 392 ng/mL for reference, while AUC(0-t ) was 66,627 +/- 41,199 ng x h/mL (test) and 70,178 +/- 42,560 ng x h/mL (reference).",Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679669/),[h·ng] / [ml],"70,178",151240,DB00682,Warfarin
,18211619,S/R ratios of AUC,The S/R ratios of AUC of warfarin enantiomers were 0.51 in hmEMs and 0.37 in PMs (P = 0.0052).,The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18211619/),,0.51,151518,DB00682,Warfarin
,18211619,S/R ratios of AUC,The S/R ratios of AUC of warfarin enantiomers were 0.51 in hmEMs and 0.37 in PMs (P = 0.0052).,The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18211619/),,0.37,151519,DB00682,Warfarin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,27,151996,DB00682,Warfarin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,80,151997,DB00682,Warfarin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),[μM] / [l],16,151998,DB00682,Warfarin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,75,151999,DB00682,Warfarin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,19.3,152000,DB00682,Warfarin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,21.5,152001,DB00682,Warfarin
,8375128,total plasma clearance,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],3.6,154686,DB00682,Warfarin
,8375128,total plasma clearance,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],3.82,154687,DB00682,Warfarin
,8375128,elimination half-life,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),h,29.5,154688,DB00682,Warfarin
,8375128,elimination half-life,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),h,25.9,154689,DB00682,Warfarin
,8375128,steady-state volume of distribution,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [kg],153,154690,DB00682,Warfarin
,8375128,steady-state volume of distribution,"The total plasma clearance of (S)-warfarin (subjects with cystic fibrosis, 3.6 +/- 0.48 ml/hr/kg; control subjects, 3.82 +/- 0.73 ml/hr/kg), elimination half-life (subjects with cystic fibrosis, 29.5 +/- 4.2 hours; control subjects, 25.9 +/- 5.4 hours); and steady-state volume of distribution (subjects with cystic fibrosis, 153 +/- 18 ml/kg; control subjects, 138 +/- 22 ml/kg) were similar in the two groups (p > 0.05).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [kg],138,154691,DB00682,Warfarin
,8375128,metabolic clearance,"The metabolic clearance of (S)-warfarin to its major metabolites mediated by CYP2C9, 6-hydroxywarfarin and 7-hydroxywarfarin, was not significantly (p > 0.05) different between the two groups (6-hydroxywarfarin: subjects with cystic fibrosis, 0.33 +/- 0.1 ml/hr/kg; control subjects, 0.41 +/- 0.1 ml/hr/kg; 7-hydroxywarfarin: subjects with cystic fibrosis, 1.34 +/- 0.49 ml/hr/kg; control subjects, 1.8 +/- 0.45 ml/hr/kg).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],0.33,154692,DB00682,Warfarin
,8375128,metabolic clearance,"The metabolic clearance of (S)-warfarin to its major metabolites mediated by CYP2C9, 6-hydroxywarfarin and 7-hydroxywarfarin, was not significantly (p > 0.05) different between the two groups (6-hydroxywarfarin: subjects with cystic fibrosis, 0.33 +/- 0.1 ml/hr/kg; control subjects, 0.41 +/- 0.1 ml/hr/kg; 7-hydroxywarfarin: subjects with cystic fibrosis, 1.34 +/- 0.49 ml/hr/kg; control subjects, 1.8 +/- 0.45 ml/hr/kg).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],0.41,154693,DB00682,Warfarin
,8375128,metabolic clearance,"The metabolic clearance of (S)-warfarin to its major metabolites mediated by CYP2C9, 6-hydroxywarfarin and 7-hydroxywarfarin, was not significantly (p > 0.05) different between the two groups (6-hydroxywarfarin: subjects with cystic fibrosis, 0.33 +/- 0.1 ml/hr/kg; control subjects, 0.41 +/- 0.1 ml/hr/kg; 7-hydroxywarfarin: subjects with cystic fibrosis, 1.34 +/- 0.49 ml/hr/kg; control subjects, 1.8 +/- 0.45 ml/hr/kg).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],1.34,154694,DB00682,Warfarin
,8375128,metabolic clearance,"The metabolic clearance of (S)-warfarin to its major metabolites mediated by CYP2C9, 6-hydroxywarfarin and 7-hydroxywarfarin, was not significantly (p > 0.05) different between the two groups (6-hydroxywarfarin: subjects with cystic fibrosis, 0.33 +/- 0.1 ml/hr/kg; control subjects, 0.41 +/- 0.1 ml/hr/kg; 7-hydroxywarfarin: subjects with cystic fibrosis, 1.34 +/- 0.49 ml/hr/kg; control subjects, 1.8 +/- 0.45 ml/hr/kg).",Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375128/),[ml] / [h·kg],1.8,154695,DB00682,Warfarin
,25475601,maximum effect (Emax ),"The mean maximum effect (Emax ) for INR after co-administration was 2.79-4.15 (mean PT Emax 41.0-62.7 s), compared with 1.41-1.74 (mean PT Emax 20.1-25.2 s) for warfarin alone.",Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475601/),,2.79-4.15,156004,DB00682,Warfarin
,25475601,Emax,"The mean maximum effect (Emax ) for INR after co-administration was 2.79-4.15 (mean PT Emax 41.0-62.7 s), compared with 1.41-1.74 (mean PT Emax 20.1-25.2 s) for warfarin alone.",Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475601/),s,41.0-62.7,156005,DB00682,Warfarin
,25475601,Emax,"The mean maximum effect (Emax ) for INR after co-administration was 2.79-4.15 (mean PT Emax 41.0-62.7 s), compared with 1.41-1.74 (mean PT Emax 20.1-25.2 s) for warfarin alone.",Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475601/),,1.41-1.74,156006,DB00682,Warfarin
,25475601,Emax,"The mean maximum effect (Emax ) for INR after co-administration was 2.79-4.15 (mean PT Emax 41.0-62.7 s), compared with 1.41-1.74 (mean PT Emax 20.1-25.2 s) for warfarin alone.",Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475601/),s,20.1-25.2,156007,DB00682,Warfarin
,10589373,oral bioavailability,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),%,52 to 55,162570,DB00682,Warfarin
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],1.01 to 1.52,162571,DB00682,Warfarin
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],2.41 to 2.85,162572,DB00682,Warfarin
,10589373,elimination half-life,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),h,3.3 to 4.9,162573,DB00682,Warfarin
,10589373,total body clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],29.2 to 58.1,162574,DB00682,Warfarin
,10589373,renal clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],6.7 to 12.8,162575,DB00682,Warfarin
,21481181,IC(50),"S35972 inhibited human thrombin with an IC(50) of 3.7 nm, and did not inhibit other serine proteases.","S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21481181/),nm,3.7,163436,DB00682,Warfarin
,21481181,bioavailability,"In the fasted dog, oral administration of 3 mg kg(-1) S35972 increased TT rapidly and for at least 8 h, and its pharmacologic bioavailability was 75.4% ± 0.1%.","S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21481181/),%,75.4,163437,DB00682,Warfarin
,9143864,total plasma concentration,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),[μg] / [ml],2.19,163446,DB00682,Warfarin
,9143864,total plasma concentration,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),[μg] / [ml],2.43,163447,DB00682,Warfarin
,9143864,percentage unbound drug in the plasma,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),%,0.61,163448,DB00682,Warfarin
,9143864,percentage unbound drug in the plasma,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),%,0.64,163449,DB00682,Warfarin
,9143864,unbound plasma concentration,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),ng,13.8,163450,DB00682,Warfarin
,9143864,unbound plasma concentration,"The total plasma concentration (2.19 vs. 2.43 micrograms.ml-1), the percentage unbound drug in the plasma (0.61 vs. 0.64%) and the unbound plasma concentration (13.8 vs. 15.1 ng.",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),ng,15.1,163451,DB00682,Warfarin
,9143864,metabolic clearance based on unbound drug,"However, the older patients had an about 30% significantly lower metabolic clearance based on unbound drug (84 vs. 115 ml.kg-1.h-1).",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),[ml] / [h·kg],84,163452,DB00682,Warfarin
,9143864,metabolic clearance based on unbound drug,"However, the older patients had an about 30% significantly lower metabolic clearance based on unbound drug (84 vs. 115 ml.kg-1.h-1).",Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143864/),[ml] / [h·kg],115,163453,DB00682,Warfarin
,12403641,Absolute bioavailability,Absolute bioavailability is about 10% under fasted conditions.,"Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),%,10,165022,DB00682,Warfarin
,12403641,volume of distribution at steady-state,"Tegaserod is approximately 98% bound to plasma proteins, primarily to alpha(1)-acid glycoprotein, and has a volume of distribution at steady-state of 368 +/- 223L.","Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),l,368,165023,DB00682,Warfarin
,12403641,plasma clearance,"The plasma clearance of tegaserod is 77 +/- 15 L/h, with an estimated terminal half-life of 11 +/- 5 hours following intravenous administration.","Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),[l] / [h],77,165024,DB00682,Warfarin
,12403641,terminal half-life,"The plasma clearance of tegaserod is 77 +/- 15 L/h, with an estimated terminal half-life of 11 +/- 5 hours following intravenous administration.","Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403641/),h,11,165025,DB00682,Warfarin
greater,2778653,T:S,The T:S of S-warfarin for the liver was greater than 10 at low concentrations and reached a limiting value of 0.25 at relatively high concentrations of the drug.,Comparative pharmacokinetics of coumarin anticoagulants. XLIX: Nonlinear tissue distribution of S-warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778653/),,10,165281,DB00682,Warfarin
greater,2778653,T:S,The T:S of S-warfarin for the liver was greater than 10 at low concentrations and reached a limiting value of 0.25 at relatively high concentrations of the drug.,Comparative pharmacokinetics of coumarin anticoagulants. XLIX: Nonlinear tissue distribution of S-warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778653/),,0.25,165282,DB00682,Warfarin
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.28,166074,DB00682,Warfarin
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,66.99,166075,DB00682,Warfarin
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.22,166076,DB00682,Warfarin
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,69.48,166077,DB00682,Warfarin
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.28,166078,DB00682,Warfarin
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,66.99,166079,DB00682,Warfarin
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.22,166080,DB00682,Warfarin
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,69.48,166081,DB00682,Warfarin
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),,33.9,166082,DB00682,Warfarin
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),,23.9,166083,DB00682,Warfarin
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,33.6,166084,DB00682,Warfarin
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,22.6,166085,DB00682,Warfarin
,9049585,Pro,"Prothrombin times, expressed as mean INR values, were not significantly altered by concomitant meloxicam treatment, being 1.20 for warfarin alone and 1.27 for warfarin with meloxicam cotreatment.",Lack of interaction between meloxicam and warfarin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),,1.20,168081,DB00682,Warfarin
,9049585,Pro,"Prothrombin times, expressed as mean INR values, were not significantly altered by concomitant meloxicam treatment, being 1.20 for warfarin alone and 1.27 for warfarin with meloxicam cotreatment.",Lack of interaction between meloxicam and warfarin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),,1.27,168082,DB00682,Warfarin
,9049585,AUCss,Geometric mean (% gCV) AUCss values for the more potent S-enantiomer were 5.07 mg.h.l-1 (27.5%) for warfarin alone and 5.64 mg.h.l-1 (28.1%) during the interaction phase.,Lack of interaction between meloxicam and warfarin in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),[h·mg] / [l],5.07,168083,DB00682,Warfarin
,9049585,AUCss,Geometric mean (% gCV) AUCss values for the more potent S-enantiomer were 5.07 mg.h.l-1 (27.5%) for warfarin alone and 5.64 mg.h.l-1 (28.1%) during the interaction phase.,Lack of interaction between meloxicam and warfarin in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),[h·mg] / [l],5.64,168084,DB00682,Warfarin
,9049585,AUCss,Respective AUCss values for R-warfarin were 7.31 mg.h.l-1 (43.8%) and 7.58 mg.h.l-1 (39.1%).,Lack of interaction between meloxicam and warfarin in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),[h·mg] / [l],7.31,168085,DB00682,Warfarin
,9049585,AUCss,Respective AUCss values for R-warfarin were 7.31 mg.h.l-1 (43.8%) and 7.58 mg.h.l-1 (39.1%).,Lack of interaction between meloxicam and warfarin in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),[h·mg] / [l],7.58,168086,DB00682,Warfarin
,6437721,apparent volume of distribution,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),l,"1300 to 11,000",168376,DB00682,Warfarin
,6437721,elimination half-life,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),d,53,168377,DB00682,Warfarin
,6437721,elimination half-life,"Although it has a short elimination half-life (1 to 3h), 2 major metabolites with antiarrhythmic effects accumulate in the plasma of patients during long term therapy.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,1 to 3,168378,DB00682,Warfarin
,6437721,elimination half-life,"Flecainide, another class Ic antiarrhythmic agent, has an elimination half-life of 14 hours which makes it suitable for twice daily dosing.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,14,168379,DB00682,Warfarin
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,9,168380,DB00682,Warfarin
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,28,168381,DB00682,Warfarin
,6437721,apparent volume of distribution,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),[l] / [kg],5.0 to 6.6,168382,DB00682,Warfarin
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,6 to 12,168383,DB00682,Warfarin
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,11 to 17,168384,DB00682,Warfarin
,6733003,elimination half-life,"In the rabbit study, elimination half-life was shorter in the propranolol treated animals (8.20 +/- 0.44 h) than in controls (10.89 +/- 0.62 h).",Interaction between warfarin and propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6733003/),h,8.20,168710,DB00682,Warfarin
,6733003,elimination half-life,"In the rabbit study, elimination half-life was shorter in the propranolol treated animals (8.20 +/- 0.44 h) than in controls (10.89 +/- 0.62 h).",Interaction between warfarin and propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6733003/),h,10.89,168711,DB00682,Warfarin
,6733003,volume of distribution,This was due to a fall in its volume of distribution from 1.13 +/- 0.10 1 kg-1 in controls to 0.81 +/- 0.08 1 kg-1 in the propranolol treated group.,Interaction between warfarin and propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6733003/),[1] / [kg],1.13,168712,DB00682,Warfarin
,6733003,volume of distribution,This was due to a fall in its volume of distribution from 1.13 +/- 0.10 1 kg-1 in controls to 0.81 +/- 0.08 1 kg-1 in the propranolol treated group.,Interaction between warfarin and propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6733003/),[1] / [kg],0.81,168713,DB00682,Warfarin
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],4.6,168775,DB00682,Warfarin
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],3.7,168776,DB00682,Warfarin
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],3.3,168777,DB00682,Warfarin
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],2.7,168778,DB00682,Warfarin
,25364857,clearance (CL),The mean clearance (CL) values of midazolam in aged monkeys (9.5 mL/min/kg) were significantly lower than those in young monkeys (13 mL/min/kg).,"Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[ml] / [kg·min],9.5,168779,DB00682,Warfarin
,25364857,clearance (CL),The mean clearance (CL) values of midazolam in aged monkeys (9.5 mL/min/kg) were significantly lower than those in young monkeys (13 mL/min/kg).,"Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[ml] / [kg·min],13,168780,DB00682,Warfarin
,20206792,formation clearance,Treatment with folic acid was associated with a significantly increased mean (SD) formation clearance of (S)-7-hydroxywarfarin (1.096 [0.816] vs 1.608 [1.302] mL/min; P = 0.048).,"Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206792/),[ml] / [min],1.096,170560,DB00682,Warfarin
,20206792,formation clearance,Treatment with folic acid was associated with a significantly increased mean (SD) formation clearance of (S)-7-hydroxywarfarin (1.096 [0.816] vs 1.608 [1.302] mL/min; P = 0.048).,"Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206792/),[ml] / [min],1.608,170561,DB00682,Warfarin
,7988100,terminal elimination half-life,"Following administration of single doses, fluvoxamine shows a biphasic elimination with a mean terminal elimination half-life of about 15 to 20 hours.",Clinical pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988100/),h,15 to 20,171285,DB00682,Warfarin
,7249487,peak plasma concentrations,"In general, peak plasma concentrations of 2 to 3 microgram/ml are achieved with 1 to 2 hours, but concomitant ingestion of food reduces and delays the peak concentrations without reducing the amount absorbed.",Clinical Pharmacokinetics of indomethacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),[μg] / [ml],2 to 3,172594,DB00682,Warfarin
,7249487,biological half-life,The drug has a biological half-life of about 5 to 10 hours and a plasma clearance of 1 to 2.5ml/kg/min.,Clinical Pharmacokinetics of indomethacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),h,5 to 10,172595,DB00682,Warfarin
,7249487,plasma clearance,The drug has a biological half-life of about 5 to 10 hours and a plasma clearance of 1 to 2.5ml/kg/min.,Clinical Pharmacokinetics of indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),[ml] / [kg·min],1 to 2.5,172596,DB00682,Warfarin
,16952487,half-life [t((1/2))],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,45.1,175305,DB00682,Warfarin
,16952487,clearance [CL],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],1.38,175306,DB00682,Warfarin
,16952487,volume of distribution [V],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,90.1,175307,DB00682,Warfarin
,16952487,t((1/2)),"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,35.7,175308,DB00682,Warfarin
,16952487,CL,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],1.3,175309,DB00682,Warfarin
,16952487,V,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,123,175310,DB00682,Warfarin
,16952487,t((1/2)),"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,4.87,175311,DB00682,Warfarin
,16952487,CL,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],21.2,175312,DB00682,Warfarin
,16952487,V,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,145,175313,DB00682,Warfarin
,16952487,oral bioavailability [F],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),,0.23,175314,DB00682,Warfarin
,16952487,t((1/2)),"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,3.31,175315,DB00682,Warfarin
,16952487,CL,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],20.4,175316,DB00682,Warfarin
,16952487,V,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,75,175317,DB00682,Warfarin
,16952487,F,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),,0.22,175318,DB00682,Warfarin
<,16952487,F,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),%,1,175319,DB00682,Warfarin
,16952487,clearance,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],0.17,175320,DB00682,Warfarin
,16952487,clearance,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],0.26,175321,DB00682,Warfarin
,16952487,distribution,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,67,175322,DB00682,Warfarin
,16952487,distribution,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,17.9,175323,DB00682,Warfarin
low,17499757,LOD,The MS detection was found to be superior over the commonly used UV detection in terms of selectivity and sensitivity with LOD as low as 0.1 microg/mL in human plasma.,Separation and determination of warfarin enantiomers in human plasma using a novel polymeric surfactant for micellar electrokinetic chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17499757/),[μg] / [ml],0.1,175419,DB00682,Warfarin
,7212893,prothrombin time,"On a regimen of 35 mg of oral warfarin sodium daily, prothrombin time was 14 s (control, 12 s).",Acquired warfarin resistance and weight-reducing diet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212893/),s,14,177861,DB00682,Warfarin
,7212893,prothrombin time,"On a regimen of 35 mg of oral warfarin sodium daily, prothrombin time was 14 s (control, 12 s).",Acquired warfarin resistance and weight-reducing diet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212893/),s,12,177862,DB00682,Warfarin
,7212893,half-life,"The half-life of her oral warfarin was 26 hours (normal, 15 to 56 hours).",Acquired warfarin resistance and weight-reducing diet. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212893/),h,26,177863,DB00682,Warfarin
,16316651,K(i),"In vitro, M55551 and M55165 competitively inhibited factor Xa with K(i) values of 3.2 nM and 2.3 nM, respectively, and prolonged clotting time in human and rat plasma.",Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16316651/),nM,3.2,178029,DB00682,Warfarin
,16316651,K(i),"In vitro, M55551 and M55165 competitively inhibited factor Xa with K(i) values of 3.2 nM and 2.3 nM, respectively, and prolonged clotting time in human and rat plasma.",Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16316651/),nM,2.3,178030,DB00682,Warfarin
,16316651,half-life,Pharmacokinetic analysis of these compounds revealed that M55551 was intravenously active with a short half-life (0.2 h) and that M55165 exhibited good bioavailability (31%) with a long half-life (3.9 h).,Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16316651/),h,0.2,178031,DB00682,Warfarin
,16316651,bioavailability,Pharmacokinetic analysis of these compounds revealed that M55551 was intravenously active with a short half-life (0.2 h) and that M55165 exhibited good bioavailability (31%) with a long half-life (3.9 h).,Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16316651/),%,31,178032,DB00682,Warfarin
,16316651,half-life,Pharmacokinetic analysis of these compounds revealed that M55551 was intravenously active with a short half-life (0.2 h) and that M55165 exhibited good bioavailability (31%) with a long half-life (3.9 h).,Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16316651/),h,3.9,178033,DB00682,Warfarin
,3277474,half-life,"Heparin pharmacokinetics are poorly understood, but when the usual doses are given intravenously, heparin is rapidly removed from the blood and has a half-life of approximately 90 minutes.",Anticoagulation: a surgical perspective. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3277474/),min,90,181021,DB00682,Warfarin
less,2878729,pro,The preliminary data indicate that patients with a baseline prothrombin time ratio (PTR) of less than 2.0 would not be expected to exceed a PTR greater than 2.5 after two weeks of concomitant administration of cimetidine at either dosage.,Safety: cimetidine and concomitant theophylline or warfarin--drug interactions and their implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878729/),,2.0,182563,DB00682,Warfarin
greater,2878729,PTR,The preliminary data indicate that patients with a baseline prothrombin time ratio (PTR) of less than 2.0 would not be expected to exceed a PTR greater than 2.5 after two weeks of concomitant administration of cimetidine at either dosage.,Safety: cimetidine and concomitant theophylline or warfarin--drug interactions and their implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878729/),,2.5,182564,DB00682,Warfarin
,7917775,percentage unbound,"3. Wide variability was observed in daily dose requirements (mean 6.1 mg; range: 2.5-12 mg), in plasma concentrations of (S)-warfarin (0.48 mg l(-1); 0.11-1.02 mg l(-1)), (R)-warfarin (0.87 mg l(-1); 0.29-1.82 mg l(-1)), (R,S)-warfarin alcohol (0.31 mg l(-1); 0.02-0.72 mg l(-1)) and (S)-7-hydroxywarfarin (0.25 mg l(-1); 0.07-0.37 mg l(-1)) and the percentage unbound of (S)-warfarin (0.53%; 0.29%-0.82%) and (R)-warfarin (0.54%; 0.26%-0.96%).",Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917775/),%,0.53,183599,DB00682,Warfarin
,7917775,percentage unbound,"3. Wide variability was observed in daily dose requirements (mean 6.1 mg; range: 2.5-12 mg), in plasma concentrations of (S)-warfarin (0.48 mg l(-1); 0.11-1.02 mg l(-1)), (R)-warfarin (0.87 mg l(-1); 0.29-1.82 mg l(-1)), (R,S)-warfarin alcohol (0.31 mg l(-1); 0.02-0.72 mg l(-1)) and (S)-7-hydroxywarfarin (0.25 mg l(-1); 0.07-0.37 mg l(-1)) and the percentage unbound of (S)-warfarin (0.53%; 0.29%-0.82%) and (R)-warfarin (0.54%; 0.26%-0.96%).",Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917775/),%,0.54,183600,DB00682,Warfarin
,7917775,percentage unbound,"3. Wide variability was observed in daily dose requirements (mean 6.1 mg; range: 2.5-12 mg), in plasma concentrations of (S)-warfarin (0.48 mg l(-1); 0.11-1.02 mg l(-1)), (R)-warfarin (0.87 mg l(-1); 0.29-1.82 mg l(-1)), (R,S)-warfarin alcohol (0.31 mg l(-1); 0.02-0.72 mg l(-1)) and (S)-7-hydroxywarfarin (0.25 mg l(-1); 0.07-0.37 mg l(-1)) and the percentage unbound of (S)-warfarin (0.53%; 0.29%-0.82%) and (R)-warfarin (0.54%; 0.26%-0.96%).",Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917775/),%,0,183601,DB00682,Warfarin
,7917775,plasma clearances,4. The mean plasma clearances of warfarin enantiomers were 7.5 1 day-1 per 70 kg (2.5-22.1) for (S)-warfarin and 3.6 1 day-1 per 70 kg (1.6-8.8) for (R)-warfarin.,Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917775/),[1] / [70·d·kg],7.5,183602,DB00682,Warfarin
,7917775,plasma clearances,4. The mean plasma clearances of warfarin enantiomers were 7.5 1 day-1 per 70 kg (2.5-22.1) for (S)-warfarin and 3.6 1 day-1 per 70 kg (1.6-8.8) for (R)-warfarin.,Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917775/),[1] / [70·d·kg],3.6,183603,DB00682,Warfarin
,32809952,k e,The k e of warfarin given a cytochrome P450 2C9 (CYP2C9) genotype ranged from 0.0189 to 0.0075 h-1.,Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32809952/),1/[h],0,184780,DB00682,Warfarin
,32809952,peak concentration (Cmax),The mean peak concentration (Cmax) was higher for wild-type (0.36±0.12 vs. 0.32±0.14 mg/L).,Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32809952/),[mg] / [l],0.36,184781,DB00682,Warfarin
,32809952,peak concentration (Cmax),The mean peak concentration (Cmax) was higher for wild-type (0.36±0.12 vs. 0.32±0.14 mg/L).,Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32809952/),[mg] / [l],0.32,184782,DB00682,Warfarin
,32809952,clearance (CL),"Likewise, the average clearance (CL) parameter was faster among non-carriers (0.22±0.03 vs. 0.17±0.05 L/h; p=0.0001), with also lower area under the curve (AUC) when compared to carriers (20.43±6.97 vs. 24.78±11.26 h mg/L; p=0.025).",Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32809952/),[l] / [h],0.22,184783,DB00682,Warfarin
,32809952,clearance (CL),"Likewise, the average clearance (CL) parameter was faster among non-carriers (0.22±0.03 vs. 0.17±0.05 L/h; p=0.0001), with also lower area under the curve (AUC) when compared to carriers (20.43±6.97 vs. 24.78±11.26 h mg/L; p=0.025).",Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32809952/),[l] / [h],0.17,184784,DB00682,Warfarin
,32809952,area under the curve (AUC),"Likewise, the average clearance (CL) parameter was faster among non-carriers (0.22±0.03 vs. 0.17±0.05 L/h; p=0.0001), with also lower area under the curve (AUC) when compared to carriers (20.43±6.97 vs. 24.78±11.26 h mg/L; p=0.025).",Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32809952/),[h·mg] / [l],20.43,184785,DB00682,Warfarin
,32809952,area under the curve (AUC),"Likewise, the average clearance (CL) parameter was faster among non-carriers (0.22±0.03 vs. 0.17±0.05 L/h; p=0.0001), with also lower area under the curve (AUC) when compared to carriers (20.43±6.97 vs. 24.78±11.26 h mg/L; p=0.025).",Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32809952/),[h·mg] / [l],24.78,184786,DB00682,Warfarin
,18502701,limit of detection,"In plasma, the limit of detection varied from 0.07 ng mL(-1) for flocoumafen to 3.21 ng mL(-1) for brodifacoum.",Multi-residue analysis of eight anticoagulant rodenticides in animal plasma and liver using liquid chromatography combined with heated electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502701/),[ng] / [ml],0.07,185081,DB00682,Warfarin
,18502701,limit of detection,"In plasma, the limit of detection varied from 0.07 ng mL(-1) for flocoumafen to 3.21 ng mL(-1) for brodifacoum.",Multi-residue analysis of eight anticoagulant rodenticides in animal plasma and liver using liquid chromatography combined with heated electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502701/),[ng] / [ml],3.21,185082,DB00682,Warfarin
,18502701,limit of detection,"In liver, the limit of detection varied from 0.37 ng g(-1) for warfarin to 4.64 ng g(-1) for chlorophacinone.",Multi-residue analysis of eight anticoagulant rodenticides in animal plasma and liver using liquid chromatography combined with heated electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502701/),[ng] / [g],0.37,185083,DB00682,Warfarin
,18502701,limit of detection,"In liver, the limit of detection varied from 0.37 ng g(-1) for warfarin to 4.64 ng g(-1) for chlorophacinone.",Multi-residue analysis of eight anticoagulant rodenticides in animal plasma and liver using liquid chromatography combined with heated electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502701/),[ng] / [g],4.64,185084,DB00682,Warfarin
,34062109,area under the curve (AUC),The area under the curve (AUC) of R- and S-WF in the CX-2 group was a significantly higher value compared to the control (77.54 vs. 35.27 mg.h/L for R-WF and 316.26 vs. 40.16 mg.h/L for S-WF; p < 0.05; Kruskal-Wallis method).,The influence of Javanese turmeric (Curcuma xanthorrhiza) on the pharmacokinetics of warfarin in rats with single and multiple-dose studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34062109/),[h·mg] / [l],77.54,186781,DB00682,Warfarin
,34062109,area under the curve (AUC),The area under the curve (AUC) of R- and S-WF in the CX-2 group was a significantly higher value compared to the control (77.54 vs. 35.27 mg.h/L for R-WF and 316.26 vs. 40.16 mg.h/L for S-WF; p < 0.05; Kruskal-Wallis method).,The influence of Javanese turmeric (Curcuma xanthorrhiza) on the pharmacokinetics of warfarin in rats with single and multiple-dose studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34062109/),[h·mg] / [l],35.27,186782,DB00682,Warfarin
,34062109,area under the curve (AUC),The area under the curve (AUC) of R- and S-WF in the CX-2 group was a significantly higher value compared to the control (77.54 vs. 35.27 mg.h/L for R-WF and 316.26 vs. 40.16 mg.h/L for S-WF; p < 0.05; Kruskal-Wallis method).,The influence of Javanese turmeric (Curcuma xanthorrhiza) on the pharmacokinetics of warfarin in rats with single and multiple-dose studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34062109/),[h·mg] / [l],316.26,186783,DB00682,Warfarin
,34062109,area under the curve (AUC),The area under the curve (AUC) of R- and S-WF in the CX-2 group was a significantly higher value compared to the control (77.54 vs. 35.27 mg.h/L for R-WF and 316.26 vs. 40.16 mg.h/L for S-WF; p < 0.05; Kruskal-Wallis method).,The influence of Javanese turmeric (Curcuma xanthorrhiza) on the pharmacokinetics of warfarin in rats with single and multiple-dose studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34062109/),[h·mg] / [l],40.16,186784,DB00682,Warfarin
,25387217,elimination half-life,The elimination half-life of albiglutide is approximately 5 days.,"Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25387217/),d,5,188501,DB00682,Warfarin
,25387217,Clearance,Clearance of albiglutide is 67 mL/h with between-subject variability of 34.9%; no covariates have been identified that would require dose adjustment of albiglutide.,"Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25387217/),[ml] / [h],67,188502,DB00682,Warfarin
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB00682,Warfarin
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,90.8,189038,DB00682,Warfarin
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,136,189039,DB00682,Warfarin
,11451211,elimination half-life,The elimination half-life was 10-15 h.,The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451211/),h,10-15,189075,DB00682,Warfarin
,11451211,Renal clearance,"Renal clearance (0.5-0.7 l/h) was independent of dose, accounting for approximately 9-12% of an oral dose.",The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451211/),[l] / [h],0.5-0.7,189076,DB00682,Warfarin
,11451211,absolute bioavailability,The absolute bioavailability of olmesartan from olmesartan medoxomil tablets was 28.6%.,The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451211/),%,28.6,189077,DB00682,Warfarin
,6282204,half life,The half life ranged from 2.0 to 3.3 h.,"Disposition of ketoconazole, an oral antifungal, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282204/),h,2.0 to 3.3,192001,DB00682,Warfarin
up to,6282204,Peak serum concentrations,"Peak serum concentrations up to 50 micrograms/ml were detected in this study, and potentially therapeutic concentrations were detectable up to 26 h after high doses.","Disposition of ketoconazole, an oral antifungal, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282204/),[μg] / [ml],50,192002,DB00682,Warfarin
,3705621,elimination t 1/2,The elimination t 1/2 of acifran from serum was 1.5 h in the rat and 3 h in the dog.,"The metabolic disposition of acifran, a new antihyperlipidemic agent, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705621/),h,1.5,192963,DB00682,Warfarin
,3705621,elimination t 1/2,The elimination t 1/2 of acifran from serum was 1.5 h in the rat and 3 h in the dog.,"The metabolic disposition of acifran, a new antihyperlipidemic agent, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705621/),h,3,192964,DB00682,Warfarin
,856978,"free fraction, f,","The free fraction, f, of warfarin in the serum of individual animals ranged from 0.303 X 10(-2) to 2.89 X 10(-2).",Comparative pharmacokinetics of coumarin anticoagulants XXI: effect of plasma protein binding on distribution kinetics of warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/856978/),,0.303 X 10(-2),193836,DB00682,Warfarin
,856978,"free fraction, f,","The free fraction, f, of warfarin in the serum of individual animals ranged from 0.303 X 10(-2) to 2.89 X 10(-2).",Comparative pharmacokinetics of coumarin anticoagulants XXI: effect of plasma protein binding on distribution kinetics of warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/856978/),,2.89 X 10(-2),193837,DB00682,Warfarin
,72819,free fraction f,"The free fraction f, of dicumarol in the serum of individual animals ranged from 0.000150 to 0.000790.",Comparative pharmacokinetics of coumarin anticoagulants XXXI: Effect of plasma protein binding on distribution kinetics of dicumarol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/72819/),,0.000150,194334,DB00682,Warfarin
,72819,free fraction f,"The free fraction f, of dicumarol in the serum of individual animals ranged from 0.000150 to 0.000790.",Comparative pharmacokinetics of coumarin anticoagulants XXXI: Effect of plasma protein binding on distribution kinetics of dicumarol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/72819/),,0.000790,194335,DB00682,Warfarin
,22674783,flow rate,The flow rate was 0.6 mL/min and the total run time was not more than 4.0 min.,Rapid LC-MS/MS determination and pharmacokinetic application of linarin in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22674783/),[ml] / [min],0.6,195480,DB00682,Warfarin
not more,22674783,total run time,The flow rate was 0.6 mL/min and the total run time was not more than 4.0 min.,Rapid LC-MS/MS determination and pharmacokinetic application of linarin in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22674783/),min,4.0,195481,DB00682,Warfarin
,9630825,"CLpo,u","The medians for (S)-warfarin CLpo,u and its 7-hydroxylation CLm obtained from heterozygotes of CYP2C9 Leu359 were significantly less than those obtained from homozygotes of the wt allele, as follows: 234 ml/min (range, 156 to 269 ml/min) versus 632 ml/min (range, 180 to 2070 ml/min) (p < 0.001) and 0.20 ml/min (range, 0.05 to 0.77 ml/min) versus 0.80 ml/min (range, 0.05 to 14.9 ml/min) (p < 0.05), respectively.",Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630825/),[ml] / [min],234,196034,DB00682,Warfarin
,9646006,plasma half-life,"Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours).",Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646006/),h,3 to 5,196622,DB00682,Warfarin
,9646006,half-life,Glucoroconjugated metabolites are excreted in urine and faeces with a half-life of about 11 hours.,Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646006/),h,11,196623,DB00682,Warfarin
,6657737,half-life,Brodifacoum disappeared slowly from serum with a half-life of 156 h.,Dispositional and pharmacodynamic characteristics of brodifacoum in warfarin-sensitive rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6657737/),h,156,197523,DB00682,Warfarin
,32160801,steady-state areas under the curve,"Median daily steady-state areas under the curve for apixaban 5 mg twice daily were 5512 ng/(mL·h) and 3406 ng/(mL·h) for patients with CrCl 25 to 30 mL/min or >30 mL/min, respectively.",Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32160801/),[ng] / [h·ml],5512,200286,DB00682,Warfarin
,32160801,steady-state areas under the curve,"Median daily steady-state areas under the curve for apixaban 5 mg twice daily were 5512 ng/(mL·h) and 3406 ng/(mL·h) for patients with CrCl 25 to 30 mL/min or >30 mL/min, respectively.",Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32160801/),[ng] / [h·ml],3406,200287,DB00682,Warfarin
,32160801,exposure,"For apixaban 2.5 mg twice daily, the median exposure was 2780 ng/(mL·h) for patients with CrCl 25 to 30 mL/min.",Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32160801/),[ng] / [h·ml],2780,200288,DB00682,Warfarin
,23614393,"AUC(0,∞) ratio","In particular, the AUC(0,∞) ratio (90% confidence interval) for coadministration of warfarin and lacosamide versus warfarin alone was 0.97 (0.94-1.00) for S-warfarin and 1.05 (1.02-1.09) for R-warfarin, and the AUCINR ratio was 1.04 (1.01-1.06).",Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23614393/),,0.97,201034,DB00682,Warfarin
,23614393,"AUC(0,∞) ratio","In particular, the AUC(0,∞) ratio (90% confidence interval) for coadministration of warfarin and lacosamide versus warfarin alone was 0.97 (0.94-1.00) for S-warfarin and 1.05 (1.02-1.09) for R-warfarin, and the AUCINR ratio was 1.04 (1.01-1.06).",Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23614393/),,1.05,201035,DB00682,Warfarin
,23614393,AUCINR ratio,"In particular, the AUC(0,∞) ratio (90% confidence interval) for coadministration of warfarin and lacosamide versus warfarin alone was 0.97 (0.94-1.00) for S-warfarin and 1.05 (1.02-1.09) for R-warfarin, and the AUCINR ratio was 1.04 (1.01-1.06).",Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23614393/),,1.04,201036,DB00682,Warfarin
,16432273,elimination half-life,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),h,3.9,201410,DB00682,Warfarin
,16432273,elimination half-life,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),h,3.5,201411,DB00682,Warfarin
,16432273,total AUC,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[μg] / [h·ml],57,201412,DB00682,Warfarin
,16432273,total AUC,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[μg] / [h·ml],55,201413,DB00682,Warfarin
,16432273,oral clearance,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[ml] / [min],32.9,201414,DB00682,Warfarin
,16432273,oral clearance,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[ml] / [min],31.6,201415,DB00682,Warfarin
,3694526,distribution,"When administered in microdoses (9 micrograms i.v.) to rats (male Wistars, 270-300 g), a steep distribution phase (T1/2 = 0.25 hr) was followed by a relatively slow beta-phase (T1/2 = 40 hr).","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),h,0.25,201486,DB00682,Warfarin
,3694526,beta-phase (T1/2,"When administered in microdoses (9 micrograms i.v.) to rats (male Wistars, 270-300 g), a steep distribution phase (T1/2 = 0.25 hr) was followed by a relatively slow beta-phase (T1/2 = 40 hr).","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),h,40,201487,DB00682,Warfarin
,3694526,volume of distribution,The observed volume of distribution was 390 ml.,"Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),ml,390,201488,DB00682,Warfarin
,3694526,volume of distribution,"This pharmacokinetic behavior contrasted highly with the one seen for higher (greater than 0.2 mg/kg) doses (unlabeled) warfarin; volume of distribution = 45 ml, T1/2 = 12.5 hr.","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),ml,45,201489,DB00682,Warfarin
,3694526,T1/2,"This pharmacokinetic behavior contrasted highly with the one seen for higher (greater than 0.2 mg/kg) doses (unlabeled) warfarin; volume of distribution = 45 ml, T1/2 = 12.5 hr.","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),h,12.5,201490,DB00682,Warfarin
,3694526,rate of appearance,The rate of appearance of [14C]warfarin was 0.3 hr-1 irrespective the 4-hydroxycoumarin used.,"Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),1/[h],0.3,201491,DB00682,Warfarin
,8846617,oral bioavailability,"Despite complete absorption, oral bioavailability in man is approximately 50% on account of first-pass hepatic metabolism.",Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,50,204181,DB00682,Warfarin
,8846617,terminal elimination half-life,Fluvoxamine shows a biphasic pattern of elimination with a mean terminal elimination half-life of 12 to 15 hours after a single oral dose; this is prolonged by 30 to 50% at steady-state.,Overview of the pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),h,12 to 15,204182,DB00682,Warfarin
,8846617,Plasma protein binding,Plasma protein binding of fluvoxamine (77%) is low compared with that of other SSRIs.,Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,77,204183,DB00682,Warfarin
,529059,liver to serum total warfarin,"The liver to serum total warfarin concentration ratios 6 hr after injection of the 0.1- and 1.0-mg/kg doses were 11.3 +/- 1.7 and 0.814 +/- 0.222, respectively (mean +/- SD, n = 6, p less than 0.001).",Comparative pharmacokinetics of coumarin anticoagulants XLIII: Concentration-dependent hepatic uptake of warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/529059/),,11.3,204965,DB00682,Warfarin
,529059,liver to serum total warfarin,"The liver to serum total warfarin concentration ratios 6 hr after injection of the 0.1- and 1.0-mg/kg doses were 11.3 +/- 1.7 and 0.814 +/- 0.222, respectively (mean +/- SD, n = 6, p less than 0.001).",Comparative pharmacokinetics of coumarin anticoagulants XLIII: Concentration-dependent hepatic uptake of warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/529059/),,0.814,204966,DB00682,Warfarin
,529059,concentration ratios,"The liver to serum total warfarin concentration ratios 6 hr after injection of the 0.1- and 1.0-mg/kg doses were 11.3 +/- 1.7 and 0.814 +/- 0.222, respectively (mean +/- SD, n = 6, p less than 0.001).",Comparative pharmacokinetics of coumarin anticoagulants XLIII: Concentration-dependent hepatic uptake of warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/529059/),,11.3,204967,DB00682,Warfarin
,529059,concentration ratios,"The liver to serum total warfarin concentration ratios 6 hr after injection of the 0.1- and 1.0-mg/kg doses were 11.3 +/- 1.7 and 0.814 +/- 0.222, respectively (mean +/- SD, n = 6, p less than 0.001).",Comparative pharmacokinetics of coumarin anticoagulants XLIII: Concentration-dependent hepatic uptake of warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/529059/),,0.814,204968,DB00682,Warfarin
,529059,ratio of the total drug concentration,The ratio of the total drug concentration in the liver to the free drug concentration in serum (mean +/- SD) was 866 +/- 105 in animals that received the 0.1-mg/kg dose and 111 +/- 42 in animals that received the 1.0-mg/kg dose (p less than 0.001).,Comparative pharmacokinetics of coumarin anticoagulants XLIII: Concentration-dependent hepatic uptake of warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/529059/),,866,204969,DB00682,Warfarin
,529059,ratio of the total drug concentration,The ratio of the total drug concentration in the liver to the free drug concentration in serum (mean +/- SD) was 866 +/- 105 in animals that received the 0.1-mg/kg dose and 111 +/- 42 in animals that received the 1.0-mg/kg dose (p less than 0.001).,Comparative pharmacokinetics of coumarin anticoagulants XLIII: Concentration-dependent hepatic uptake of warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/529059/),,111,204970,DB00682,Warfarin
,15801938,area under the plasma concentration-time curve [AUC((0-infinity))],"Gemfibrozil decreased the mean (+/-SD) area under the plasma concentration-time curve [AUC((0-infinity))] of S-warfarin by 11%, from 19.9 +/- 5.2 mg l(-1) h to 17.6 +/- 4.7 mg l(-1) h (95% CI on the difference -3.7, -0.78; P < 0.01) and that of R-warfarin by 6% from 31.3 +/- 7.5 mg l(-1) h during the gemfibrozil phase to 29.5 +/- 6.9 mg l(-1) h during the placebo phase (95% CI -3.3, -0.33; P < 0.05).",Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801938/),[h·mg] / [l],19.9,206788,DB00682,Warfarin
,15801938,area under the plasma concentration-time curve [AUC((0-infinity))],"Gemfibrozil decreased the mean (+/-SD) area under the plasma concentration-time curve [AUC((0-infinity))] of S-warfarin by 11%, from 19.9 +/- 5.2 mg l(-1) h to 17.6 +/- 4.7 mg l(-1) h (95% CI on the difference -3.7, -0.78; P < 0.01) and that of R-warfarin by 6% from 31.3 +/- 7.5 mg l(-1) h during the gemfibrozil phase to 29.5 +/- 6.9 mg l(-1) h during the placebo phase (95% CI -3.3, -0.33; P < 0.05).",Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801938/),[h·mg] / [l],17.6,206789,DB00682,Warfarin
,15801938,area under the plasma concentration-time curve [AUC((0-infinity))],"Gemfibrozil decreased the mean (+/-SD) area under the plasma concentration-time curve [AUC((0-infinity))] of S-warfarin by 11%, from 19.9 +/- 5.2 mg l(-1) h to 17.6 +/- 4.7 mg l(-1) h (95% CI on the difference -3.7, -0.78; P < 0.01) and that of R-warfarin by 6% from 31.3 +/- 7.5 mg l(-1) h during the gemfibrozil phase to 29.5 +/- 6.9 mg l(-1) h during the placebo phase (95% CI -3.3, -0.33; P < 0.05).",Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801938/),[h·mg] / [l],31.3,206790,DB00682,Warfarin
,15801938,area under the plasma concentration-time curve [AUC((0-infinity))],"Gemfibrozil decreased the mean (+/-SD) area under the plasma concentration-time curve [AUC((0-infinity))] of S-warfarin by 11%, from 19.9 +/- 5.2 mg l(-1) h to 17.6 +/- 4.7 mg l(-1) h (95% CI on the difference -3.7, -0.78; P < 0.01) and that of R-warfarin by 6% from 31.3 +/- 7.5 mg l(-1) h during the gemfibrozil phase to 29.5 +/- 6.9 mg l(-1) h during the placebo phase (95% CI -3.3, -0.33; P < 0.05).",Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801938/),[h·mg] / [l],29.5,206791,DB00682,Warfarin
,9483171,plasma half-life,The plasma half-life of phenprocoumon was approximately 350 h (normal 120-150 h).,Vitamin K metabolism in a patient resistant to vitamin K antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9483171/),h,350,209422,DB00682,Warfarin
,3598902,clearance,"Thus, the median clearance of the S-enantiomer (1.96 liters/h) was 25% less than that of the R-isomer (2.58 liters/h).",Pharmacokinetics of pentobarbital enantiomers as determined by enantioselective radioimmunoassay after administration of racemate to humans and rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598902/),[l] / [h],1.96,213259,DB00682,Warfarin
,3598902,clearance,"Thus, the median clearance of the S-enantiomer (1.96 liters/h) was 25% less than that of the R-isomer (2.58 liters/h).",Pharmacokinetics of pentobarbital enantiomers as determined by enantioselective radioimmunoassay after administration of racemate to humans and rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598902/),[l] / [h],2.58,213260,DB00682,Warfarin
,12818629,bioavailability,"Ximelagatran is therefore much better than melagatran at penetrating the gastrointestinal barrier and, as a consequence, has sufficient bioavailability (20%) for oral administration.",The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818629/),%,20,213333,DB00682,Warfarin
,10640513,K(i),Lornoxicam 5'-hydroxylation was competitively inhibited in vitro by both phenprocoumon (K(i) = 1.2 +/- 0.4 microM) and acenocoumarol (K(i) = 5.5 +/- 3.5 microM).,Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640513/),μM,1.2,214118,DB00682,Warfarin
,10640513,K(i),Lornoxicam 5'-hydroxylation was competitively inhibited in vitro by both phenprocoumon (K(i) = 1.2 +/- 0.4 microM) and acenocoumarol (K(i) = 5.5 +/- 3.5 microM).,Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640513/),μM,5.5,214119,DB00682,Warfarin
,31587090,time to achieve the first therapeutic INR,"Compared to the control group, the median time to achieve the first therapeutic INR was longer (5 vs. 2 days), to stable anticoagulation was shorter (29.0 vs. 96.5 days), to over-anticoagulation was longer (15.0 vs. 4.0 days).",Personalised Warfarin Dosing in Children Post-cardiac Surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31587090/),d,5,215601,DB00682,Warfarin
,31587090,time to achieve the first therapeutic INR,"Compared to the control group, the median time to achieve the first therapeutic INR was longer (5 vs. 2 days), to stable anticoagulation was shorter (29.0 vs. 96.5 days), to over-anticoagulation was longer (15.0 vs. 4.0 days).",Personalised Warfarin Dosing in Children Post-cardiac Surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31587090/),d,2,215602,DB00682,Warfarin
,31587090,time to achieve the first therapeutic INR,"Compared to the control group, the median time to achieve the first therapeutic INR was longer (5 vs. 2 days), to stable anticoagulation was shorter (29.0 vs. 96.5 days), to over-anticoagulation was longer (15.0 vs. 4.0 days).",Personalised Warfarin Dosing in Children Post-cardiac Surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31587090/),,15.0,215603,DB00682,Warfarin
,31587090,time to achieve the first therapeutic INR,"Compared to the control group, the median time to achieve the first therapeutic INR was longer (5 vs. 2 days), to stable anticoagulation was shorter (29.0 vs. 96.5 days), to over-anticoagulation was longer (15.0 vs. 4.0 days).",Personalised Warfarin Dosing in Children Post-cardiac Surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31587090/),,4.0,215604,DB00682,Warfarin
,31587090,%TTR,"No significant differences in INR control were found between model and conventional dosing phases; mean %ITR was 68.82% versus 67.9% (p = 0.84) and mean %TTR was 85.47% versus 80.2% (p = 0.09), respectively.",Personalised Warfarin Dosing in Children Post-cardiac Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31587090/),%,85.47,215605,DB00682,Warfarin
,31587090,%TTR,"No significant differences in INR control were found between model and conventional dosing phases; mean %ITR was 68.82% versus 67.9% (p = 0.84) and mean %TTR was 85.47% versus 80.2% (p = 0.09), respectively.",Personalised Warfarin Dosing in Children Post-cardiac Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31587090/),%,80.2,215606,DB00682,Warfarin
,12648026,bioavailability,"Tamoxifen and toremifene have a bioavailability of approximately 100%, whereas that of raloxifene is only 2%.",Pharmacokinetics of selective estrogen receptor modulators. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648026/),%,100,217207,DB00682,Warfarin
,12648026,bioavailability,"Tamoxifen and toremifene have a bioavailability of approximately 100%, whereas that of raloxifene is only 2%.",Pharmacokinetics of selective estrogen receptor modulators. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648026/),%,2,217208,DB00682,Warfarin
,12648026,terminal elimination half-lives,The terminal elimination half-lives of these drugs range from 27.7 hours to 7 days.,Pharmacokinetics of selective estrogen receptor modulators. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648026/),h,27.7,217209,DB00682,Warfarin
,12648026,terminal elimination half-lives,The terminal elimination half-lives of these drugs range from 27.7 hours to 7 days.,Pharmacokinetics of selective estrogen receptor modulators. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648026/),d,7,217210,DB00682,Warfarin
,10456491,apparent formation clearance,"The reduction of apparent clearance of R-warfarin by cimetidine was found to be the effect of inhibition of the formation of warfarin metabolites as determined by apparent formation clearance values (+/-SD) of R-6-hydroxywarfarin (31.1+/-7.4 ml/h baseline; 18.5+/-4.5 ml/h at end of cimetidine treatment; P < 0.01), and R-7-hydroxywarfarin (6.9+/-1.3 ml/h baseline; 4.3+/-1.1 ml/h at end of cimetidine treatment; P < 0.01).",The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456491/),[ml] / [h],31.1,217419,DB00682,Warfarin
,10456491,apparent formation clearance,"The reduction of apparent clearance of R-warfarin by cimetidine was found to be the effect of inhibition of the formation of warfarin metabolites as determined by apparent formation clearance values (+/-SD) of R-6-hydroxywarfarin (31.1+/-7.4 ml/h baseline; 18.5+/-4.5 ml/h at end of cimetidine treatment; P < 0.01), and R-7-hydroxywarfarin (6.9+/-1.3 ml/h baseline; 4.3+/-1.1 ml/h at end of cimetidine treatment; P < 0.01).",The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456491/),[ml] / [h],18.5,217420,DB00682,Warfarin
,10456491,apparent formation clearance,"The reduction of apparent clearance of R-warfarin by cimetidine was found to be the effect of inhibition of the formation of warfarin metabolites as determined by apparent formation clearance values (+/-SD) of R-6-hydroxywarfarin (31.1+/-7.4 ml/h baseline; 18.5+/-4.5 ml/h at end of cimetidine treatment; P < 0.01), and R-7-hydroxywarfarin (6.9+/-1.3 ml/h baseline; 4.3+/-1.1 ml/h at end of cimetidine treatment; P < 0.01).",The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456491/),[ml] / [h],6.9,217421,DB00682,Warfarin
,10456491,apparent formation clearance,"The reduction of apparent clearance of R-warfarin by cimetidine was found to be the effect of inhibition of the formation of warfarin metabolites as determined by apparent formation clearance values (+/-SD) of R-6-hydroxywarfarin (31.1+/-7.4 ml/h baseline; 18.5+/-4.5 ml/h at end of cimetidine treatment; P < 0.01), and R-7-hydroxywarfarin (6.9+/-1.3 ml/h baseline; 4.3+/-1.1 ml/h at end of cimetidine treatment; P < 0.01).",The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456491/),[ml] / [h],4.3,217422,DB00682,Warfarin
,11286326,time to reach peak concentration (tmax),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),h,2,217445,DB00682,Warfarin
,11286326,peak plasma drug concentration (Cmax),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[mg] / [l],3 to 4,217446,DB00682,Warfarin
,11286326,elimination half-life (t(1/2)),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),h,0.55 to 0.89,217447,DB00682,Warfarin
,11286326,Recovery,Recovery of drug-related material in urine and faeces is nearly 100%.,Clinical pharmacokinetics of capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),%,100,217448,DB00682,Warfarin
,11286326,Cmax,Plasma concentrations of the cytotoxic moiety fluorouracil are very low [with a Cmax of 0.22 to 0.31 mg/L and area under the concentration-time curve (AUC) of 0.461 to 0.698 mg x h/L].,Clinical pharmacokinetics of capecitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[mg] / [l],0.22 to 0.31,217449,DB00682,Warfarin
,11286326,area under the concentration-time curve (AUC),Plasma concentrations of the cytotoxic moiety fluorouracil are very low [with a Cmax of 0.22 to 0.31 mg/L and area under the concentration-time curve (AUC) of 0.461 to 0.698 mg x h/L].,Clinical pharmacokinetics of capecitabine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[h·mg] / [l],0.461 to 0.698,217450,DB00682,Warfarin
,30073671,flow rate,"Both artemitin and warfarin sodium (internal standard, IS) were separated on an Agela Venusil XBP Phenyl column through the isocratic elution mode of methanol-water containing 0.1% formic acid (80:20, v/v), at a flow rate of 0.4 mL/min.",Development of an LC-MS/MS-based assay to determine artemitin in rat plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30073671/),[ml] / [min],0.4,219125,DB00682,Warfarin
,30073671,m,"The MS/MS system was operated in a positive ion and ESI multiple reaction monitoring mode, and the multiple reaction monitoring transition was optimized as m/z 389.0 → 373.0 for artemitin and 309.2 → 163.0 for IS.",Development of an LC-MS/MS-based assay to determine artemitin in rat plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30073671/),,389.0,219126,DB00682,Warfarin
,30073671,m,"The MS/MS system was operated in a positive ion and ESI multiple reaction monitoring mode, and the multiple reaction monitoring transition was optimized as m/z 389.0 → 373.0 for artemitin and 309.2 → 163.0 for IS.",Development of an LC-MS/MS-based assay to determine artemitin in rat plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30073671/),,309.2,219127,DB00682,Warfarin
>,30073671,extraction efficiency,"The extraction efficiency and absolute recovery were >66.5 and 71.3%, respectively.",Development of an LC-MS/MS-based assay to determine artemitin in rat plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30073671/),%,66.5,219128,DB00682,Warfarin
,30073671,absolute recovery,"The extraction efficiency and absolute recovery were >66.5 and 71.3%, respectively.",Development of an LC-MS/MS-based assay to determine artemitin in rat plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30073671/),%,71.3,219129,DB00682,Warfarin
,7378103,apparent absorption rate constant,"According to the results from the best computerized curve fitting, absorption is rapid, the apparent absorption rate constant being 0.258 min -1.",A model solution for intestinal absorption of warfarin. A drug with non-linear distribution pharmacokinetics in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378103/),-1·min,0.258,220785,DB00682,Warfarin
,870833,half-life,"The half-life of total warfarin concentration in the plasma from 1-12h remained unchanged with all the doses used, but that of free warfarin was shorter with 40 mg/kg, possibly as the result of an increase in the binding of the drug to plasma proteins as the high total warfarin concentration decreased.","Distribution pharmacokinetics of warfarin in the rat, a non-linear multicompartment model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/870833/),h,1-12,224644,DB00682,Warfarin
,10728776,Kd,"The Kd values determined by fluorescence spectroscopy for wild type, R218H, R218P and R218M HSA binding to warfarin were 1.35, 5.38, 5.61, and 8.34 microM, respectively.",Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728776/),μM,1.35,227561,DB00682,Warfarin
,10728776,Kd,"The Kd values determined by fluorescence spectroscopy for wild type, R218H, R218P and R218M HSA binding to warfarin were 1.35, 5.38, 5.61, and 8.34 microM, respectively.",Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728776/),μM,5.38,227562,DB00682,Warfarin
,10728776,Kd,"The Kd values determined by fluorescence spectroscopy for wild type, R218H, R218P and R218M HSA binding to warfarin were 1.35, 5.38, 5.61, and 8.34 microM, respectively.",Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728776/),μM,5.61,227563,DB00682,Warfarin
,10728776,Kd,"The Kd values determined by fluorescence spectroscopy for wild type, R218H, R218P and R218M HSA binding to warfarin were 1.35, 5.38, 5.61, and 8.34 microM, respectively.",Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728776/),μM,8.34,227564,DB00682,Warfarin
,4091996,terminal half-life,"The pharmacokinetics of vitamin K1 in patients were similar to those reported previously in healthy volunteers, terminal half-life 1.7 h.",Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091996/),h,1.7,229024,DB00682,Warfarin
,4091996,plasma concentrations,Steady state warfarin plasma concentrations ranged from 0.5 to 1.4 micrograms ml-1.,Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091996/),,0.5 to 1.4,229025,DB00682,Warfarin
,4091996,Pro,Prothrombin complex activity ranged from 15 to 28.5%.,Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091996/),%,15 to 28.5,229026,DB00682,Warfarin
,4091996,CPmax,"All the patients on warfarin had measurable levels (CPmax 0.3-1.2 micrograms ml-1) of vitamin K1 2, 3-epoxide.",Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091996/),[μg] / [ml],0.3-1.2,229027,DB00682,Warfarin
,21692828,clearance,"The S-warfarin clearance was estimated to be 0.144 l h⁻¹ (95% confidence interval 0.131, 0.157) in a 70 kg woman aged 69.8 years with the wild-type CYP2C9 genotype, and the volume of distribution was 16.6 l (95% confidence interval 13.5, 19.7).",The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692828/),h⁻¹·l,0.144,229577,DB00682,Warfarin
,21692828,volume of distribution,"The S-warfarin clearance was estimated to be 0.144 l h⁻¹ (95% confidence interval 0.131, 0.157) in a 70 kg woman aged 69.8 years with the wild-type CYP2C9 genotype, and the volume of distribution was 16.6 l (95% confidence interval 13.5, 19.7).",The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692828/),l,16.6,229578,DB00682,Warfarin
,21692828,clearance,"The R-warfarin clearance was estimated to be 0.125 l h⁻¹ (95% confidence interval 0.115, 0.135) in a 70 kg individual aged 69.8 years with the wild-type CYP2C19 and CYP3A4 genotypes, and the volume of distribution was 10.9 l (95% confidence interval 8.63, 13.2).",The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692828/),h⁻¹·l,0.125,229579,DB00682,Warfarin
,21692828,volume of distribution,"The R-warfarin clearance was estimated to be 0.125 l h⁻¹ (95% confidence interval 0.115, 0.135) in a 70 kg individual aged 69.8 years with the wild-type CYP2C19 and CYP3A4 genotypes, and the volume of distribution was 10.9 l (95% confidence interval 8.63, 13.2).",The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692828/),l,10.9,229580,DB00682,Warfarin
,24615060,flow rate,Chromatographic separation was achieved on a reverse phase C18 column with a gradient mobile phase of CH3CN-water with 0.1 % HCOOH at a flow rate of 0.3 mL/min.,"Pharmacokinetics study of asperosaponin VI and its metabolites cauloside A, HN saponin F and hederagenin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24615060/),[ml] / [min],0.3,230303,DB00682,Warfarin
,24615060,m,"Sample analysis was simultaneously performed with a multiple reaction monitoring mode using target determination ions at m/z 927.5 → 603.4 for asperosaponin VI, m/z 811.1 → 603.4 for cauloside A, m/z 649.4 → 603.4 for HN saponin F, m/z 71.4 → 393.3 for hederagenin and m/z 307.0 → 161.1 for warfarin as the internal standard.","Pharmacokinetics study of asperosaponin VI and its metabolites cauloside A, HN saponin F and hederagenin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24615060/),,649.4,230304,DB00682,Warfarin
,24615060,m/z,"Sample analysis was simultaneously performed with a multiple reaction monitoring mode using target determination ions at m/z 927.5 → 603.4 for asperosaponin VI, m/z 811.1 → 603.4 for cauloside A, m/z 649.4 → 603.4 for HN saponin F, m/z 71.4 → 393.3 for hederagenin and m/z 307.0 → 161.1 for warfarin as the internal standard.","Pharmacokinetics study of asperosaponin VI and its metabolites cauloside A, HN saponin F and hederagenin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24615060/),,71.4,230305,DB00682,Warfarin
,24615060,m/z,"Sample analysis was simultaneously performed with a multiple reaction monitoring mode using target determination ions at m/z 927.5 → 603.4 for asperosaponin VI, m/z 811.1 → 603.4 for cauloside A, m/z 649.4 → 603.4 for HN saponin F, m/z 71.4 → 393.3 for hederagenin and m/z 307.0 → 161.1 for warfarin as the internal standard.","Pharmacokinetics study of asperosaponin VI and its metabolites cauloside A, HN saponin F and hederagenin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24615060/),,393.3,230306,DB00682,Warfarin
,24615060,m,"Sample analysis was simultaneously performed with a multiple reaction monitoring mode using target determination ions at m/z 927.5 → 603.4 for asperosaponin VI, m/z 811.1 → 603.4 for cauloside A, m/z 649.4 → 603.4 for HN saponin F, m/z 71.4 → 393.3 for hederagenin and m/z 307.0 → 161.1 for warfarin as the internal standard.","Pharmacokinetics study of asperosaponin VI and its metabolites cauloside A, HN saponin F and hederagenin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24615060/),,307.0,230307,DB00682,Warfarin
,24615060,T max,"As a result, the pharmacokinetic parameters of cauloside A, HN saponin F and hederagenin such as T max were obtained at 9.33 ± 2.49, 7.33 ± 0.47 and 12.33 ± 2.36 h, respectively.","Pharmacokinetics study of asperosaponin VI and its metabolites cauloside A, HN saponin F and hederagenin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24615060/),h,9.33,230308,DB00682,Warfarin
,24615060,T max,"As a result, the pharmacokinetic parameters of cauloside A, HN saponin F and hederagenin such as T max were obtained at 9.33 ± 2.49, 7.33 ± 0.47 and 12.33 ± 2.36 h, respectively.","Pharmacokinetics study of asperosaponin VI and its metabolites cauloside A, HN saponin F and hederagenin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24615060/),h,7.33,230309,DB00682,Warfarin
,24615060,T max,"As a result, the pharmacokinetic parameters of cauloside A, HN saponin F and hederagenin such as T max were obtained at 9.33 ± 2.49, 7.33 ± 0.47 and 12.33 ± 2.36 h, respectively.","Pharmacokinetics study of asperosaponin VI and its metabolites cauloside A, HN saponin F and hederagenin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24615060/),h,12.33,230310,DB00682,Warfarin
exceeded,8071848,half-life of elimination,Warfarin accumulated to saturation (40-50 pmol/mg of protein) in liver microsomes to remain prolongedly bound and the half-life of elimination exceeded 7 days.,Target-based warfarin pharmacokinetics in the rat: the link with the anticoagulant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8071848/),d,7,230379,DB00682,Warfarin
less,8071848,Emax,Emax appeared to be significantly less than 100% (95% confidence intervals; 83-91%).,Target-based warfarin pharmacokinetics in the rat: the link with the anticoagulant effect. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8071848/),%,100,230380,DB00682,Warfarin
,12974871,Oral bioavailability,"Oral bioavailability, measured as the plasma concentration of the active metabolite, seems to be higher for ximelagatran (20%) than for BIBR 1048 (estimated to 5%).",Oral direct thrombin inhibitors in clinical development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),%,20,230458,DB00682,Warfarin
,12974871,Oral bioavailability,"Oral bioavailability, measured as the plasma concentration of the active metabolite, seems to be higher for ximelagatran (20%) than for BIBR 1048 (estimated to 5%).",Oral direct thrombin inhibitors in clinical development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),%,5,230459,DB00682,Warfarin
,12974871,half-life,"BIBR 953 has a longer half-life (about 12 h) than does melagatran (3-5 h) after oral administration of BIBR 1048 and ximelagatran, respectively.",Oral direct thrombin inhibitors in clinical development. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),h,12,230460,DB00682,Warfarin
,12974871,half-life,"BIBR 953 has a longer half-life (about 12 h) than does melagatran (3-5 h) after oral administration of BIBR 1048 and ximelagatran, respectively.",Oral direct thrombin inhibitors in clinical development. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),h,3-5,230461,DB00682,Warfarin
,8786976,bioavailability,"All compounds showed linear pharmacokinetics, and significant bioavailability of MKH was also observed following the administration of 1 (188%), 2 (87%) and 3 (135%).",Vitamin K prodrugs: 2. water-soluble prodrugs of menahydroquinone-4 for systemic site-specific delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786976/),%,188,230630,DB00682,Warfarin
,8786976,bioavailability,"All compounds showed linear pharmacokinetics, and significant bioavailability of MKH was also observed following the administration of 1 (188%), 2 (87%) and 3 (135%).",Vitamin K prodrugs: 2. water-soluble prodrugs of menahydroquinone-4 for systemic site-specific delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786976/),%,87,230631,DB00682,Warfarin
,8786976,bioavailability,"All compounds showed linear pharmacokinetics, and significant bioavailability of MKH was also observed following the administration of 1 (188%), 2 (87%) and 3 (135%).",Vitamin K prodrugs: 2. water-soluble prodrugs of menahydroquinone-4 for systemic site-specific delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786976/),%,135,230632,DB00682,Warfarin
,8786976,AUCliver,"Prodrug 1 caused the following increases; AUCliver of MKO from 70.7 +/- 5.77 (H-MK-4) to 167 +/- 7.89 nmol.h/g, MRTliver of MKO, from 3.87 +/- 0.307 to 8.57 +/- 0.432 h.",Vitamin K prodrugs: 2. water-soluble prodrugs of menahydroquinone-4 for systemic site-specific delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786976/),[h·nM] / [g],70.7,230633,DB00682,Warfarin
,8786976,AUCliver,"Prodrug 1 caused the following increases; AUCliver of MKO from 70.7 +/- 5.77 (H-MK-4) to 167 +/- 7.89 nmol.h/g, MRTliver of MKO, from 3.87 +/- 0.307 to 8.57 +/- 0.432 h.",Vitamin K prodrugs: 2. water-soluble prodrugs of menahydroquinone-4 for systemic site-specific delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786976/),[h·nM] / [g],167,230634,DB00682,Warfarin
,8786976,MRTliver,"Prodrug 1 caused the following increases; AUCliver of MKO from 70.7 +/- 5.77 (H-MK-4) to 167 +/- 7.89 nmol.h/g, MRTliver of MKO, from 3.87 +/- 0.307 to 8.57 +/- 0.432 h.",Vitamin K prodrugs: 2. water-soluble prodrugs of menahydroquinone-4 for systemic site-specific delivery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786976/),h,3.87,230635,DB00682,Warfarin
,8786976,MRTliver,"Prodrug 1 caused the following increases; AUCliver of MKO from 70.7 +/- 5.77 (H-MK-4) to 167 +/- 7.89 nmol.h/g, MRTliver of MKO, from 3.87 +/- 0.307 to 8.57 +/- 0.432 h.",Vitamin K prodrugs: 2. water-soluble prodrugs of menahydroquinone-4 for systemic site-specific delivery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786976/),h,8.57,230636,DB00682,Warfarin
,2228341,plasma half-life,"However the plasma half-life of famotidine was slightly, but statistically significantly longer (p less than 0.05) during maintenance treatment with warfarin (mean +/- s.e.m.: 2.58 +/- 0.14 h versus 2.96 +/- 0.16 h respectively).",Lack of interaction between famotidine and warfarin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2228341/),h,2.58,230946,DB00682,Warfarin
,2228341,plasma half-life,"However the plasma half-life of famotidine was slightly, but statistically significantly longer (p less than 0.05) during maintenance treatment with warfarin (mean +/- s.e.m.: 2.58 +/- 0.14 h versus 2.96 +/- 0.16 h respectively).",Lack of interaction between famotidine and warfarin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2228341/),h,2.96,230947,DB00682,Warfarin
up to,28287050,proth,"Anticoagulant activity significantly increased, with prothrombin time (PT) up to 199 ± 33 s in coadministered group (approximately ten-fold compared with rats received warfarin alone).",The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28287050/),s,199,231253,DB00682,Warfarin
,28287050,IC50,"Incubation experiments illustrated FA inhibited CYP2C6 and CYP3A1/2 with the IC50 values of 6.98 and 16.14 μM, and inhibited the metabolism of warfarin (Ki value of 2.21 μM).",The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28287050/),μM,6.98,231254,DB00682,Warfarin
,28287050,IC50,"Incubation experiments illustrated FA inhibited CYP2C6 and CYP3A1/2 with the IC50 values of 6.98 and 16.14 μM, and inhibited the metabolism of warfarin (Ki value of 2.21 μM).",The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28287050/),μM,16.14,231255,DB00682,Warfarin
,28287050,Ki,"Incubation experiments illustrated FA inhibited CYP2C6 and CYP3A1/2 with the IC50 values of 6.98 and 16.14 μM, and inhibited the metabolism of warfarin (Ki value of 2.21 μM).",The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28287050/),μM,2.21,231256,DB00682,Warfarin
,11168910,steady-state concentration,Pharmacodynamic modeling suggested that each cat had a narrow therapeutic range of the steady-state concentration of total warfarin required to appropriately block prothrombin complex synthesis (median: 265.2-358.7 ng/mL).,Pharmacodynamics of warfarin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168910/),[ng] / [ml],265.2-358.7,231995,DB00682,Warfarin
,23037995,m/,Rupestonic acid and the internal standard (IS) warfarin sodium were detected at m/z 247.2 → 203.1 and 307.1 → 161.3 in positive ion and multiple reaction monitoring mode respectively.,Quantitative determination of rupestonic acid in rat plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23037995/),,247.2,233173,DB00682,Warfarin
,23037995,m/,Rupestonic acid and the internal standard (IS) warfarin sodium were detected at m/z 247.2 → 203.1 and 307.1 → 161.3 in positive ion and multiple reaction monitoring mode respectively.,Quantitative determination of rupestonic acid in rat plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23037995/),,307.1,233174,DB00682,Warfarin
,23037995,m/,Rupestonic acid and the internal standard (IS) warfarin sodium were detected at m/z 247.2 → 203.1 and 307.1 → 161.3 in positive ion and multiple reaction monitoring mode respectively.,Quantitative determination of rupestonic acid in rat plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23037995/),,161,233175,DB00682,Warfarin
,10027662,areas under the concentration-time curve (AUC),The median (range) areas under the concentration-time curve (AUC) for (R)-acenocoumarol were 3458 (3035-7312) microg x h 1(-1) in the absence of and 3667 (2907-7741) microg x h 1(-1) in the presence of lornoxicam.,No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027662/),h·μg,3458,233825,DB00682,Warfarin
,10027662,areas under the concentration-time curve (AUC),The median (range) areas under the concentration-time curve (AUC) for (R)-acenocoumarol were 3458 (3035-7312) microg x h 1(-1) in the absence of and 3667 (2907-7741) microg x h 1(-1) in the presence of lornoxicam.,No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027662/),h·μg,3667,233826,DB00682,Warfarin
,18429757,clearance,"Wild type homozygotes (1) had the highest warfarin clearance (3,51 ml/min).",[Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18429757/),[ml] / [min],"3,51",235517,DB00682,Warfarin
,18429757,clearance,"In carriers of 2C9 *2(2) and 2C9 *3(3) warfarin clearance was significantly lower (2.42 and 1.82 ml/min; p1 - 2 = 0,05; p1 - 3 = 0,0008).",[Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18429757/),[ml] / [min],2.42,235518,DB00682,Warfarin
,18429757,clearance,"In carriers of 2C9 *2(2) and 2C9 *3(3) warfarin clearance was significantly lower (2.42 and 1.82 ml/min; p1 - 2 = 0,05; p1 - 3 = 0,0008).",[Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18429757/),[ml] / [min],1.82,235519,DB00682,Warfarin
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB00682,Warfarin
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB00682,Warfarin
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB00682,Warfarin
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB00682,Warfarin
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB00682,Warfarin
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB00682,Warfarin
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB00682,Warfarin
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB00682,Warfarin
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB00682,Warfarin
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB00682,Warfarin
,27503578,CL(S),"Significant predictors of CL(S) included clinical (age, body weight and sex) and genotypic (CYP2C9*2,*3 and *8) factors, as well as African American ethnicity, the median CL(S) being 30% lower in the latter than in Asians and whites (170 versus 243 and 250 ml h-1, P<0.01).","Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27503578/),[ml] / [h],170,238308,DB00682,Warfarin
,27503578,CL(S),"Significant predictors of CL(S) included clinical (age, body weight and sex) and genotypic (CYP2C9*2,*3 and *8) factors, as well as African American ethnicity, the median CL(S) being 30% lower in the latter than in Asians and whites (170 versus 243 and 250 ml h-1, P<0.01).","Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27503578/),[ml] / [h],243,238309,DB00682,Warfarin
,27503578,CL(S),"Significant predictors of CL(S) included clinical (age, body weight and sex) and genotypic (CYP2C9*2,*3 and *8) factors, as well as African American ethnicity, the median CL(S) being 30% lower in the latter than in Asians and whites (170 versus 243 and 250 ml h-1, P<0.01).","Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27503578/),[ml] / [h],250,238310,DB00682,Warfarin
,8620673,pro,"This stereoselective interaction was accompanied by an increase in mean morning (predose) and evening (12-hour postdose) prothrombin times from 17.5 to 19.8 seconds and 17.1 to 19.1 seconds, respectively; the corresponding changes in the placebo group were from 18.1 to 18.8 seconds and 17.3 to 17.5 seconds.",Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620673/),seconds,17.5 to 19.8,239236,DB00682,Warfarin
,15001972,daily dose requirement,The mean warfarin daily dose requirement in milligrams fell from 4.06 +/- 1.72 mg in homozygous wild-type patients to 3.63 +/- 1.78 mg for *1/*2-positive patients and 2.70 +/- 1.36 mg for *1/*3-positive patients.,"Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001972/),,4.06,240870,DB00682,Warfarin
,15001972,daily dose requirement,The mean warfarin daily dose requirement in milligrams fell from 4.06 +/- 1.72 mg in homozygous wild-type patients to 3.63 +/- 1.78 mg for *1/*2-positive patients and 2.70 +/- 1.36 mg for *1/*3-positive patients.,"Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001972/),mg,3.63,240871,DB00682,Warfarin
,15001972,daily dose requirement,The mean warfarin daily dose requirement in milligrams fell from 4.06 +/- 1.72 mg in homozygous wild-type patients to 3.63 +/- 1.78 mg for *1/*2-positive patients and 2.70 +/- 1.36 mg for *1/*3-positive patients.,"Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001972/),mg,2.70,240872,DB00682,Warfarin
,3871765,half-life,Fluoxetine disappears from plasma with a half-life of 1-3 days; its metabolite norfluoxetine has a plasma half-life of 7-15 days.,Fluoxetine: clinical pharmacology and physiologic disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3871765/),d,1-3,240991,DB00682,Warfarin
,3871765,plasma half-life,Fluoxetine disappears from plasma with a half-life of 1-3 days; its metabolite norfluoxetine has a plasma half-life of 7-15 days.,Fluoxetine: clinical pharmacology and physiologic disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3871765/),d,7-15,240992,DB00682,Warfarin
,11248285,anti-Xa/anti-IIa ratios,"The anti-Xa/anti-IIa ratios of the drug substances were comparable at 1.5 and 1.7 for tinzaparin and the tinzaparin-like LMWH, respectively.",Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),,1.5,245557,DB00682,Warfarin
,11248285,anti-Xa/anti-IIa ratios,"The anti-Xa/anti-IIa ratios of the drug substances were comparable at 1.5 and 1.7 for tinzaparin and the tinzaparin-like LMWH, respectively.",Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),,1.7,245558,DB00682,Warfarin
,11248285,maximum plasma anti-Xa activity (A(max)),Mean maximum plasma anti-Xa activity (A(max)) was approximately 0.818 IU/ml at 4 h following tinzaparin injection.,Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),[iu] / [ml],0.818,245559,DB00682,Warfarin
,11248285,maximum plasma anti-IIa activity,Mean maximum plasma anti-IIa activity was 0.308 IU/ml at 5 h postdose.,Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248285/),[iu] / [ml],0.308,245560,DB00682,Warfarin
,16123911,bioavailability,"The bioavailability of melagatran, the active form of ximelagatran, after oral administration of ximelagatran is approximately 20% with low inter- and intra-individual variability.",Pharmacokinetics and pharmacodynamics of ximelagatran. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123911/),%,20,245703,DB00682,Warfarin
,16123911,half-life,"Peak plasma melagatran concentrations are reached approximately 2 hours after oral dosing of ximelagatran to healthy volunteers, and melagatran is eliminated with a half-life of approximately 3 hours with clearance predominantly by renal excretion.",Pharmacokinetics and pharmacodynamics of ximelagatran. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123911/),h,3,245704,DB00682,Warfarin
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),,98.,248833,DB00682,Warfarin
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,53.1,248834,DB00682,Warfarin
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,45.2,248835,DB00682,Warfarin
,33754183,apparent oral clearance,Mean apparent oral clearance was 0.56 L/hr and volume of distribution was 35.5 L.,S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754183/),[l] / [h],0.56,250714,DB00682,Warfarin
,33754183,volume of distribution,Mean apparent oral clearance was 0.56 L/hr and volume of distribution was 35.5 L.,S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754183/),l,35.5,250715,DB00682,Warfarin
,10217316,peak plasma concentration,"The pharmacokinetics of warfarin after a single dose were not altered in the presence of ginseng; peak plasma concentration (control 7.8+/-0.5; ginseng 7.3+/-2.5 microg mL(-1)), time to peak (control 2.6+/-1.0; ginseng 3.1+/-1.1 h), elimination half-life (control 14.3+/-5.8; ginseng 10.6+/-3.1 h), and oral clearance (control 17.5+/-3.3; ginseng 20.2+/-5.5 mL h(-1)) were not significantly different (P>0.05).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),[μg] / [ml],7.8,251459,DB00682,Warfarin
,10217316,peak plasma concentration,"The pharmacokinetics of warfarin after a single dose were not altered in the presence of ginseng; peak plasma concentration (control 7.8+/-0.5; ginseng 7.3+/-2.5 microg mL(-1)), time to peak (control 2.6+/-1.0; ginseng 3.1+/-1.1 h), elimination half-life (control 14.3+/-5.8; ginseng 10.6+/-3.1 h), and oral clearance (control 17.5+/-3.3; ginseng 20.2+/-5.5 mL h(-1)) were not significantly different (P>0.05).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),[μg] / [ml],7.3,251460,DB00682,Warfarin
,10217316,time to peak,"The pharmacokinetics of warfarin after a single dose were not altered in the presence of ginseng; peak plasma concentration (control 7.8+/-0.5; ginseng 7.3+/-2.5 microg mL(-1)), time to peak (control 2.6+/-1.0; ginseng 3.1+/-1.1 h), elimination half-life (control 14.3+/-5.8; ginseng 10.6+/-3.1 h), and oral clearance (control 17.5+/-3.3; ginseng 20.2+/-5.5 mL h(-1)) were not significantly different (P>0.05).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),h,2.6,251461,DB00682,Warfarin
,10217316,time to peak,"The pharmacokinetics of warfarin after a single dose were not altered in the presence of ginseng; peak plasma concentration (control 7.8+/-0.5; ginseng 7.3+/-2.5 microg mL(-1)), time to peak (control 2.6+/-1.0; ginseng 3.1+/-1.1 h), elimination half-life (control 14.3+/-5.8; ginseng 10.6+/-3.1 h), and oral clearance (control 17.5+/-3.3; ginseng 20.2+/-5.5 mL h(-1)) were not significantly different (P>0.05).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),h,3.1,251462,DB00682,Warfarin
,10217316,elimination half-life,"The pharmacokinetics of warfarin after a single dose were not altered in the presence of ginseng; peak plasma concentration (control 7.8+/-0.5; ginseng 7.3+/-2.5 microg mL(-1)), time to peak (control 2.6+/-1.0; ginseng 3.1+/-1.1 h), elimination half-life (control 14.3+/-5.8; ginseng 10.6+/-3.1 h), and oral clearance (control 17.5+/-3.3; ginseng 20.2+/-5.5 mL h(-1)) were not significantly different (P>0.05).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),h,14.3,251463,DB00682,Warfarin
,10217316,elimination half-life,"The pharmacokinetics of warfarin after a single dose were not altered in the presence of ginseng; peak plasma concentration (control 7.8+/-0.5; ginseng 7.3+/-2.5 microg mL(-1)), time to peak (control 2.6+/-1.0; ginseng 3.1+/-1.1 h), elimination half-life (control 14.3+/-5.8; ginseng 10.6+/-3.1 h), and oral clearance (control 17.5+/-3.3; ginseng 20.2+/-5.5 mL h(-1)) were not significantly different (P>0.05).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),h,10.6,251464,DB00682,Warfarin
,10217316,oral clearance,"The pharmacokinetics of warfarin after a single dose were not altered in the presence of ginseng; peak plasma concentration (control 7.8+/-0.5; ginseng 7.3+/-2.5 microg mL(-1)), time to peak (control 2.6+/-1.0; ginseng 3.1+/-1.1 h), elimination half-life (control 14.3+/-5.8; ginseng 10.6+/-3.1 h), and oral clearance (control 17.5+/-3.3; ginseng 20.2+/-5.5 mL h(-1)) were not significantly different (P>0.05).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),[ml] / [h],17.5,251465,DB00682,Warfarin
,10217316,oral clearance,"The pharmacokinetics of warfarin after a single dose were not altered in the presence of ginseng; peak plasma concentration (control 7.8+/-0.5; ginseng 7.3+/-2.5 microg mL(-1)), time to peak (control 2.6+/-1.0; ginseng 3.1+/-1.1 h), elimination half-life (control 14.3+/-5.8; ginseng 10.6+/-3.1 h), and oral clearance (control 17.5+/-3.3; ginseng 20.2+/-5.5 mL h(-1)) were not significantly different (P>0.05).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),[ml] / [h],20.2,251466,DB00682,Warfarin
,10217316,area under the prothrombin time vs time curve,"Under both dosing conditions, ginseng also showed no significant impact on the pharmacodynamics of warfarin as assessed by the area under the prothrombin time vs time curve (multiple dosing; control 3776+/-619, ginseng 3830+/-362 sh) and maximum prothrombin time (control 57.2+/-11.8, ginseng 63.3+/-9.1 s).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),sh,3776,251467,DB00682,Warfarin
,10217316,area under the prothrombin time vs time curve,"Under both dosing conditions, ginseng also showed no significant impact on the pharmacodynamics of warfarin as assessed by the area under the prothrombin time vs time curve (multiple dosing; control 3776+/-619, ginseng 3830+/-362 sh) and maximum prothrombin time (control 57.2+/-11.8, ginseng 63.3+/-9.1 s).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),sh,3830,251468,DB00682,Warfarin
,10217316,maximum prothrombin time,"Under both dosing conditions, ginseng also showed no significant impact on the pharmacodynamics of warfarin as assessed by the area under the prothrombin time vs time curve (multiple dosing; control 3776+/-619, ginseng 3830+/-362 sh) and maximum prothrombin time (control 57.2+/-11.8, ginseng 63.3+/-9.1 s).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),s,57.2,251469,DB00682,Warfarin
,10217316,maximum prothrombin time,"Under both dosing conditions, ginseng also showed no significant impact on the pharmacodynamics of warfarin as assessed by the area under the prothrombin time vs time curve (multiple dosing; control 3776+/-619, ginseng 3830+/-362 sh) and maximum prothrombin time (control 57.2+/-11.8, ginseng 63.3+/-9.1 s).",Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217316/),s,63.3,251470,DB00682,Warfarin
,10749518,apparent volume of distribution,"Celexocib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 455+/-166L in humans.",Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),l,455,252478,DB00682,Warfarin
,10749518,elimination half-life,Celecoxib is metabolised primarily by the cytochrome P450 (CYP) 2C9 isoenzyme and has an elimination half-life of about 11 hours in healthy individuals.,Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),h,11,252479,DB00682,Warfarin
,27462142,T max,"There were significant differences between the WFO and WFN groups, the WFO group showed a decrease of 63.8% and 70% in AUC0- t and C max, respectively; the delay in T max between the WN and WFN groups (mean, from 132-432 minutes) was significantly different; the mean retention time from 0 to time (MRT0- t ) between the WO and WFO groups (mean, from 718.31-606.13 minutes) also showed a significant difference.",The effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27462142/),min,132-432,253575,DB00682,Warfarin
,27462142,retention time from 0 to time (MRT0- t ),"There were significant differences between the WFO and WFN groups, the WFO group showed a decrease of 63.8% and 70% in AUC0- t and C max, respectively; the delay in T max between the WN and WFN groups (mean, from 132-432 minutes) was significantly different; the mean retention time from 0 to time (MRT0- t ) between the WO and WFO groups (mean, from 718.31-606.13 minutes) also showed a significant difference.",The effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27462142/),min,718.31-606.13,253576,DB00682,Warfarin
,7924124,kd,"The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),1/[h],0.054,254945,DB00682,Warfarin
,7924124,"Cu50,S","The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),[mg] / [l],0.0026,254946,DB00682,Warfarin
,7924124,"Cu50,R","The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),[mg] / [l],3.45,254947,DB00682,Warfarin
,7924124,gamma,"The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),,0.90,254948,DB00682,Warfarin
,7924124,td,"The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),h,8.2,254949,DB00682,Warfarin
>,31430835,process efficiencies,Acceptable analytical recovery (>55%) was achieved with process efficiencies >41.5% and matrix effects <139.9% over the analytical range.,Development and validation of an ultra-high-performance liquid chromatography-tandem mass spectrometry method to determine the bioavailability of warfarin and its major metabolite 7-hydroxy warfarin in rats dosed with oral formulations containing different polymorphic forms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31430835/),%,41.5,255213,DB00682,Warfarin
,9484872,half-life,"It reaches peak plasma levels around 2 h after administration, then declines bi-exponentially, with an extended half-life of around 12 h.",Pharmacokinetics of grepafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9484872/),h,12,255441,DB00682,Warfarin
,4000042,half-life,"The plasma warfarin level fell rapidly (half-life, 21.7 h), and there was no convincing evidence for dose-dependency in its disposition.",Plasma warfarin concentrations after a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4000042/),h,21.7,256626,DB00682,Warfarin
,19941044,clearance,The presence of a single *2 or *3 CYP2C9 allele reduced mean [SE (standard error)] S-warfarin clearance by 35% from 0.276 (0.04) to 0.180 (0.11) l/h.,Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19941044/),[l] / [h],0.276,257160,DB00682,Warfarin
,19941044,clearance,The presence of a single *2 or *3 CYP2C9 allele reduced mean [SE (standard error)] S-warfarin clearance by 35% from 0.276 (0.04) to 0.180 (0.11) l/h.,Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19941044/),[l] / [h],0.180,257161,DB00682,Warfarin
,19941044,"C (50,S)","Subjects with VKORC1 haplotype groups of H7H7 had increased mean (SE) C (50,S) (concentration of S-warfarin required to achieve 50% of maximum effect) of 479 (7.3) compared to 206 (6.7) ng/ml in subjects with the H1H1 groups.",Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19941044/),[ng] / [ml],479,257162,DB00682,Warfarin
,19941044,"C (50,S)","Subjects with VKORC1 haplotype groups of H7H7 had increased mean (SE) C (50,S) (concentration of S-warfarin required to achieve 50% of maximum effect) of 479 (7.3) compared to 206 (6.7) ng/ml in subjects with the H1H1 groups.",Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19941044/),[ng] / [ml],206,257163,DB00682,Warfarin
,19941044,"C (50,S)","For subjects with the H1H7 haplotype, mean (SE) C (50,S) increased 1.4 times to 288 (1.3) ng/ml compared to subjects with H1H1 haplotypes.",Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19941044/),[ng] / [ml],288,257164,DB00682,Warfarin
,8729584,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),min,30,257876,DB00682,Warfarin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,40,257877,DB00682,Warfarin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,60,257878,DB00682,Warfarin
,903865,body clearance,There was a small but statistically significant (p less than 0.05) decrease in the body clearance of (S)-(-)-warfarin (from 4.84 to 4.37 ml/hr/kg) and an increase in the serum free fraction of racemic warfarin (added to serum in vitro) from 0.00850 to 0.0107 (p less than 0.05).,Comparative pharmacokinetics of coumarin anticoagulants XXIX: Elimination kinetics and anticoagulant activity of (S)-(-)-warfarin in rats before and after chronic administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/903865/),[ml] / [h·kg],4.84,258230,DB00682,Warfarin
,903865,body clearance,There was a small but statistically significant (p less than 0.05) decrease in the body clearance of (S)-(-)-warfarin (from 4.84 to 4.37 ml/hr/kg) and an increase in the serum free fraction of racemic warfarin (added to serum in vitro) from 0.00850 to 0.0107 (p less than 0.05).,Comparative pharmacokinetics of coumarin anticoagulants XXIX: Elimination kinetics and anticoagulant activity of (S)-(-)-warfarin in rats before and after chronic administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/903865/),[ml] / [h·kg],4.37,258231,DB00682,Warfarin
,903865,serum free fraction,There was a small but statistically significant (p less than 0.05) decrease in the body clearance of (S)-(-)-warfarin (from 4.84 to 4.37 ml/hr/kg) and an increase in the serum free fraction of racemic warfarin (added to serum in vitro) from 0.00850 to 0.0107 (p less than 0.05).,Comparative pharmacokinetics of coumarin anticoagulants XXIX: Elimination kinetics and anticoagulant activity of (S)-(-)-warfarin in rats before and after chronic administration. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/903865/),,0.008,258232,DB00682,Warfarin
,903865,serum free fraction,There was a small but statistically significant (p less than 0.05) decrease in the body clearance of (S)-(-)-warfarin (from 4.84 to 4.37 ml/hr/kg) and an increase in the serum free fraction of racemic warfarin (added to serum in vitro) from 0.00850 to 0.0107 (p less than 0.05).,Comparative pharmacokinetics of coumarin anticoagulants XXIX: Elimination kinetics and anticoagulant activity of (S)-(-)-warfarin in rats before and after chronic administration. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/903865/),,0.,258233,DB00682,Warfarin
,23515956,CL,"Using IVIVE, the predicted mean CL of S-warfarin for patients with CYP2C9*1/*3 (0.092 l/h, n = 11) was 57 % less than for those with wild-type *1/*1 (0.215 l/h, n = 186).",Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23515956/),[l] / [h],0.092,260544,DB00682,Warfarin
,23515956,CL,"Using IVIVE, the predicted mean CL of S-warfarin for patients with CYP2C9*1/*3 (0.092 l/h, n = 11) was 57 % less than for those with wild-type *1/*1 (0.215 l/h, n = 186).",Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23515956/),[l] / [h],0.215,260545,DB00682,Warfarin
,16531476,unbound fractions,"Both molecules were very highly bound to plasma proteins in all the tested species with unbound fractions in plasma in the range of 0.4 to 1.8% and 0.2 to 1.2% for deferasirox and Fe-[ICL670]2, respectively; binding of the iron complex was either similar or higher in all the species.","In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16531476/),%,0.4 to 1.8,261788,DB00682,Warfarin
,16531476,unbound fractions,"Both molecules were very highly bound to plasma proteins in all the tested species with unbound fractions in plasma in the range of 0.4 to 1.8% and 0.2 to 1.2% for deferasirox and Fe-[ICL670]2, respectively; binding of the iron complex was either similar or higher in all the species.","In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16531476/),%,0.2 to 1.2,261789,DB00682,Warfarin
,16531476,fraction,The high plasma protein binding was in line with a distribution mainly into the plasma fraction of blood; the fraction in plasma was around 100% for Fe-[ICL670]2 in all the species and 65 to 95% for deferasirox depending on the species.,"In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16531476/),%,100,261790,DB00682,Warfarin
,16531476,fraction,The high plasma protein binding was in line with a distribution mainly into the plasma fraction of blood; the fraction in plasma was around 100% for Fe-[ICL670]2 in all the species and 65 to 95% for deferasirox depending on the species.,"In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16531476/),%,65 to 95,261791,DB00682,Warfarin
,16029066,terminal half-life,E 3174 is 10- to 40-fold more potent than its parent compound and its estimated terminal half-life ranges from 6 to 9 hours.,Clinical pharmacokinetics of losartan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029066/),h,6 to 9,263266,DB00682,Warfarin
,22568694,steady-state C(max),"With the therapeutic dose, steady-state C(max) (11-12 nmol/L) and AUC (∼150 nmol · h/L) are approximately 1.3-fold greater than after a single dose, indicating little drug accumulation with repeat dosing.",Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),[nM] / [l],11-12,263484,DB00682,Warfarin
,22568694,AUC,"With the therapeutic dose, steady-state C(max) (11-12 nmol/L) and AUC (∼150 nmol · h/L) are approximately 1.3-fold greater than after a single dose, indicating little drug accumulation with repeat dosing.",Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),[h·nM] / [l],∼150,263485,DB00682,Warfarin
,22568694,oral bioavailability,The oral bioavailability of linagliptin estimated with this model is approximately 30%.,Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),%,30,263486,DB00682,Warfarin
>,22568694,terminal half-life,"Linagliptin has a long terminal half-life (>100 hours); however, its accumulation half-life is much shorter (approximately 10 hours), accounting for the rapid attainment of steady state.",Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),h,100,263487,DB00682,Warfarin
,22568694,accumulation half-life,"Linagliptin has a long terminal half-life (>100 hours); however, its accumulation half-life is much shorter (approximately 10 hours), accounting for the rapid attainment of steady state.",Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),h,10,263488,DB00682,Warfarin
,22568694,inhibition constant,"Linagliptin potently inhibits DPP-4 (inhibition constant 1 nmol/L), and trough drug concentrations achieved with therapeutic dosing inhibit >80% of plasma DPP-4 activity, the threshold associated with maximal antihyperglycaemic effects in animal models.",Clinical pharmacokinetics and pharmacodynamics of linagliptin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568694/),[nM] / [l],1,263489,DB00682,Warfarin
,1195101,biological half-life,"Individual rats eliminated warfarin by apparent first-order kinetics, with a biological half-life of 5.9-41 hr and a total plasma clearance of 2.4-22 ml kg(-1) hr(-1).","Comparative pharmacokinetics of coumarin anticoagulants. XIV: relationship between protein binding, distribution, and elimination kinetics of warfarin in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195101/),h,5.9-41,264626,DB00682,Warfarin
,1195101,total plasma clearance,"Individual rats eliminated warfarin by apparent first-order kinetics, with a biological half-life of 5.9-41 hr and a total plasma clearance of 2.4-22 ml kg(-1) hr(-1).","Comparative pharmacokinetics of coumarin anticoagulants. XIV: relationship between protein binding, distribution, and elimination kinetics of warfarin in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195101/),[ml] / [hr·kg],2.4-22,264627,DB00682,Warfarin
,1195101,free fraction of drug (f),"There was no apparent concentration dependance of warfarin binding to serum proteins over a wide concentration range, but there were pronounced intersubject variations in protein binding, with the free fraction of drug (f) in serum ranging from 0.172 x 10(-2) to 1.53 x 10(-2).","Comparative pharmacokinetics of coumarin anticoagulants. XIV: relationship between protein binding, distribution, and elimination kinetics of warfarin in rats. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195101/),,0.172 x 10(-2),264628,DB00682,Warfarin
,1195101,free fraction of drug (f),"There was no apparent concentration dependance of warfarin binding to serum proteins over a wide concentration range, but there were pronounced intersubject variations in protein binding, with the free fraction of drug (f) in serum ranging from 0.172 x 10(-2) to 1.53 x 10(-2).","Comparative pharmacokinetics of coumarin anticoagulants. XIV: relationship between protein binding, distribution, and elimination kinetics of warfarin in rats. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195101/),,1.53 x 10(-2),264629,DB00682,Warfarin
,28371488,t½,"The main pharmacokinetic parameters for film-coated and sugar-coated warfarin were the following: t½ , 103.5 ± 18.8 and 105.8 ± 21.3 hours; Tmax , 0.7 ± 0.5 and 1.3 ± 0.8 hours; Cmax , 347.8 ± 74.8 and 322.9 ± 75.7 ng/mL; AUC0∼360 , 16,024.2 ± 3713.9 and 15,586.6 ± 3477.0 ng·mL-1 ·h; AUC0∼∞ , 17,335.7 ± 4089.1 and 16,912.0 ± 3911.2 ng·mL-1 ·h, respectively.",Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371488/),h,103.5,265562,DB00682,Warfarin
,28371488,t½,"The main pharmacokinetic parameters for film-coated and sugar-coated warfarin were the following: t½ , 103.5 ± 18.8 and 105.8 ± 21.3 hours; Tmax , 0.7 ± 0.5 and 1.3 ± 0.8 hours; Cmax , 347.8 ± 74.8 and 322.9 ± 75.7 ng/mL; AUC0∼360 , 16,024.2 ± 3713.9 and 15,586.6 ± 3477.0 ng·mL-1 ·h; AUC0∼∞ , 17,335.7 ± 4089.1 and 16,912.0 ± 3911.2 ng·mL-1 ·h, respectively.",Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371488/),h,105.8,265563,DB00682,Warfarin
,28371488,Tmax,"The main pharmacokinetic parameters for film-coated and sugar-coated warfarin were the following: t½ , 103.5 ± 18.8 and 105.8 ± 21.3 hours; Tmax , 0.7 ± 0.5 and 1.3 ± 0.8 hours; Cmax , 347.8 ± 74.8 and 322.9 ± 75.7 ng/mL; AUC0∼360 , 16,024.2 ± 3713.9 and 15,586.6 ± 3477.0 ng·mL-1 ·h; AUC0∼∞ , 17,335.7 ± 4089.1 and 16,912.0 ± 3911.2 ng·mL-1 ·h, respectively.",Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371488/),h,0.7,265564,DB00682,Warfarin
,28371488,Tmax,"The main pharmacokinetic parameters for film-coated and sugar-coated warfarin were the following: t½ , 103.5 ± 18.8 and 105.8 ± 21.3 hours; Tmax , 0.7 ± 0.5 and 1.3 ± 0.8 hours; Cmax , 347.8 ± 74.8 and 322.9 ± 75.7 ng/mL; AUC0∼360 , 16,024.2 ± 3713.9 and 15,586.6 ± 3477.0 ng·mL-1 ·h; AUC0∼∞ , 17,335.7 ± 4089.1 and 16,912.0 ± 3911.2 ng·mL-1 ·h, respectively.",Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371488/),h,1.3,265565,DB00682,Warfarin
,28371488,Cmax,"The main pharmacokinetic parameters for film-coated and sugar-coated warfarin were the following: t½ , 103.5 ± 18.8 and 105.8 ± 21.3 hours; Tmax , 0.7 ± 0.5 and 1.3 ± 0.8 hours; Cmax , 347.8 ± 74.8 and 322.9 ± 75.7 ng/mL; AUC0∼360 , 16,024.2 ± 3713.9 and 15,586.6 ± 3477.0 ng·mL-1 ·h; AUC0∼∞ , 17,335.7 ± 4089.1 and 16,912.0 ± 3911.2 ng·mL-1 ·h, respectively.",Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371488/),[ng] / [ml],347.8,265566,DB00682,Warfarin
,28371488,Cmax,"The main pharmacokinetic parameters for film-coated and sugar-coated warfarin were the following: t½ , 103.5 ± 18.8 and 105.8 ± 21.3 hours; Tmax , 0.7 ± 0.5 and 1.3 ± 0.8 hours; Cmax , 347.8 ± 74.8 and 322.9 ± 75.7 ng/mL; AUC0∼360 , 16,024.2 ± 3713.9 and 15,586.6 ± 3477.0 ng·mL-1 ·h; AUC0∼∞ , 17,335.7 ± 4089.1 and 16,912.0 ± 3911.2 ng·mL-1 ·h, respectively.",Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371488/),[ng] / [ml],322.9,265567,DB00682,Warfarin
,28371488,AUC0∼360,"The main pharmacokinetic parameters for film-coated and sugar-coated warfarin were the following: t½ , 103.5 ± 18.8 and 105.8 ± 21.3 hours; Tmax , 0.7 ± 0.5 and 1.3 ± 0.8 hours; Cmax , 347.8 ± 74.8 and 322.9 ± 75.7 ng/mL; AUC0∼360 , 16,024.2 ± 3713.9 and 15,586.6 ± 3477.0 ng·mL-1 ·h; AUC0∼∞ , 17,335.7 ± 4089.1 and 16,912.0 ± 3911.2 ng·mL-1 ·h, respectively.",Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371488/),[h·ng] / [ml],"16,024.2",265568,DB00682,Warfarin
,28371488,AUC0∼360,"The main pharmacokinetic parameters for film-coated and sugar-coated warfarin were the following: t½ , 103.5 ± 18.8 and 105.8 ± 21.3 hours; Tmax , 0.7 ± 0.5 and 1.3 ± 0.8 hours; Cmax , 347.8 ± 74.8 and 322.9 ± 75.7 ng/mL; AUC0∼360 , 16,024.2 ± 3713.9 and 15,586.6 ± 3477.0 ng·mL-1 ·h; AUC0∼∞ , 17,335.7 ± 4089.1 and 16,912.0 ± 3911.2 ng·mL-1 ·h, respectively.",Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371488/),[h·ng] / [ml],"15,586.6",265569,DB00682,Warfarin
,28371488,AUC0∼∞,"The main pharmacokinetic parameters for film-coated and sugar-coated warfarin were the following: t½ , 103.5 ± 18.8 and 105.8 ± 21.3 hours; Tmax , 0.7 ± 0.5 and 1.3 ± 0.8 hours; Cmax , 347.8 ± 74.8 and 322.9 ± 75.7 ng/mL; AUC0∼360 , 16,024.2 ± 3713.9 and 15,586.6 ± 3477.0 ng·mL-1 ·h; AUC0∼∞ , 17,335.7 ± 4089.1 and 16,912.0 ± 3911.2 ng·mL-1 ·h, respectively.",Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371488/),[h·ng] / [ml],"17,335.7",265570,DB00682,Warfarin
,28371488,AUC0∼∞,"The main pharmacokinetic parameters for film-coated and sugar-coated warfarin were the following: t½ , 103.5 ± 18.8 and 105.8 ± 21.3 hours; Tmax , 0.7 ± 0.5 and 1.3 ± 0.8 hours; Cmax , 347.8 ± 74.8 and 322.9 ± 75.7 ng/mL; AUC0∼360 , 16,024.2 ± 3713.9 and 15,586.6 ± 3477.0 ng·mL-1 ·h; AUC0∼∞ , 17,335.7 ± 4089.1 and 16,912.0 ± 3911.2 ng·mL-1 ·h, respectively.",Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371488/),[h·ng] / [ml],"16,912.0",265571,DB00682,Warfarin
,24430725,terminal half-life,"The mean terminal half-life ranged from 5.6 to 13.1 h in single rising-dose studies, and from 10.3 to 18.8 h in multiple-dose studies.","Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24430725/),h,5.6 to 13.1,265997,DB00682,Warfarin
,24430725,terminal half-life,"The mean terminal half-life ranged from 5.6 to 13.1 h in single rising-dose studies, and from 10.3 to 18.8 h in multiple-dose studies.","Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24430725/),h,10.3 to 18.8,265998,DB00682,Warfarin
,858804,half-life,The mean warfarin half-life of 29.9+/-5.0 (S.E.M.) hours for renal patients was significantly shorter than the 44.8+/-6.0 hours half-life for normal controls (P less than 0.05).,Warfarin elimination and responsiveness in patients with renal dysfunction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/858804/),h,29.9,267208,DB00682,Warfarin
,858804,half-life,The mean warfarin half-life of 29.9+/-5.0 (S.E.M.) hours for renal patients was significantly shorter than the 44.8+/-6.0 hours half-life for normal controls (P less than 0.05).,Warfarin elimination and responsiveness in patients with renal dysfunction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/858804/),h,44.8,267209,DB00682,Warfarin
,19582440,international normalized ratio,We enrolled 125 patients on stable warfarin anticoagulant therapy with an international normalized ratio maintained between 1.5 and 3.0.,Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19582440/),,1.5,267607,DB00682,Warfarin
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,17.8,268318,DB00682,Warfarin
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,27.7,268319,DB00682,Warfarin
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,30.8,268320,DB00682,Warfarin
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,38.8,268321,DB00682,Warfarin
>,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,100,268322,DB00682,Warfarin
>,25264242,[I]/Ki ratio,"The results of a static model indicated an [I]/Ki ratio >0.1 for CYP1A2, 2C8, 2C9 and 2C19.",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),,0.1,268323,DB00682,Warfarin
<,25264242,AUC ratios,Simulation of the area under the plasma concentration-time curve (AUC) of these four CYP substrates in the presence and absence of orteronel revealed geometric mean AUC ratios <1.25.,Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),,1.25,268324,DB00682,Warfarin
,8630630,elimination half-life (t1/2),The elimination half-life (t1/2) of meloxicam is approximately 20 h.,A review of the clinical pharmacokinetics of meloxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),h,20,268516,DB00682,Warfarin
,8630630,total plasma clearance (CL),This is reflected in a total plasma clearance (CL) of 0.42-0.48 1/h.,A review of the clinical pharmacokinetics of meloxicam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),[1] / [h],0.42-0.48,268517,DB00682,Warfarin
,6317740,Systemic bioavailability,Systemic bioavailability is approximately 70% with cimetidine and 50% with ranitidine.,Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),%,70,269860,DB00682,Warfarin
,6317740,Systemic bioavailability,Systemic bioavailability is approximately 70% with cimetidine and 50% with ranitidine.,Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),%,50,269861,DB00682,Warfarin
,6317740,elimination half-lives,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),h,1.7-2.1,269862,DB00682,Warfarin
,6317740,elimination half-lives,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),h,2.1-3.1,269863,DB00682,Warfarin
,6317740,apparent volumes of distribution,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),l,50,269864,DB00682,Warfarin
,6317740,apparent volumes of distribution,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),l,75,269865,DB00682,Warfarin
,6661352,elimination half-life,"The mean elimination half-life of S-warfarin was increased from 25 to 46 h during phenylbutazone administration, whilst that of the R-isomer was decreased from 37 to 25 h.",Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661352/),h,25 to 46,269888,DB00682,Warfarin
,6661352,elimination half-life,"The mean elimination half-life of S-warfarin was increased from 25 to 46 h during phenylbutazone administration, whilst that of the R-isomer was decreased from 37 to 25 h.",Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661352/),h,37 to 25,269889,DB00682,Warfarin
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,13.00,270253,DB00682,Warfarin
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,25.83,270254,DB00682,Warfarin
,16413247,clearance,"Flurbiprofen clearance (29-33 mL/min) and elimination half-life (3.3-3.4 hours) did not differ significantly among trials 1, 2, 3, and 4.","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),[ml] / [min],29-33,272901,DB00682,Warfarin
,16413247,elimination half-life,"Flurbiprofen clearance (29-33 mL/min) and elimination half-life (3.3-3.4 hours) did not differ significantly among trials 1, 2, 3, and 4.","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),h,3.3-3.4,272902,DB00682,Warfarin
,16413247,clearance,"However, clearance in the fluconazole treatment condition (trial 5) was significantly reduced compared with the placebo control (17 +/- 5 mL/min versus 31 +/- 8 mL/min, P <.05), and the half-life was prolonged (5.3 +/- 1.6 hours versus 3.3 +/- 0.8 hours, P <.05).","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),[ml] / [min],17,272903,DB00682,Warfarin
,16413247,clearance,"However, clearance in the fluconazole treatment condition (trial 5) was significantly reduced compared with the placebo control (17 +/- 5 mL/min versus 31 +/- 8 mL/min, P <.05), and the half-life was prolonged (5.3 +/- 1.6 hours versus 3.3 +/- 0.8 hours, P <.05).","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),[ml] / [min],31,272904,DB00682,Warfarin
,16413247,half-life,"However, clearance in the fluconazole treatment condition (trial 5) was significantly reduced compared with the placebo control (17 +/- 5 mL/min versus 31 +/- 8 mL/min, P <.05), and the half-life was prolonged (5.3 +/- 1.6 hours versus 3.3 +/- 0.8 hours, P <.05).","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),h,5.3,272905,DB00682,Warfarin
,16413247,half-life,"However, clearance in the fluconazole treatment condition (trial 5) was significantly reduced compared with the placebo control (17 +/- 5 mL/min versus 31 +/- 8 mL/min, P <.05), and the half-life was prolonged (5.3 +/- 1.6 hours versus 3.3 +/- 0.8 hours, P <.05).","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),h,3.3,272906,DB00682,Warfarin
,25103614,trough level,The average dabigatran trough level was 69.3 ± 55.5 ng/ml and the average dabigatran peak level was 112.7 ± 66.6 ng/ml.,Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103614/),[ng] / [ml],69.3,273242,DB00682,Warfarin
,25103614,peak level,The average dabigatran trough level was 69.3 ± 55.5 ng/ml and the average dabigatran peak level was 112.7 ± 66.6 ng/ml.,Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103614/),[ng] / [ml],112.7,273243,DB00682,Warfarin
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],2.8,273446,DB00682,Warfarin
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],5.2,273447,DB00682,Warfarin
,9068926,bioavailability,The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food.,The clinical pharmacokinetics of levofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),%,100,273448,DB00682,Warfarin
,9068926,Cmax,"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],0.6 to 9.4,273449,DB00682,Warfarin
,9068926,area under the concentration-time curve (AUC),"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[h·mg] / [l],4.7 to 108,273450,DB00682,Warfarin
,9068926,volume of distribution,"Levofloxacin is widely distributed throughout the body, with a mean volume of distribution of 1.1 L/kg, and penetrates well into most body tissues and fluids.",The clinical pharmacokinetics of levofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[l] / [kg],1.1,273451,DB00682,Warfarin
,9068926,plasma elimination half-life (t1/2 beta),The plasma elimination half-life (t1/2 beta) ranges from 6 to 8 hours in individuals with normal renal function.,The clinical pharmacokinetics of levofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),h,6 to 8,273452,DB00682,Warfarin
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],3016,274191,DB00682,Warfarin
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],233,274192,DB00682,Warfarin
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],2929,274193,DB00682,Warfarin
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],220,274194,DB00682,Warfarin
